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The stage  
 
The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of diseases characterised by 
an acquired progressive muscle weakness and the presence of inflammatory infiltrates in skeletal 
muscle tissue in the absence of a clear causative agent 5. The three main disorders grouped under the 
heading IIM are: dermatomyositis (DM), polymyositis (PM), and inclusion body myositis (IBM). These 
are very distinct disease entities with their own clinical features, pathological abnormalities, and 
pathophysiologic mechanisms. Chapter 2 and Chapter 3 discuss these diseases, which will constitute 
the stage of the research described in this thesis.  
Because much of the work in this thesis focuses on the presence and clinical usefulness of certain 
autoantibodies in the different forms of IIM, it is crucial to establish the validity of the diagnostic criteria 
used. Therefore a recent dispute over the diagnostic criteria for IIM, and especially for PM is 
discussed in Chapter 4.  By performing a structured literature search we examined the historical basis 
of a presumed histological feature of PM, which presence is, according to some, a prerequisite for the 
diagnosis. Our study showed that it is erroneous that this presumed histological feature should be a 
prerequisite for the diagnosis PM because the patients on which this association is based may have 
had IBM instead of PM. Therefore, the diagnostic criteria used in this thesis, which do not always 
require the presence of certain histological characteristics, are valid.  
 
 
The players 
 
It has been shown that sera from over 90% of patients with IIM contain autoantibodies 134. Most of 
these autoantibodies are not specific for myositis because they are also found in sera from patients 
with other inflammatory connective tissue diseases (ICTDs) without the presence of myositis. A subset 
of autoantibodies appears to be specific for IIM 116. These so-called myositis specific autoantibodies 
(MSAs) are the players in this thesis. Chapter 5 provides an overview of the most common MSAs and 
the state-of-the-art knowledge at the time the work described in this thesis started.  
The pathophysiology of IIM is not fully understood but it appears that both environmental as well as 
genetic factors are involved. Results from studies performed in different parts of the world and in 
populations with another genetic background can therefore not automatically be extrapolated to the 
European and Dutch situation. Chapter 6 and Chapter 7 present two large studies on the prevalence 
and clinical association of the most common MSAs in a large group of European and Dutch IIM 
patients. Furthermore, several up-to-date techniques of autoantibody detection are described. 
The specificity of MSAs for IIM has been established compared to other ICTDs 128, 183. The differential 
diagnosis of IIM not only includes other ICTDs but also other neuromuscular disorders because 
muscle weakness and myalgia may be the primary symptoms at presentation. In Chapter 8 we studied 
the specificity of the most common MSAs and established the fact that they are truly myositis specific.       
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The characters 
 
The three most common MSAs, anti-Jo-1, anti-SRP, and anti-Mi-2, are addressed in more detail. The 
anti-Jo-1 autoantibody is the most common representative of the so-called anti-aminoacyl-tRNA 
synthetase autoantibodies (anti-ARS) 116. The presence of anti-ARS autoantibodies is associated with 
the anti-synthetase syndrome consisting of myositis, interstitial lung disease, polyarthritis, and 
Raynaud’s phenomenon 116. In Chapter 9, three cases of the anti-synthetase syndrome are presented 
to illustrate this specific clinical syndrome and to stress the importance of a multidisciplinary approach. 
The clinical differentiation between IBM and PM can be difficult to make, even histological 42. Yet, this 
differentiation is of clinical importance because the latter responds to immunosuppressive therapy 
whereas the former does not 18. In Chapter 10 it is shown that determination of anti-Jo-1 
autoantibodies can aid in this differential diagnosis by virtually excluding the diagnosis IBM in case of 
anti-Jo-1 positivity. Nevertheless, a few anti-Jo-positive patients with IBM were encountered. One of 
these patients is described in the second part of Chapter 10. Besides having the anti-Jo-1 
autoantibody, this patient with IBM had a second remarkable feature: a marked and sustained 
treatment response, which is usual in IBM patients.    
The anti-SRP autoantibody is far less common than the anti-Jo-1 autoantibody. Most studies 
describing patients with the anti-SRP autoantibody only describe a few cases, and hardly ever in a 
systematic manner 125, 128, 129, 153. In Chapter 11, the largest study to date on the clinical characteristics 
of patients with anti-SRP autoantibodies is presented. In this study, 27 patients are described 
systematically and it is shown that the anti-SRP autoantibody is a marker of an immune mediated 
necrotizing myopathy. 
As was the case with anti-SRP, most studies on the clinical characteristics of patients with anti-Mi-2 
autoantibodies only describe a small number of patients 125, 129, 138, 167. Furthermore, previous studies 
used techniques in which only autoantibody activity directed against certain parts of the Mi-2β 
autoantigen could be detected, although autoantibody activity against other parts of the Mi-2β 
autoantigen has been shown to exist in patients with myositis 117. The largest systematic study on the 
clinical characteristics of patients with autoantibodies to different parts of the Mi-2β autoantigen is 
described in Chapter 12. It is shown that, unlike anti-Jo-1 and anti-SRP, the anti-Mi-2 autoantibody is 
not a marker for a specific form of IIM. The presence of autoantibodies directed against the N-terminal 
fragment of the Mi-2β autoantigen may be associated with an increased risk of developing 
malignancy.   
 
 
The plot 
 
In the years between the start of the research presented in this thesis and the writing of the concluding 
remarks on the final pages, the landscape of MSAs has changed drastically. New theories on 
autoantibody formation were formulated and better insights into their clinical usefulness have 
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emerged. Chapter 13 presents an overview of our knowledge on MSAs at the time the research 
presented in this thesis was ended.  
As can be concluded from the results presented in this thesis, MSAs have helped us to better 
understand IIM. They aided in the identification of several distinct disease entities which were once 
included under the heading IIM, usually under the diagnosis PM. But the MSAs still hold many 
mysteries, including their function and role in the pathophysiology of these enigmatic diseases. As is 
stated in Chapter 14, continuing research is needed in order to further elucidate the pathophysiologic 
role of MSAs and to advance on the road towards a better understanding of these potentially 
debilitating diseases.    
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Introduction 
 
Although the skeletal muscle tissue is the largest organ of the human body in terms of mass, it is 
rarely the site of an extensive immune response. The incidence of the most frequently encountered 
inflammatory myopathies is roughly one per one hundred thousand 1, 2. The inflammatory myopathies 
can be divided into two groups: the symptomatic and the idiopathic inflammatory myopathies (table 1). 
The group of the idiopathic inflammatory myopathies (IIM) consists of several diseases of which 
dermatomyositis (DM), polymyositis (PM), and inclusion body myositis (IBM) are the most common. 
DM, PM, and IBM are not three diseases within the same spectrum, but distinct clinical, histological, 
serological, and pathophysiological disease-entities (table 2). This chapter deals with DM and PM, two 
diseases that are closely related clinically. 
 
 
 
 
Table 1: Classification of the inflammatory myopathies. 
 
  
symptomatic  
  
virus adenovirus, arbovirus, CMV, coxackie, echovirus, hepatits B, HIV, HSV, HTLV-1, 
measles, mumps, para-influenza, RSV 
bacteria pyomyositis 
parasites cysticercosis, toxoplasmosis, trichinosis, worms 
fungi actinomyocosis, candida, cryptococcus, histoplasmosis, sporotrichosis 
drugs/toxins penicillamine, interferon-alpha 
  
  
idiopathic  
  
generalised polymyositis, dermatomyositis, inclusion body myositis (hereditary and sporadic), 
overlap syndromes, eosinophilic myositis, diffuse fasciitis with eosinophilia, 
granulomatous myositis, sarcoïd myopathy 
focal ocular myositis, monomelic myositis, focal nodular myositis, angiopathic myositis, 
focal eosinophilic myositis, inflammatory pseudo-tumour, proliferative myositis 
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        Table 2: C
haracteristics of D
M
, P
M
, and IB
M
.  
  
  
 
 
 
 
 
D
M
 
PM
 
IBM
 
 
 
 
 
 
 
epidem
iology 
 
 
 
 
    age 
children and adults 
adults 
elderly (>50 years) 
 
    sex 
fem
ale > m
ale 
fem
ale > m
ale 
m
ale > fem
ale 
 
signs and sym
ptom
s 
 
 
 
 
    onset 
(sub)acute 
(sub)acute 
insidious 
 
    w
eakness 
sym
m
etric (proxim
al > distal) 
sym
m
etric (proxim
al > distal) 
asym
m
etric (distal + proxim
al) 
 
    rash 
yes 
som
etim
es 
no 
 
    m
alaise 
yes 
yes 
no 
 
    associated conditions 
ILD
, m
yocarditis, autoim
m
une 
diseases, cancer 
ILD
, m
yocarditis, autoim
m
une 
diseases 
polyneuropathy 
 
laboratory investigations 
 
 
 
 
    serum
 C
K
 
10-50x elevated (som
etim
es norm
al) 
10-50x elevated 
up to 5x elevated 
 
    M
SA 
25%
 
25%
 
1%
 
 
    E
M
G
 
m
yopathic 
m
yopathic 
m
yopathic and neurogenic 
 
    m
uscle biopsy 
perivascular infiltrate (T4 and B
 cells) 
perifascicular atrophy 
endom
ysial infiltrate (T8 cells and 
m
acrophages) 
endom
ysial infiltrate (T8 cells and 
m
acrophages), basophilic rim
m
ed 
vacuoles 
 
treatm
ent 
 
 
 
 
    response 
good 
m
oderate to good 
none 
           A
bbreviations used: C
K
: creatine kinase; E
M
G
: electrom
yography; ILD
: interstitial lung disease; M
S
A
: m
yositis specific autoantibodies
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Diagnostic criteria 
 
Dermatomyositis and PM are clinical diagnosis. There is no gold standard on basis of which the 
disease can be diagnosed or be excluded with certainty. The main elements contributing to the 
diagnosis are: an acquired symmetric proximal muscle weakness, typical dermatological 
abnormalities, an elevated level of serum creatine kinase (CK), myopathic abnormalities with 
spontaneous activity on electromyographic examination (EMG), and the presence of inflammatory 
infiltrates in skeletal muscle tissue. Over the years, several diagnostic criteria have been proposed 
(table 3-5). 
Twenty-five years ago, Bohan and Peter proposed their research-criteria 3. These criteria have been 
used as the gold standard in myositis research for a long time. Even today they are used frequently, 
especially by rheumatologists. The sensitivity and specificity of the Bohan and Peter criteria are 
approximately 90% 4. The specificity has only been determined in comparison to other rheumatic 
diseases and not in comparison to other neuromuscular disorders. Bohan and Peter evaded this 
shortcoming by listing a number of exclusion criteria. In case one of these exclusion criteria is present, 
the diagnosis DM/PM strongly needs to be questioned. These exclusion criteria include almost all 
neuromuscular disorders: muscular dystrophies, metabolic and toxic myopathies, motor neuron 
diseases, and neuropathies. Another shortcoming of the Bohan and Peter criteria is the fact that IBM 
is not recognised as a separate disease entity. Almost all IBM patients meet the Bohan and Peter 
criteria for PM. Due to these shortcomings the Bohan and Peter criteria are not very useful in clinical 
daily practice. Also the grading of “possible”, “probable”, and “definite” is not useful in case of an 
individual patient. 
In 1991, Dalakas published his diagnostic criteria which clearly make a distinction between DM, PM, 
and IBM 5. These criteria have never been accepted widely, mainly because sensitivity and specificity 
are unknown. An additional problem is that some definitions are very extensive and it is not clear 
whether for instance all histological characteristics need to be present in order to make the diagnosis 
or only a few.  
Four years later, Tanimoto et al. published diagnostic criteria for DM and PM 6. These criteria, 
although far from ideal, have several advantages. Sensitivity and specificity are known, also compared 
to other neuromuscular disorders. For DM, the sensitivity is 94% and the specificity compared to other 
systemic rheumatic diseases is 90%. The sensitivity for PM is 99% with a 95% specificity compared to 
other neuromuscular and rheumatic diseases. Furthermore, IBM is recognised as a separate disease 
entity and the criteria stress the fact that DM and PM are systemic diseases. 
In conclusion, it can be stated that presently we do not have widely accepted diagnostic criteria for DM 
and PM. In daily clinical practice, one has to rely on clinical judgement. The diagnostic criteria 
described above can be used for guidance. It is therefore a prerequisite that the treating physician is 
familiar with the clinical presentations of DM and PM, the value of additional investigations, the 
differential diagnosis, and the extra-muscular manifestations of these diseases.             
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Table 3:  Bohan and Peter criteria for DM and PM. 3 
 
  
Elements 
  
1. symmetrical weakness of the limb-girdle muscles and anterior neck flexors, progressing over 
weeks to months, with or without dysphagia or respiratory muscle involvement 
2. muscle biopsy evidence of muscle fibre necrosis, phagocytosis, regeneration with basophilia, large 
vesicular sarcolemmal nuclei and prominent nucleoli, atrophy (in DM frequently perifascicular), 
variation in fibre size, and inflammatory exudate (in DM usually perivascular, in PM usually 
endomysial) 
3. elevated levels of skeletal-muscle enzymes 
4. electromyographic triad of short, small, polyphasic motor units, fibrillations, positive sharp waves 
and insertional irritability, and bizarre, high-frequency repetitive discharges 
5. dermatologic features including a lilac discoloration of the eyelids (heliotrope) with periorbital 
edema, a scaly, erythematous dermatitis over the dorsum of the hands, and involvement of the 
knees, elbows and medial malleoli, as well as the face, neck, and upper torso 
  
  
Assessment 
 
possible DM: element 5 is present and 1 other element 
probable DM: element 5 is present and 2 other elements 
definite DM: element 5 is present and 3 other elements 
 
possible PM: 2 elements are present, element 5 is absent 
probable PM: 3 elements are present, element 5 is absent 
definite PM: 4 elements are present, element 5 is absent 
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Table 4:  Dalakas criteria for DM and PM 5. 
 
   
criterion               dermatomyositis                      polymyositis 
 mild/early definite probable definite 
     
muscle strength seemingly 
normal 
myopathic weakness myopathic weakness myopathic weakness 
EMG findings myopathic / non-
specific 
myopathic myopathic myopathic 
muscle enzymes normal/elevated 
(up to 10x) 
normal/elevated (up 
to 50x) 
elevated (up to 50x) elevated (up to 50x) 
muscle biopsy non-specific / 
diagnostic 
diagnostic non-specific / 
diagnostic 
diagnostic 
rash/calcinosis present present absent absent 
 
Definitions: 
myopathic muscle weakness: muscle weakness affecting proximal muscles more than distal ones and sparing 
eye and facial muscles, is characterised by a subacute onset (weeks to months) and rapid progression in patients 
who have no family history of neuromuscular disease, no endocrinopathy, no exposure to myotoxic drugs or 
toxins, and no biochemical muscle disease (excluded on the basis of muscle-biopsy findings) 
diagnostic muscle biopsy DM: perifascicular atrophy is diagnostic, even in the absence of inflammatory infiltrates; 
other characteristics are perivascular inflammatory infiltrates and capillary abnormalities 
diagnostic muscle biopsy PM: endomysial inflammatory infiltrates with invasion of non-necrotic muscle fibres 
rash: heliotrope rash, Gottron’s sign, and other dermatomyositis rashes 
Abbreviations used: EMG: electromyography. 
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Table 5: Tanimoto criteria for DM and PM 6. 
 
  
Elements 
  
1. skin lesions: 
a. heliotrope rash (red purple edematous erythema on the upper palpebra) 
b. Gottron’s sign (red purple keratotic, atrophic erythema, or macules on the extensor surface 
             of finger joints) 
c. erythema on the extensor surface of extremity joints: slightly raised red purple erythema  
      over elbows and knees 
2. proximal muscle weakness (upper or lower extremity and trunk) 
3. elevated serum CK or aldolase levels 
4. muscle pain on grasping or spontaneous pain 
5. myogenic changes on EMG (short-duration, polyphasic motor unit potentials with spontaneous 
fibrillation potentials) 
6. positive anti-Jo-1 antibody 
7. non-destructive arthritis or arthralgias 
8. systemic inflammatory signs (fever: more than 370C at axilla, elevated serum CRP level or 
accelerated ESR of more than 20 mm/h) 
9. pathological findings compatible with inflammatory myositis (inflammatory infiltration of skeletal 
muscle with degeneration or necrosis of muscle fibres; active phagocytosis, central nuclei, or 
evidence of active regeneration may be seen) 
  
  
Assessment 
  
DM: at least 1 item from element 1 and at least 4 elements from element 2-9 are present 
PM: at least 4 elements from element 2-9 are present 
 
Abbreviations used: CK: creatine kinase; CRP: C-reactive protein; EMG: electromyography; ESR: erythrocyte 
sedimentation rate. 
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Clinical characteristics 
 
The muscle weakness in DM and PM usually has a subacute onset (weeks-months) and is mainly 
located symmetrically in the proximal muscles 5, 7.  Distal weakness can occur in the course of the 
disease but the proximal weakness continues to dominate. The facial muscles are rarely involved and 
the extraocular muscles are always spared 5. In 30% of cases, weakness of the oropharyngeal 
muscles results in dysphagia 5. Involvement of the respiratory muscles can cause respiratory 
insufficiency. Usually the weakness is accompanied by myalgia (spontaneous or on palpation). Over 
time, muscle atrophy occurs. 
The dermatologic changes in DM usually precede or accompany the muscle weakness. The most 
characteristic changes are a blue-purple discoloration of the upper eyelids, usually accompanied by 
perioribital edema (heliotrope rash) and a raised violaceous erythemato(squamous) dermatitis over 
the extensor side of the proximal interphalangeal and metacarpophalangeal joints (Gottron’s sign) 
(figure 1) 8.  A similar rash can be found over the extensor sides of larger joints (elbows, knees) and 
over the medial malleoli 8. Other rashes that occur in DM are a sunlight sensitive erythema in the face, 
the neck, the upper torso (“V-sign”) and the shoulders (“shawl-sign”) 8. Over time (de)pigmentations 
occur. The lateral and palmer areas of the fingers may become rough with cracked, “dirty” horizontal 
lines, resembling “mechanic’s hands” 8. At the base of the fingernails dilated capillary loops can be 
seen with thrombi, microhaemorrhages, and micro-infarctions (figure 1) 5. Some patients with the 
typical DM skin changes never develop muscle weakness. In these patients, the disease is referred to 
as dermatomyositis sine myositis 9-12. Rashes can also be seen in PM, usually atypical erythema. A 
patient with myositis and a rash is not by definition suffering from DM, as long as the typical DM 
rashes are not present. 
Besides muscle weakness and skin changes, most patients also complain of more general signs and 
symptoms like general malaise, weight loss, a slight rise in body temperature, and Raynaud’s 
phenomenon 5. 
 
                                        
vcvcv  
 Figure 1: Gottron’s sign (A and B) and cuticular infarctions (B) in dermatomyositis. 
A B
A
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Additional investigations 
 
Laboratory investigations 
Necrosis of muscle fibres results in elevation of serum levels of CK, aspartate aminotransferase 
(ASAT), alanine aminotransferase (ALAT), lactate dehydrogenase (LDH), aldolase, and myoglobulin. 
The serum CK level is the most specific and sensitive parameter of muscle fibre destruction and is 
elevated in over 90% of cases up to ten to 50 times the upper limit of normal 7. The degree of 
elevation of serum CK is not directly correlated with the severity of the muscle weakness and 
especially in children serum CK levels can be normal or only slightly elevated 7. In daily clinical 
practice, serum CK levels are a reasonable parameter for monitoring the degree of active 
inflammation. The erythrocyte sedimentation rate is usually normal or only slightly elevated 7. 
In a large proportion of patients, autoantibodies can be found of unknown significance. Most of these 
autoantibodies are aspecific and are also found in patients with other autoimmune diseases. In about 
20-40% of patients, autoantibodies can be found that are considered to be specific for myositis 13. 
These myositis specific autoantibodies (MSAs) are directed against cytoplasmic proteins involved in 
the process of translation, and are only seen in DM and PM 13. The presence of certain MSAs seems 
to be associated with certain clinical characteristics 13. For instance, the most prevalent MSA, the anti-
Jo-1 autoantibody, is associated the so-called anti-synthetase syndrome consisting of DM/PM, 
idiopathic interstitial lung disease, arthritis, Raynaud’s phenomenon, and a moderate response to 
immunosuppressive treatment 13. 
 
Electromyography 
The typical EMG findings in inflammatory myopathies are an increased insertional activity with 
spontaneous activity consisting of fibrillation potentials, positive sharp waves, and sometimes the 
presence of pseudomyotonia and complex repetitive discharges 14. Polyphasic motor unit potentials 
are frequently seen with low amplitude and a short duration. The recruitment can de decreased in 
longstanding cases due to loss of entire motor units and insertional activity can be decreased as a 
result of fibrosis 7. Polyphasic motor unit potentials with long duration can be formed due to fibre 
splitting and regeneration 7. The degree of spontaneous EMG activity is correlated to the degree of 
active inflammation 7. This feature can be used to differentiate between a relapse of myositis and the 
presence of a steroid myopathy. In the latter, there is no spontaneous activity on EMG 7. 
 
Muscle biopsy 
Every patient suspected of DM or PM needs to undergo a muscle biopsy in a centre with expertise in 
performing and evaluating muscle biopsies because the histological evaluation has a high specificity 
for diagnosing a group of diseases that require long-term treatment with immunosuppressives. 
The earliest histological finding in DM is the deposition of membrane attack complex (MAC) in the 
capillaries 15. This is followed by the formation of perivascular inflammatory infiltrates usually located in 
the perimysium (figure 2a) 15. These infiltrates mainly consist of macrophages, B-cells, and helper T-
cells. The most characteristic histological finding, the perifascicular atrophy, can be seen in 90% of 
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juvenile DM patients and in over 50% of adult DM patients (figure 2b) 5. Sometimes, wedge-shaped 
micro-infarctions can be seen in muscle fascicles 5, 7.  
                                
  
 
Figure 2: Muscle biopsy findings in dermatomyositis. B) perivascular inflammatory infiltrates. C) 
perifascicular atrophy. Bar 50 µm. 
 
 
PM is histologically characterised by variability in muscle fibre diameter, the presence of necrotic and 
regenerating muscle fibres, and endomysial inflammatory infiltrates with invasion of non-necrotic 
muscle fibres (figure 3c) 15. These infiltrates mainly consist of cytotoxic T-cells and macrophages. 
Furthermore, aberrant HLA-ABC expression is present on the sarcolemma (figure 3b) 5, 7.     
 
 
 
 
Figure 3: Muscle biopsy findings in polymyositis. A) HLA-ABC stain in normal skeletal muscle tissue, 
only the capillaries stain positive. B) HLA-ABC stain in PM with extensive staining of the sarcolemma. 
C) endomysial inflammatory infiltrate. 
 
A CB 
B
A 
A C 
B 
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Differential diagnosis 
 
The differential diagnosis consists of all diseases that can cause an acquired symmetric proximal 
muscle weakness in adults (table 6).  
 
 
Table 6:  Differential diagnosis of DM and PM. 
 
  
myopathies limb-girdle muscular dystrophies, Becker muscular dystrophy, 
fascioscapulohumeral muscular dystrophy, inclusion body myositis, 
metabolic myopathy, mitochondrial myopathies, toxic myopathies (e.g. 
drugs) 
neuromuscular junction myasthenia gravis, Lambert-Eaton myasthenic syndrome 
neurogenic amyotrophic lateral sclerosis 
rheumatic Rheumatoid arthritis, systemic lupus erythematosus, Sjögren, systemic 
sclerosis, CREST, mixed connective tissue disease 
endocrine hypothyroidism 
 
Abbreviations used: CREST: calcinosis, Raynaud’s phenomenon, oesophageal sclerosis, sclerodactaly, 
teleangiectasias. 
 
 
 
Extramuscular manifestations 
 
DM and PM are systemic autoimmune diseases. Multiple organ systems can be involved in the 
disease, although the muscle and skin involvement usually dominate the clinical presentation. The 
extramuscular manifestations are the main cause of the mortality the disease still carries. The extra-
muscular manifestations can precede, coincide, or follow the emergence of the muscular and 
dermatologic symptoms.    
 
Lung 
Five to 40 percent of patients with DM and PM develop an idiopathic interstitial lung disease (ILD) 
characterised by interstitial inflammation followed by fibrosis 16. There is no difference between DM 
and PM with regard to ILD. Clinically, patients complain of dyspnoea on exertion and a non-productive 
cough. Basal crepitations can be heard on auscultation. ILD can develop acutely and rapidly lead to 
respiratory insufficiency. In most cases the disease starts insidiously and has a chronic course. In a 
few cases, ILD remains asymptomatic.  
The diagnosis is based on pulmonary function tests and imaging. A plain X-ray of the thorax reveals 
bilateral reticulonodular abnormalities over the basal lung fields 7, 16. High Resolution Computed 
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Tomography (HRCT) shows the degree and type of pulmonary abnormalities. So-called 
“honeycombing” correlates with chronic fibrotic abnormalities and “ground glass with consolidations” 
with active inflammation 16. Pulmonary function tests reveal a restrictive pattern (as in various 
neuromuscular diseases) and a decreased carbon monoxide (CO) diffusion capacity 16, 17. Especially 
the CO diffusion capacity is a very sensitive parameter and in patients with DM/PM reasonably 
specific 16. More than half of the DM/PM patients with ILD have autoantibodies directed against 
histidine tRNA-synthetase, the so-called anti-Jo-1 autoantibodies 5, 7, 18, 19. The presence of these 
autoantibodies is therefore a reason to perform pulmonary function tests regularly. 
The differential diagnosis of respiratory insufficiency in a patient with DM/PM consists of ILD, 
weakness of the respiratory musculature, aspiration, and a methotrexate pneumonitis 5. 
 
Heart 
Cardiac abnormalities are seen in approximately 40% of patients with DM/PM 5. Usually, these 
abnormalities are asymptomatic and their clinical and prognostic significance is uncertain 20. 
Significant abnormalities are only found in 5% of patients 20. The presence of symptomatic cardiac 
involvement in DM/PM is strongly associated with an increased mortality 18. Electrocardiographic 
abnormalities, including arrhythmias and conduction disorders are frequently seen 5, 7, 20. Heart failure, 
sometimes associated with a dilating cardiomyopathy, pericarditis, and myocarditis are also frequently 
encountered 5, 7, 20. Cardiac involvement in DM/PM can occur at any time during the course of the 
disease and is not associated with the severity of the muscle weakness. 
An electrocardiography (ECG) should be performed in every patient with DM/PM. In case of an 
abnormal ECG, the patient should be referred to a cardiologist. Sometimes, Holter-registration may be 
indicated. A more detailed cardiac evaluation is required in case of heart failure. 
Elevated serum CKMB levels are not necessarily correlated with cardiac abnormalities. In most 
patients, serum CKMB is produced by regenerating skeletal muscle fibres 17. A detailed cardiac 
evaluation is indicated if also the serum troponin I is elevated.  
 
Joints 
Arthralgia and symmetric polyarthritis occur with a high frequency in DM and PM 7, 20, 21. Small and 
large joints can be affected (fingers, wrists, elbows, knees), thus strongly resembling rheumatoid 
arthritis 17, 22. The polyarthritis in DM and PM is non-erosive, unlike the arthritis seen in rheumatoid 
arthritis 17. 
 
Gastro-intestinal 
Besides the involvement of the skeletal muscle tissue in the upper two-third of the oesophagus, the 
smooth muscle tissue of the gastro-intestinal tract can also be affected resulting in delayed gastric 
emptying, reflux, and constipation 7, 17, 20. However, symptomatic involvement of smooth muscle is 
extremely rare 17. In DM, mucosal vasculitis can result in ulcerations, perforations, and haemorrhage 7, 
20. Mucosal vasculitis is mainly seen in children 7. 
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Vasculitis 
Besides the skin, skeletal muscle, and gastro-intestinal tract, the vasculitis in DM can also affect other 
organs including retina, conjunctiva, kidneys, and lung 7. In daily practice, these extramuscular 
manifestations of the disease are extremely rare. 
 
Malignancy 
DM is associated with the presence of a malignancy 5, 23-25. The incidence of a malignancy in DM 
varies between 18 to 32 percent 23. All types of malignancies are seen in DM, only ovariumcarcinoma 
is clearly overrepresented 25. The risk of malignancy is especially increased during the first 3-5 years 
following the diagnosis of DM 23-25.  
A search for an underlying malignancy is indicated in every patient with DM. A complete history and 
adequate physical examination including a gynaecological examination are the cornerstones for this 
search 22. A routine chest X-ray and mammogram, and a routine laboratory examination should be 
performed. Additional laboratory investigations need to be guided by findings of physical examination 
and history taking. Ancillary investigations are not indicated in case of no abnormalities and physical 
examination should be repeated after one year 5. 
The association between PM and malignancy is unclear. In daily practice one can assume that such 
an association is not present 5, 23, 25. Additional investigations are therefore not indicated. 
 
 
Treatment 
 
Most treatments for DM and PM are empirical and based on uncontrolled studies. Nevertheless, 
based on the medical literature and on own experience, an overview can be given of the treatment of 
these diseases 7, 26, 27. Treatment can be divided into an induction phase and a consolidation phase 
(table 7). The efficacy of the treatment should be determined clinically, especially muscle strength, and 
not biochemically (e.g. serum CK). 
 
Induction phase 
The main goal of treatment is to decrease the active inflammation load as soon as possible. Usually 
this is achieved by starting with high-dose corticosteroids, most frequently oral prednisone (1-2 
mg/kg/day). After two months, one can switch overnight to an alternate day regime. The maximum 
effect is reached after 4-6 weeks of treatment, after which one tapers the dosage slowly (5 mg every 2 
weeks). Antacids are only indicated in patients with complaints or a previous history of peptic ulcers. 
The prescription of Didrokit® and other drugs to prevent osteoporosis (e.g. Fosamax®) is only 
indicated in case of long-term use of corticosteroids and after an abnormal bone-densitometry.  
A common clinical problem is the occurrence of progressive muscle weakness during corticosteroid 
treatment. Sometimes this is caused by a steroid myopathy and the dosage should be reduced. But 
this can also be a result of an increase in active inflammation requiring a higher dosage of prednisone. 
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In case of the former, serum CK levels will not be elevated and EMG will not reveal spontaneous 
activity. 
Besides oral prednisone, dexamethasone pulse-therapy can be given 28. Some studies suggest that 
this is accompanied by fewer side effects. In DM, intravenous immunoglobulin can also been tried. 
 
Consolidation phase 
Most patients with DM and PM are treated for several years. Because the long-term use of 
corticosteroids is strongly associated with severe side effects, other drugs are preferred for long-term 
immunosuppression and immunomodulation. Most of these drugs become effective after several 
months. It is therefore wise to start these drugs as soon as possible so that they are effective by the 
time one tries to taper the dosage of corticosteroids. The most frequently used drugs are methotrexate 
and azathioprine. There is no clear advantage of one over the other. It is not known how long patients 
need to be treated. Usually, one starts to taper dosages after two years, closely monitoring the 
disease activity. 
 
Treatment resistance 
Occasionally, the inflammation activity does not subside despite high-dose corticosteroids and long-
term use of azathioprine or methotrexate. In a trial-and-error situation, the following medications can 
be used: cyclosporine, chloramphenicol, and cyclophosphamide. Also newer treatment modalities can 
be used, such as tacrolimus, cellcept, and anti-TNF 29-31. Rarely, stem cell transplantations are 
performed 32. 
It is of the utmost importance that a patient with treatment resistant DM/PM is seen in a specialised 
centre with expertise in neuromuscular disorders because an erroneous diagnosis is still the most 
common reason for treatment resistance.  
 
Extramuscular manifestations 
The rash in DM does not always respond as well as the weakness to treatment. Chloroquine can be 
given in patients who do not respond favourable to prednisone, azathioprine, and methotrexate. A 
good sunscreen should also be tried. 
In case of pulmonary and/or cardiac manifestations, a referral to a specialised centre is always 
indicated because these manifestations can rapidly lead to death and their treatment is complex. 
 
 
Prognosis 
 
The prognosis of DM and PM is usually favourable, especially in case of no malignancy. The 5-years 
survival of adults is 70-93% 33, 34. Prognostic unfavourable factors are: older age, presence of ILD, 
cardiac manifestations, anti-Jo-1 autoantibodies, and a delayed and insufficient treatment 14, 27, 35-38. 
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Table 7:  Treatment of DM and PM. 
 
 
Induction phase 
drug dosage dosage adjustment monitoring 
    
prednisone 1-2 mg/kg/day after 2 months alternate 
day; after 4-6 months 
decrease 5 mg/2 weeks 
- 
dexamethasone 40 mg/day first 4 days of 
the month, for 3 months 
- - 
IvIga 1 g/kg first 2 days of the 
month, for 2 months 
- - 
 
 
Consolidation phase 
drug dosage dosage adjustment monitoring 
    
methotrexateb 7,5 mg once a week + 
folic acid 5 mg/day 
increase with 2,5 
mg/week, max 25 
mg/week 
FBC, liver function tests 
every 2 weeks, after 6 
weeks once a month 
azathioprine 25-50 mg/day increase with 25mg every 
2 weeks, max 200 
mg/day 
FBC, liver function tests 
once a week, after 8 
weeks once every 3 
months 
 
 
Skin 
drug dosage dosage adjustment monitoring 
    
chloroquine 150-400 mg/day - ophthalmologic 
monitoring once every 3 
months, low-frequency 
FBC 
 
a only in DM; b not in case of ILD. Abbreviations used:  IvIG: intravenous immunoglobulin; FBC: full blood count 
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 Overlap syndromes 
 
Dermatomyositis and PM can occur together with another well-defined inflammatory connective tissue 
disorder (ICTD), in which case the term overlap syndrome is frequently used (table 8). DM/PM as part 
of an overlap syndrome do not differ from DM/PM without an associated ICTD. Occasionally, the 
myositis as part of an overlap syndrome is less outspoken due to the immunosuppressive treatment 
patients are already using for their associated ICTD. The prognosis mainly depends on the associated 
ICTD.  
Most patients with an ICTD and muscle weakness do not have myositis. Muscle weakness in these 
patients is more commonly due to a steroid myopathy or inactivity. 
 
 
 
Table 8:  Overlap syndromes with myositis. 
 
   
ICTD frequency of myositis remarks 
   
scleroderma 5-17% DM as frequent as PM, also in CREST and systemic 
sclerosis 
Sjögren’s syndrome relatively rare DM as frequent as PM 
SLE rare - 
rheumatoid arthritis relatively rare rheumatoid arthritis is diagnosed in 13% of DM/PM 
patients 
MCTD frequent DM more frequent than PM 
 
Abbreviations used: ICTD: inflammatory connective tissue disease; SLE: systemic lupus erythematosus; CREST: 
calcinosis Raynaud’s phenomenon, oesophageal immobility, sclerodactaly, teleangiectasia; MCTD: mixed 
connective tissue disease 
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Introduction 
 
Inclusion body myositis (IBM) is the most common acquired myopathy above the age of 50 years with 
an estimated prevalence in the general population of 5-10 per 100.000 39, 40. The disease is, contrary 
to dermatomyositis (DM) and polymyositis (PM), more common in men than in women 40. IBM is 
characterised by a slowly progressive asymmetric proximal and marked distal muscle weakness, 
mildly elevated serum creatine kinase (CK), and typical electromyographic and histological features 5, 
7, 41, 42.  
 
 
Clinical characteristics 
 
Inclusion body myositis is characterised by a slowly progressive (years) asymmetric proximal and 
distal muscle weakness. Especially the quadriceps, forearm flexors, and dorsal flexors of the foot are 
severely affected 42. Weakness of the quadriceps can result in a pseudo-acute presentation because 
the patient suddenly starts to fall. Dysphagia occurs in 40% of patients and can be the presenting 
symptom 43. More general signs and symptoms such as myalgia and malaise are not present. 
 
 
Diagnostic criteria and additional investigations 
 
There are several diagnostic criteria for IBM, none of them validated. The most frequently used criteria 
are presented in table 9. 
 
Laboratory investigations 
Serum CK is, as are the other “muscle-associated” enzymes, only slightly elevated (up to 5 times the 
upper limit of normal) 7. Myositis specific autoantibodies are hardly ever found in IBM (approximately in 
1-3%), a feature that can be used in the differentiation with PM 44. 
 
Electromyography 
Spontaneous activity in the form of positive sharp waves and fibrillation potentials are frequently seen 
45. At submaximal voluntary contraction, myopathic and neurogenic motor unit potentials can be seen 
in the same muscle (mixed pattern) 45. There is usually a full interference pattern with relatively large 
amplitudes at maximal voluntary contraction. The interference pattern can be reduced due to marked 
loss of muscle fibres. The electromyographic abnormalities are usually most outspoken in the typical 
“IBM muscles” (quadriceps, forearm flexors, dorsal flexors of the foot). 
 
Muscle biopsy 
The histological findings in IBM strongly resemble those of PM with endomysial inflammatory infiltrates 
invading non-necrotic muscle fibres and aberrant HLA-ABC expression on the sarcolemma. On light 
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microscopy, muscle fibres can be seen with basophilic rimmed vacuoles, eosinophilic cytoplasmic and 
intranuclear inclusions, amyloid-depositions, and an increased number of ragged red fibres (figure 4a) 
41, 46. Electron microscopy reveals the presence of 15-21 nm cytoplasmic and intranuclear 
tubulofilaments, together with cytoplasmic clusters of 6-10 nm amyloid-like fibrils (figure 4b) 41, 46. 
Occasionally, several muscle biopsies need to be performed before one encounters the typical IBM 
abnormalities, sometimes several years after the initial presentation 42, 47. 
 
 
 
     
Figure 4: Muscle biopsy findings in inclusion body myositis. A) muscle fibre with basophilic rimmed 
vacuoles (arrows).  B) 15-21 cytoplasmic tubulofilaments.  
 
 
Extramuscular manifestations 
 
Inclusion body myositis is, unlike DM and PM, not associated with cardiac or pulmonary involvement 7. 
Furthermore, there is no association with malignancy 48. Other autoimmune disease such as systemic 
lupus erythematosus, Sjögren’s syndrome and scleroderma are seen more frequently in IBM patients 
(up to 15%) than in the general population 43, 49-51. 
 
 
Treatment 
 
One of the characteristics of IBM is the fact that the disease does not clearly respond to 
immunosuppressive or immunomodulating therapies. Treatment with corticosteroids is therefore 
usually not indicated. Another reason for not recommending standard treatment are the expected side-
effects of corticosteroids in elderly patients. Many neurologists who have an extensive experience with 
IBM patients have seen an occasional patient with a marked and significant improvement on 
A B
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immunosuppressives. However, these rare cases do not justify the standard use of 
immunosuppressives in IBM. 
 
 
Table 9:  Diagnostic criteria for inclusion body myositis 41 
 
 
Elements 
  
A clinical characteristics: 
 1 disease duration > 6 months 
 2 age at onset > 30 years 
 3 proximal and distal muscle weakness with at least one of the following: 
  - weakness finger flexors 
  - weakness wrist flexors > weakness wrist extensors 
  - quadriceps weakness 
B laboratory: 
 1 CK < 12 times upper limit of normal 
 2 muscle biopsy: 
  a  mononuclear inflammatory infiltrate with invasion of non-necrotic muscle fibres 
  b  vacuoles 
  c  intracellular amyloid-depositions or 15-18 nm tubulofilaments on EM 
 3 EMG compatible with myositis 
   
   
 
Interpretation 
 
definite IBM: all B2 criteria are met 
possible IBM: criteria A1-3, B1, B2a and B3 are met 
 
Abbreviations used: CK: serum creatine kinase; EM: electron microscopy; EMG: electromyography; nm: 
nanometre 
 
 
Prognosis 
 
Inclusion body myositis is a slowly progressive disease that does not clearly respond to treatment. Life 
expectancy is usually not decreased but the quality of life can be severely affected due to impairment 
of mobility and independence 52.  
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Immunopathophysiology 
 
The exact pathogenesis of IBM is unknown. The fact that immunosuppression and immunomodulation 
does not result in a marked clinical improvement suggests that IBM, unlike dermatomyositis and PM, 
is not a primary autoimmune disease. In a study by Barohn et al. eight patients were treated with 
immunosuppressives for a long time 53. None of the patients improved clinically despite a clear 
decrease of serum CK and a clear reduction in the extent of inflammation seen on repeated muscle 
biopsies. The repeated muscle biopsies showed a marked increase in the number of rimmed vacuoles 
and amount of amyloid-depositions.  
Several studies have suggested that IBM is a degenerative muscle disease with secondary 
inflammation. This hypothesis is strongly based on the presence of several “Alzheimer” proteins in the 
muscle fibres of IBM patients. β-amyloid, C- and N-terminal epitopes of the β-amyloid precursor 
protein, prion proteins, apolipoprotein E, α1-antichymotrypsine, ubiquitine, and hyperphosphorylated 
tau protein can all be detected 41, 54, 55. Recently, it was found that the messenger RNAs of β-amyloid 
precursor protein (β-APP) and prion protein (PrP) are present in high concentrations, possibly due to 
an increased transcription of the β-APP and PrP genes. The exact pathophysiological meaning of 
these “Alzheimer” proteins is still unknown. 
The mitochondrial abnormalities that are seen in IBM (ragged red fibres, mitochondrial DNA 
mutations) are probably not the primary cause of the myopathy but should be seen as a secondary 
phenomenon 57. 
Despite all the uncertainties with regard to the exact pathogenesis of IBM, the hypothesis that the 
disease is a primary degenerative myopathy with secondary inflammation holds very well in daily 
practice. The hypothesis explains the most important clinical characteristics of the disease: the slow 
but inevitable progression and the poor to absent response to immunosuppressive therapy.       
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Introduction 
 
A dispute has erupted over the diagnostic criteria for polymyositis, a disorder characterised by 
progressive muscle weakness and the presence of inflammatory infiltrates in skeletal muscle tissue 
that could leave many myositis patients diagnostically adrift and excluded from receiving potentially 
effective treatment. It might also lead to the results of clinical studies performed by one specialist not 
being accepted by another because of disagreement over the diagnostic criteria used. The dispute 
focuses on the histopathological characteristics of polymyositis and whether the presence of 
inflammatory infiltrates invading non-necrotic muscle fibres is a prerequisite for the diagnosis.  
In order to examine the validity of this presumed histological characteristic of polymyositis, we traced 
the original source of this statement by performing a structured literature search. We subsequently 
studied the original source in the light of present day knowledge on myositis.    
 
 
The dispute 
 
The idiopathic inflammatory myopathies are a group of heterogeneous disorders characterised by 
acquired progressive muscle weakness and inflammatory infiltrates in skeletal muscle tissue. The 
three main disorders in this group are dermatomyositis, polymyositis, and inclusion body myositis. 
These diseases differ strongly from each other, both clinically and pathophysiologically. 
Dermatomyositis seems to be a humorally mediated angiopathy resulting in myositis and a typical 
dermatitis 15. Polymyositis is traditionally seen as an inflammatory myopathy mediated by cytotoxic T 
cells, which can occur in the context of another inflammatory connective tissue disease such as 
systemic sclerosis 15. Inclusion body myositis, which is seen mainly in elderly people and is clinically 
characterised by slowly progressive asymmetric muscle weakness, is thought to be a degenerative 
myopathy with secondary inflammation 42, 53.  
Diagnosing dermatomyositis, polymyositis, or inclusion body myositis depends on the combination of 
clinical characteristics, results of laboratory investigations (including levels of muscle associated 
enzymes, serology, electromyography, and muscle biopsy), and responses to treatment. Only rarely 
are all typical features of a disease present simultaneously, and the correct diagnosis may only 
become apparent over time. Dermatomyositis and polymyositis are, unlike inclusion body myositis, 
multi-specialty disorders, and patients with these diseases are treated by rheumatologists, 
neurologists, dermatologists, and specialists in internal medicine.  
The diagnoses of dermatomyositis and inclusion body myositis are straightforward, but diagnosing 
polymyositis is controversial. Over the past year, a dispute, primarily between rheumatologists and 
neurologists, has erupted over the diagnostic criteria for polymyositis. Rheumatologists tend to rely on 
clinical signs, symptoms, and serology, whereas neurologists rely more on histopathology in order to 
exclude other myopathies. This dispute was recently aired in the Lancet by a group of rheumatologists 
commenting on a review article on polymyositis and dermatomyositis 15, 57. Another example is an 
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article accompanied by an editorial, and the correspondence these elicited, published in Neurology in 
which the authors stated that polymyositis hardly exists 58-62.  
While rheumatologists usually use the Bohan and Peter criteria for polymyositis 3, neurologists feel a 
need to confirm the diagnosis, and to exclude other myopathies, by muscle biopsy. In their view, 
polymyositis is histologically characterised by the presence of endomysial inflammatory infiltrates 
consisting of CD8 T cells invading non-necrotic muscle fibres that express major histocompatibility 
complex class I molecules on the sarcolemma, as is shown by the criteria proposed in the recent 
Lancet review 15.    
 
 
The history examined 
 
To solve this dispute, we not only need rheumatologists and neurologists to understand each other’s 
viewpoint, but we also need to identify the source of the dispute, preferably from a historical 
perspective. We therefore examined the historical background and validity of the histopathological 
definition of polymyositis by studying the medical literature in a structured manner.  
We started with the recent Lancet review article on dermatomyositis and polymyositis 15. The authors 
write “in polymyositis, multifocal lymphocytic infiltrates surround and invade healthy muscle fibres” and 
provide six references to support this statement: four review articles and two book chapters (figure 5) 5, 
21, 63-66. We then studied the four reviews (the book chapters did not contain primary records or original 
data). All these reviews mention the presumed histological feature of polymyositis, and three of them 
provide references for this statement. In total 20 references are provided, including three of the initial 
six references 5, 18, 21, 65, 67-70, 74, 82, 124.  
Examination of all journal articles resulted in our being referred to several other articles and book 
chapters. In total, we were referred to 205 references in order to find the original source of the 
statement that polymyositis is characterised by invasion of non-necrotic muscle fibres. Several of the 
references refer to each other, resulting in 28 original references 5, 18, 21, 63-70, 74-89, 124. Only four of these 
references provide original data 67-70. The other 24 references are review articles (14), books (8), 
abstracts (1), or non-existent (1). It was remarkable that 19 of the 28 identified references were from 
just two research groups 5, 18, 21, 65, 66, 68, 70, 74, 76, 78-80, 82-84, 87-89, 124.  
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Figure 5 
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The original sources 
 
In the most recent of the four articles containing original data, Emslie-Smith et al studied the 
expression of major histocompatibility complex class I antigens, the immunolocalisation of interferon 
subtypes, and T cell mediated cytotoxicity in dermatomyositis, polymyositis, inclusion body myositis, or 
Duchenne’s muscular dystrophy, and normal controls 70. The authors found invasion of non-necrotic 
muscle fibres by inflammatory infiltrates in all diseases studied except dermatomyositis. They did not 
quantify their findings. 
In the second article Ringel et al quantitatively assessed the histopathology of 57 patients with 
myositis 69. They included patients with dermatomyositis and polymyositis diagnosed according to the 
Bohan and Peter criteria and excluded all patients with inclusion body myositis without specifying how 
these patients had been identified 3. With the exception of perifascicular atrophy, no histological 
feature could invariably distinguish the different disorders. Invasion of non-necrotic muscle fibres was 
not mentioned. 
The earliest article is a review article on the pathology of inflammatory muscle disorders and includes 
some observations made by the authors 67. The authors state that they observed “mononuclear cells 
(indenting) the cytoplasm of non-necrotic muscle cells” in eight out of 16 polymyositis patients. They 
did not provide clinical data or specify the diagnostic criteria used. 
In the fourth article, published in 1984, Arahata and Engel studied the histopathological features of 
patients with dermatomyositis, polymyositis, inclusion body myositis, scleroderma, Duchenne’s 
muscular dystrophy, and normal controls 68. They found invasion of non-necrotic muscle fibres in 
patients with Duchenne’s muscular dystrophy, dermatomyositis, polymyositis, and inclusion body 
myositis. The invasion was clearly more extensive in polymyositis and inclusion body myositis than in 
the other diseases, and the authors concluded that polymyositis (and inclusion body myositis) was 
characterised by invasion of non-necrotic muscle fibres by endomysial located inflammatory infiltrates. 
Crucial for the validity of this conclusion is how these patients were diagnosed, and especially how 
inclusion body myositis was differentiated from polymyositis.  
 
 
Arahata and Engel’s patients 
 
Although it had been described earlier, inclusion body myositis was not recognised as a distinct entity 
until the early 1980s. Until then, patients usually had been diagnosed with “treatment resistant” 
polymyositis. The “treatment resistance” reflects the most important clinical difference between 
inclusion body myositis and polymyositis: polymyositis responds to immunosuppressive and 
immunomodulatory treatment whereas inclusion body myositis does not.  
Histopathologically, inclusion body myositis can easily be mistaken for polymyositis because both 
disorders are characterised by endomysial inflammatory infiltrates with invasion of non-necrotic 
muscle fibres 42. The histological difference between inclusion body myositis and polymyositis consists 
of the presence of basophilic rimmed vacuoles, amyloid depositions, and accumulation of cytoplasmic 
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and intranuclear tubulofilamentous inclusions demonstrated under electron microscopy in inclusion 
body myositis 42. However, these typical features can be absent in the initial muscle biopsies from 
patients with inclusion body myositis, 42, 71 and the diagnosis of inclusion body myositis (as opposed to 
polymyositis) in those cases relies almost entirely on the typical clinical phenotype 42.  
Arahata and Engel’s diagnosis of myositis was “based on conventional criteria”, for which the reader is 
referred to the Bohan and Peter criteria and a review article by Whitaker 3, 72. Whitaker describes 
dermatomyositis and polymyositis, and only mentions inclusion body myositis in a classification table. 
Arahata and Engel state that all their patients with a diagnosis of inclusion body myositis had the 
typical histological findings, including vacuoles and filamentous inclusions shown by electron 
microscopy. All other cases, including those we would now identify as inclusion body myositis on the 
basis of the typical clinical phenotype (which was not fully recognised at the time the article was 
published) but without the vacuoles and filamentous inclusions, were diagnosed as polymyositis 42. It 
is thus conceivable that some of Arahata and Engel’s polymyositis patients actually had early inclusion 
body myositis.  
This is in accordance with the results of a recent study by Van der Meulen et al, which found that 
myositis patients who met the histological criterion of invasion of non-necrotic muscle fibres by 
endomysial inflammatory infiltrates all had atypical polymyositis with several clinical characteristics of 
inclusion body myositis 58.  
 
 
Conclusions 
 
Several conclusions can be drawn from our review of the medical literature: some are applicable to 
medicine in general and some to medical literature, and some are important for doctors interested in 
myositis.   
Firstly, an observation made in the past sometimes escapes reassessment of its validity even if recent 
advances in medical knowledge warrant such a reassessment. This especially seems to be the case if 
conclusions are cited in review articles and subsequent review articles cite only the first review article 
instead of the original publication. Through repetition, conclusions - even though they have become 
invalid over time - become embedded in the medical literature, the pathophysiologic concepts of 
disease, and the minds of clinicians and researchers. Using review articles as references can lead to 
authors not familiarising themselves with the original publications. The use of review articles as 
references is strongly encouraged by the editorial limitations placed on the number of references that 
authors can provide for a manuscript. By lifting the restriction on the number of references, medical 
journals will become slightly thicker, but their quality might increase significantly.  
Secondly, some authors have a strong tendency to refer to themselves. Of the 28 references found in 
our literature search, 68% were from only two research groups, one of them not providing any original 
data. This latter group referred to their own work 29 times, all being review articles and book chapters 
5, 18, 65, 66, 74, 79-85, 87, 88, 124. Such repetition affects the opinion of not only readers, but also of the authors. 
By repeating oneself, one can become convinced of the validity of one’s own statement. Furthermore, 
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admitting that one’s conclusions are incorrect becomes practically impossible because credibility and 
ego are at stake. Editorial boards of medical journals should be more critical with regard to the use of 
references, especially because they have limited their number. References should be checked for 
their validity and articles (especially review articles) should not unnecessarily refer to other review 
articles and book chapters but mainly to the original publications. We require detailed descriptions of 
the methods used for laboratory experiments, but apparently we feel no need for a detailed description 
of the sources of statements on pathophysiology and concepts of disease. 
As for the field of myositis, invasion of non-necrotic muscle fibres by endomysial inflammatory 
infiltrates is a feature of inclusion body myositis and possibly of polymyositis, but in the latter disease 
this still needs to be confirmed. Diagnostic criteria in which the presence of this histopathological 
feature is a prerequisite for a diagnosis of polymyositis are erroneous and are not based on solid 
original data. 
Myositis is a true multi-specialty disorder, and it must be recognised as such by all who deal with 
myositis patients. The current dispute can be turned into a positive development if we recognise that 
we now need to bridge the gap between dermatologists, internists, rheumatologists and neurologists. 
Internationally agreed criteria, acceptable to all, need to be developed. The recent ENMC (European 
Neuro Muscular Centre) workshop on idiopathic inflammatory myopathies is a first step in that 
direction 73. Hopefully, this initiative will be followed so that we finally can agree on diagnostic criteria 
for these enigmatic diseases.  
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Introduction 
 
The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of disorders characterized 
by an acquired muscle weakness and the presence of inflammatory infiltrates in skeletal muscle tissue 
5. The main disorders within the group of IIM are dermatomyositis (DM), polymyositis (PM), and 
inclusion body myositis (IBM) 5. The pathogenesis of these disorders is unknown. In all three diseases 
there is an abnormal immune response, which seems to be primary in DM and PM and secondary in 
IBM 90, 124. As part of the abnormal immune response, autoantibodies can be found in the sera of most 
patients with IIM 134. Many of these autoantibodies are not specific for IIM and are also encountered in 
patients with other autoimmune diseases without myositis. These myositis-associated autoantibodies 
are not discussed here. We will deal with autoantibodies that are specific for myositis (myositis-
specific autoantibodies [MSAs]) and are found in approximately half the patients with IIM.  
 
Ever since the first description of the anti-Jo-1 autoantibody in 1980, the MSAs have played an 
important role in myositis research 91. Disease-specific autoantibodies were discovered for a group of 
disorders that were barely understood and it was thought that the MSAs were the touchstone for 
understanding IIM 132. Soon more MSAs were discovered, although all were less prevalent than anti-
Jo-1. It became clear that specific types of MSAs were associated with specific clinical syndromes 
within the spectrum of IIM and as a result, new classification systems were proposed based on the 
presence of specific MSAs 129.  
 
 
Overview of myositis specific autoantibodies 
 
Although the MSAs are specific for the muscle disorder myositis, the targeted antigens are not specific 
for muscle tissue. Most MSAs are directed against cytoplasmic RNA-protein (ribonucleoprotein) 
complexes which are present in all cells and in most cases are involved in the process of protein 
synthesis 124, 139. The targeted antigens include several aminoacyl-tRNA-synthetases, tRNAs, 
components of the signal recognition particle, translation factors, and components of a nucleosome 
remodeling complex 121, 122, 130, 131, 133, 137, 138, 141, 151. Why these antigens are targeted by the immune 
response in IIM is unknown. It is also not known whether the MSAs play a role in the pathophysiology 
of IIM or whether they are merely an epiphenomenon.  
 
Several clinical and epidemiological studies have shown that MSAs are associated with specific 
clinical characteristics 37, 129. Some of these associations are well-defined and are of clinical 
significance (eg, anti-Jo-1 and the antisynthetase syndrome, reviewed in 92, 129, 132, 143; others are 
questionable and can cause unnecessary anxiety for both patients and physicians (eg, anti-SRP and 
cardiac complications 129, 153). Table 10 gives an overview of the MSAs and their clinical associations. 
 
 





	

	



 
Table 10: M
yositis specific autoantibodies 
 
 
 
 
 
 
 
 
 
 
 
M
S
A 
Antigen 
Frequency
† 
C
linical association 
 
 
 
 
 
 
A
nti-am
inoacyl-tR
N
A
 synthetases 
 
 
 
 
anti-Jo-1 
tR
N
A
hissynthetase 
11-20%
 
anti-synthetase syndrom
e* 
 
anti-PL-7 
tR
N
A
thrsynthetase 
2%
 
anti-synthetase syndrom
e* 
 
anti-PL-12 
tR
N
A
alasynthetase 
1%
 
anti-synthetase syndrom
e* 
 
anti-EJ 
tR
N
A
glysynthetase 
1-3%
 
anti-synthetase syndrom
e* 
 
anti-O
J 
tR
N
A
ilesynthetase 
1%
 
anti-synthetase syndrom
e* 
 
anti-KS 
tR
N
A
aspsynthetase 
<1%
 
anti-synthetase syndrom
e* 
 
 
 
 
 
 
A
nti-tR
N
A
 
 
 
 
 
anti-tR
N
A
his 
tR
N
A
his 
7%
 
anti-synthetase syndrom
e* 
 
anti-tR
N
A
ala 
tR
N
A
ala 
1%
 
anti-synthetase syndrom
e* 
 
 
 
 
 
 
M
iscellaneous 
 
 
 
 
anti-SR
P 
SR
P-com
plex 
4%
 
PM
 w
ith poor response to treatm
ent and relative high m
ortality  
 
anti-M
i-2 
nuclear helicase 
4-14%
 
classic D
M
 w
ith good response to treatm
ent, occurs in 10%
 of P
M
 patients  
 
anti-FER
 
elongation factor 1
∝
 
<1%
 
- 
 
anti-KJ 
unknow
n protein 
<1%
 
- 
            † frequency in sera from
 patients w
ith IIM
. * m
yositis w
ith arthritis, idiopathic interstitial lung disease, and R
aynaud phenom
enon. A
bbreviations used: M
S
A
: m
yositis  
       specific autoantibody; S
R
P
: signal recognition particle; P
M
: polym
yositis; D
M
: derm
atom
yositis. 
	
	

	

	

Anti-aminoacyl-tRNA-synthetases 
The most prevalent MSAs are directed against aminoacyl-tRNA-synthetases (ARS) (figure 6). These 
cytoplasmic enzymes catalyze the binding of an amino acid to its cognate tRNA. In patients with IIM, 
autoantibodies can be found against ARS specific for histidine (Jo-1), threonine (PL-7), alanine (PL-
12), glycine (EJ), asparagine (KS), and isoleucine (OJ) 122, 130, 131, 137, 151. OJ is part of a multi-enzyme 
complex with synthetase specificity for 9 amino acids 149. In some patients with anti-OJ autoantibodies, 
antibodies can be found against lysyl-tRNA-synthetase and probably also leucyl-tRNA-synthetase, 
both components of the same enzymatic complex 149. 
 
Autoantibodies against ARS (anti-ARS) are found in 16-26% of patients with IIM 125, 128, 129. The anti-
Jo-1 autoantibody is the most prevalent and is found in 11-20% of IIM patients 125, 128, 129. The other 
autoantibodies within this group are only present in 1-3% of patients with IIM 125, 128, 129.  
 
The presence of anti-ARS is strongly associated with the antisynthetase syndrome. This syndrome 
consists of myositis (DM or PM), idiopathic interstitial lung disease, arthritis and Raynaud 
phenomenon 92, 125, 128, 129, 143. There is also a frequent occurrence of unexplained fever and 
mechanic’s hands 125, 129.   
 
Anti-tRNA 
In some patients with anti-Jo-1 or anti-PL-12 autoantibodies, antibodies directed to the cognate tRNA 
can be found also. Anti-tRNAAla is detected in the sera of most patients with anti-PL-12  and anti-
tRNAHis is present in approximately a third of patients with anti-Jo-1 121, 122. The antigenic determinants 
on these tRNAs differ considerably. In the case of tRNAAla the epitope is formed by modified 
nucleotides within the anticodon loop structure, whereas in the case of tRNAHis the D- and T-loop 
structures appeared important 115, 121. Clinically, these MSAs are associated with the anti-synthetase 
syndrome as described above. 
 
Anti-SRP 
The signal recognition particle (SRP) is a cytoplasmic ribonucleoprotein complex consisting of one 
small RNA (7SL RNA) and 6 proteins (SRP 9, 14, 19, 54, 68, and 72). The SRP-complex is involved in 
the cotranslational transport of proteins to the endoplasmic reticulum 152. Anti-SRP autoantibodies 
(anti-SRP) are present in about 4% of IIM patients and are most frequently directed at the SRP 54 
protein 120, 125, 128, 129, 133, 153, 166. Anti-SRP is mainly seen in PM 120, 125, 128, 129, 133, 153, 166. In larger cohorts 
of patients, the prevalence of anti-SRP is 7-9% in PM versus 2-3% in DM and IBM 128, 129. 
 
Several studies have reported an association between anti-SRP and cardiac involvement, a poor 
response to immunosuppressive treatment, and a high mortality rate 125, 128, 129, 153. This association is 
less convincing than that between anti-Jo-1 and the antisynthetase syndrome because of the small 
number of anti-SRP-positive patients in these studies and the variation in clinical definitions used.   
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Figure 6: Structure and cellular location of the major autoantigens (Jo-1, Mi-2, and SRP) 
targeted by myositis specific autoantibodies (Adapted with permission 114). 
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The presumed association between cardiac involvement and anti-SRP is based on two studies with a 
total of 20 patients with anti-SRP 129, 153. Eleven patients from this group reported palpitations but no 
further investigations were conducted. All were on high-dose steroids at the time of the study. Only in 
one patient was a cardiomyopathy diagnosed 153.  
  
The poor response to immunosuppressive treatment in anti-SRP-positive patients has also not been 
proven unequivocally. Some reports merely state that patients required continuous 
immunosuppression without specifying types of drugs, dosages, and degree of response 125, 128. 
Others conclude that there is a relative resistance to immunosuppression because most of the 
patients used cytotoxic drugs like methotrexate or azathioprine 153. The use of methotrexate or 
azathioprine in IIM is part of good clinical practice because of the steroid-reducing effect, and can not 
automatically be interpreted as a sign of therapy resistance. Only one study has shown that anti-SRP-
positive patients may indeed have a less favorable response to immunosuppression 129. In this study it 
was shown that none of the anti-SRP positive patients (n=7) were ever without immunosuppressive 
drugs and that they experienced significantly more relapses during dosage reductions.  
 
The presumed association between anti-SRP and a high mortality rate is based on two studies 129, 153. 
One study reports that 2 out of 13 patients had died, without mentioning the time or cause of death 153. 
Mortality figures are only presented in the paper by Love et al. 129. In their study, 5 out of 7 patients 
died as a result of myositis complications within 5 years after the diagnosis IIM. 
 
Anti-Mi-2 
The only well-described MSA directed against a nuclear antigen is anti-Mi-2 138. Mi-2 is a 220 kD 
protein, which is part of a proteinaceous complex containing histone deacetylase and ATP-dependent 
nucleosome remodeling activities 141. Acetylation and deacetylation modulates the binding between 
DNA and histones and can thus allow or prevent gene transcription 141. 
 
Autoantibodies against Mi-2 (anti-Mi-2) are present in 4-14% of patients with IIM 120, 125, 129, 138.  Most 
patients with anti-Mi-2 have DM. Anti-Mi-2 has only been described in two PM patients and never in 
IBM 138. For this reason, anti-Mi-2 is primarily seen as a DM specific autoantibody, occuring in 13-21% 
of DM patients 120, 125, 129, 138. Most anti-Mi-2-positive patients have a good response to 
immunosuppressive treatment. Anti-Mi-2 is not associated with any specific clinical characteristic 
besides the dermatomyositis rash.  
 
Other myositis-specific antibodies 
In a small number of patients, autoantibodies are found to other cytoplasmic antigens involved in the 
process of protein synthesis. Because of the rare occurrence of these autoantibodies, their specificity 
and potential associations with clinical characteristics are unknown. Examples of these very rare 
MSAs are anti-KJ, a 30-34 kD protein which may function as a translation factor, and anti-FER 
directed to the 48 kD elongation factor 1-alpha 92, 93, 143.      
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Recent developments  
 
Epidemiological studies and clinical associations 
Schmidt et al. examined the occurrence of anti-Jo-1 autoantibodies in a large population of patients 
with a suspected inflammatory connective tissue disease 94. Patients with a suspected inflammatory 
connective tissue disease from two rheumatology clinics and one pulmonology clinic were screened 
for anti-Jo-1 autoantibodies by enzyme-linked immunosorbent assay (ELISA). Positive responses to 
Jo-1 were confirmed by immunodiffusion and/or immunoblotting. A total of 25 anti-Jo-1 positive sera 
could be identified; ten of them could not be confirmed by immunodiffusion or immunoblotting. All 
patients with a confirmed positivity for anti-Jo-1 had the antisynthetase syndrome. Only three of the 10 
patients with merely a positive ELISA had the antisynthetase syndrome. All three showed high titers in 
the ELISA test. The other 7 patients, without the antisynthetase syndrome, had low titers in the ELISA 
test, and none of them had myositis. This study thus supports a previous recommendation of Charles 
et al. that an ELISA test is an ideal test for screening but that confirmation by a second method (eg, 
immunodiffusion or immunoblotting) is necessary 95. Because the clinical picture of the antisynthetase 
syndrome is rather variable, especially at the onset of the disease, Schmidt et al. recommend routine 
screening for anti-Jo-1autoantibodies. In clinical daily practice this would mean that the ELISA-test for 
Jo-1 would be carried out very frequently and would only rarely turn out positive (Schmidt et al. had 
only 25 positive Jo-1 results for three centers over a period of five years). It would make more sense to 
reserve the test for patients with one of three key-symptoms of the antisynthetase syndrome: myositis, 
idiopathic interstitial lung disease, or arthritis.    
 
New autoantibodies in myositis 
Kajihara et al. described the detection of anti-Wa autoantibodies in two patients with a clinical picture 
resembling the antisynthetase syndrome 96. Clinically, the anti-Wa antibody seems of little significance 
because of the very small number of myositis patients who have this autoantibody and because it is a 
myositis-associated antibody (it occurs more frequently in patients with systemic sclerosis) 97.  
 
Casciola-Rosen et al. reported that the anti-PMS-1 autoantibody, directed against a DNA mismatch 
repair enzyme, is specific for myositis 98. In a large study, sera from 51 patients with IIM,  50 patients 
with systemic lupus erythematosus (SLE), 44 patients with scleroderma, and 39 healthy controls were 
screened for the presence of anti-PMS-1. The antibody was found in 4 of the IIM patients (8%). The 
antibody was not detected in any of the SLE or scleroderma patients nor in the healthy controls. 
Interestingly, all anti-PMS-1 positive patients had also autoantibodies directed to other DNA mismatch 
repair enzymes or other proteins involved in DNA repair and remodeling, such as PMS-2, MLH-1, poly 
(ADP-ribose) polymerase, DNA-dependent protein kinase, and Mi-2. The authors also showed that 
these nuclear autoantigens can be efficiently cleaved by granzyme-B, a protease injected into cells 
that are targeted by cytotoxic T-cells. It is hypothesized that the unique fragments which are generated 
from autoantigens during cell death (and often are chemically modified) could trigger the initial immune 
response responsible for the generation of autoantibodies (reviewed in 99, 100).  
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Heegaard et al. identified autoantibodies to the C1 and C2 heterogeneous nuclear ribonucleoproteins 
in three patients, one of them having a long-standing PM and psoriasis 101. This paper is relevant 
because the authors used a rather novel technique, ie, mass spectrometric analysis of the 
immunoprecipitated proteins after seperation by two-dimensional gel electrophoresis, to characterize 
the autoantigen. This upcoming technique should also allow the analysis of minute amounts of 
autoantigens in the disease-affected tissue and allow the identification of possible modifications of the 
autoantigen. Because the generation of autoantibodies is probably a local process, the use of this 
mass spectrometric technique might create new possibilities to elucidate why autoantibodies are made 
and why they are disease specific.  
       
Pathophysiology 
Nagaraju et al. demonstrated that the conditional upregulation of major histocompatibility complex 
(MHC) I in skeletal muscle can lead to anti-Jo-1 positive myositis 102. A controllable muscle-specific 
promoter system was used to upregulate MHC class I in the skeletal muscles of young mice. All mice 
developed a myopathy with the clinical, biochemical, and histological characteristics of PM. 
Interestingly, 35% of these “myositis” mice had anti-Jo-1 autoantibodies, versus none in control mice. 
None of the animals had any other feature of the antisynthetase syndrome. Besides providing an 
excellent animal model for the study of myositis and MSAs, this study suggests that the upregulation 
of MHC class I antigens precedes the occurrence of the clinical and histological characteristics of 
myositis. A case-report of a female patient who developed myositis as a side effect of interferon-α 
treatment (interferon-α causes MHC class I upregulation) provides evidence that this process may 
also occur in human skeletal  muscle tissue 103. 
 
One of the major questions in MSA research is: why is Jo-1 autoantigenic in myositis? 
Although many autoantigens are ubiquitously expressed, they often show restriction with respect to the 
autoimmune disease in which they are autoantigenic. Jo-1 is a prime example of this. There are 20 
aminoacyl-tRNA synthetases in every cell in the human body, but only the histidine-tRNA synthetase (Jo-
1) is a major autoantigen, targeted by autoantibodies in only one disease, that is myositis. To understand 
why this is the case, we first have to understand the etiology of autoimmunity in general. 
 
The factors that are known to be involved in the etiology of systemic autoimmune disorders, including 
myositis, can be subdivided into at least three groups: hormonal, genetic, and environmental. The fact that 
women have an approximately threefold higher chance than men of developing an autoimmune disorder 
is a clear indication that sex hormones play an important role. In addition, several genetic factors have 
been shown to be involved in the development of autoimmunity, including MHC class II. Environmental 
factors that may affect the development of systemic autoimmunity include ultraviolet light, mercury 
intoxication, and several immunomodulatory drugs. Although all these factors can be involved in the 
development of autoimmunity, the primary cause of these diseases remains unclear. In the past, several 
hypotheses have been proposed. For example, the molecular mimicry model implies that immune 
responses directed to non-self-proteins (eg, of viral origin) may spread to autoantigens that resemble 
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these non-self-proteins, thus triggering an autoimmune response (reviewed in 104). An alternative model 
hypothesizes that anti-idiotypic antibodies may be involved in the generation of autoimmunity, eg, 
antibodies directed against a viral protein that interacts with a host receptor may induce anti-idiotypic 
antibodies that also recognize the host receptor, thus initiating an autoimmune response 105. One recent 
and very attractive hypothesis is the idea that certain self-proteins become modified (for example, 
during a localized apoptotic process or as a result of a local inflammatory or infectious process) and 
that such modified self-proteins are recognized as non-self by the immune system. The subsequent 
immune reaction might, via epitope spreading, evolve into a full-blown immune reaction directed to the 
whole protein, including the non-modified parts (reviewed in 99, 100, 106). The consequence of this 
hypothesis in the case of Jo-1 would be that (part of) the Jo-1 protein in the muscle tissue of the 
myositis patient is modified. This still remains to be proven. 
 
The basis of the “modified self” hypothesis is that the change from self to modified self (= non-self) 
occurs locally, in the diseased tissue. A very instructive example of this idea can be found in research 
on rheumatoid arthritis (RA). Some years ago it was discovered that patients with RA produce 
autoantibodies directed to citrullinated antigens 107. Anticitrulline antibodies in RA are 98% specific and 
are detectable in at least 80% of the patients 107, 160. They are present very early in disease and high 
titers of these antibodies point to erosive disease (reviewed in 108-110). Citrulline is a deiminated form of 
arginine, but the enzymes (PAD, peptidylarginine deiminase) that catalyzes the citrullination of 
arginine in proteins is normally not active. It becomes, however, activated during the final stages of 
differentiation of epithelial cells or during apoptosis of some types of cells. For yet unknown reasons, 
peptidylarganine deiminase becomes activated in the inflamed synovium of patients with RA, which 
results in the citrullination of synovial fibrin and possibly some other proteins 111-113. The modification of 
these self-proteins could trigger the breaking of tolerance and initiate the specific autoimmune 
response to citrullinated proteins in patients with RA. 
 
From this example it is clear that modification(s) of self-proteins may lead to autoimmunity. Following 
this line of thinking, the autoimmune reaction directed to Jo-1 in myositis patients might be initiated by 
an aberrant modification of Jo-1 (and not of the other tRNA synthetases), and might only occur in the 
diseased muscle and not in tissues which are not relevant for the disease. 
 
 
Conclusions 
 
Although our knowledge on the biochemical nature of the autoantigens has increased considerably in 
the past 20 years, we are still no closer to unraveling the pathogenesis of IIM. In daily clinical practice 
only anti-Jo-1 has proven its usefulness by defining the antisynthetase syndrome. The other MSAs are 
more rarely encountered, which makes significant clinical correlations difficult. It therefore would make 
sense to combine efforts of many clinics and laboratories (worldwide if necessary) so that significant 
numbers of patients can be studied. 
           Chapter Six
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Introduction 
 
The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic diseases 
characterised by progressive proximal muscle weakness, elevated serum creatine kinase, 
characteristic electromyographic abnormalities, and inflammatory infiltrates in skeletal muscles 5, 21. 
The three major categories of IIM are dermatomyositis (DM), polymyositis (PM), and inclusion body 
myositis (IBM) 5.  
Various autoantibodies against nuclear and cytoplasmic antigens are found in up to 89% of patients 
with IIM 134. Most of these autoantibodies, referred to as myositis associated autoantibodies (MAAs), 
are not specific for IIM and are also frequently encountered in rheumatic disorders without the 
presence of myositis. A subset of patients has unique autoantibodies which are specific for IIM (table 
11). Most of these myositis specific autoantibodies (MSAs) bind to cytoplasmic ribonucleoproteins 
involved in the process of translation 124, 139. The known autoantigens include five aminoacyl-transfer 
RNAs 122, 130, 131, 137, two transfer RNAs 121, 122, proteins of the signal recognition particle 133, and a 220 
kDa protein in a nuclear protein complex containing histone deacetylase and nucleosome remodelling 
activities 138, 141. So far, epidemiological and clinical studies suggest that each type of MSA defines a 
unique IIM syndrome that differs from others in clinical manifestation, disease severity, response to 
immunosuppressive treatment, prognosis, epidemiological features, and immunoregulation 37, 129, 132.  
Although our knowledge of MSAs has increased tremendously since their first description, there are 
still many questions concerning their clinical applicability that remain unanswered. First of all, while 
some of the MSA defined syndromes are based on solid grounds (e.g. anti-Jo-1), others are highly 
questionable because they are based on a very small number of patients and the characteristics with 
which they are associated are very poorly defined (e.g. anti-SRP). Secondly, different diagnostic 
criteria have been used in the different studies making comparison of data very difficult. Some studies 
used the Bohan and Peter criteria which do not distinguish between PM and IBM 120, while others used 
more recent criteria which do recognise IBM as a separate diagnosis 129. Thirdly, the prevalence of 
MSAs in IIM may vary between geographical regions because of differences in genetic background 
and/or exposure to environmental factors between different populations 127. Therefore, data from 
previous studies cannot automatically be applied to the West-European population. In order to answer 
some of these questions we clinically evaluated, systematically and prospectively, 125 Dutch patients 
with IIM and subsequently tested their sera for the presence of MAAs and MSAs by immunoblotting, 
enzyme-linked immunosorbent assay (ELISA), and immunoprecipitation.  
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Table 11: Characteristics of myositis specific autoantibodies according to the literature 121, 129, 132, 141. 
 
    
MSA antigen frequency† clinical characteristics 
    
anti-aminoacyl tRNA    
    anti-Jo-1 tRNAHis synthetase 20% anti-synthetase sindrome* 
    anti-PL-7 tRNAThr synthetase 2% anti-synthetase sindrome* 
    anti-PL-12 tRNAAla synthetase <1% anti-synthetase sindrome* 
    anti-EJ tRNAGly synthetase 3% anti-synthetase sindrome* 
    anti-OJ tRNAIle synthetase 1% anti-synthetase sindrome* 
anti-tRNA    
    anti-tRNAHis tRNAHis  7% - 
    anti-tRNAAla tRNAAla  - anti-synthetase sindrome* 
miscellaneous    
    anti-SRP SRP-complex 3% severe PM with myalgia, cardiac  
Involvement and poor response 
    anti-Mi-2 unidentified protein 5% classic mild DM, good response  
† Frequency in sera from myositis patients, * severe myositis with arthritis, Raynaud’s phenomenon, 
interstitial lung disease, and a moderate response to treatment 
 
 
Patients and Methods 
 
Patients and patient evaluation 
One hundred and twenty-five adult patients with IIM, seen between 1995-1997 at the Neuromuscular 
Centre Nijmegen of the Radboud University Nijmegen Medical Centre, were clinically and serologically 
evaluated. The study was approved by the Ethics Committee of the Radboud University Nijmegen 
Medical Centre and informed consent was obtained prior to inclusion. Patients were classified 
according to the classification scheme by Bohan and Peter, as modified by Cronin et al. 3, 123. 
Diagnoses were made according to established criteria 5, 140. The studied patient population consisted 
of 31 patients with DM, 41 with PM, 28 with IBM (14 definite IBM, 13 probable IBM, 1 possible IBM), 
19 with myositis associated with another rheumatic disorder (CTM; 6 with DM, 13 with PM), 3 with 
myositis associated with malignancy (CAM; 1 with DM, 2 with PM), and 3 with a miscellaneous IIM 
diagnosis (including orbital myositis and granulomatous myositis). Clinical data were obtained by a 
standardised history taking and physical examination of the patients, and by reviewing their charts. 
Data were recorded on a standardised format and included: demographic data, symptoms and signs, 
presence of associated disorders, levels of muscle-associated enzymes at peak severity, results of 
EMG studies and muscle biopsies (including HLA-ABC and CD4/CD8 staining, and in some cases 
electromicroscopic studies), and therapeutic experiences. Treatment response was classified as 
complete (total recovery without clinical evidence of active disease), partial (evidence of clinical 
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improvement short of a complete response), or none (no evidence of clinical improvement). 
Immunosuppressive treatment consisted most frequently of corticosteroids, azathioprine and/or 
methotrexate.    
 
Serological assays 
Sera were tested for the presence of following autoantibodies: anti-Jo-1, anti-tRNAHis, anti-Mi-2, anti-
SRP, anti-Ro52, anti-Ro60, anti-La, anti-PM/Scl75, and anti-PM/Scl100. 
 
Anti-Jo-1 and anti-tRNAHis - Anti-synthetase autoantibodies were detected by immunoprecipitation (IP) 
using HeLa cell S100 extract as described previously 121. Anti-Jo-1 autoantibodies were distinguished 
from other anti-synthetase autoantibodies by performing additional immunoblotting and ELISA 
analyses as described previously 135. All anti-Jo-1 sera were positive in both IP and ELISA or 
immunoblot. In addition, anti-synthetase positive sera were analysed for the presence of anti-tRNA 
autoantibodies by IP using total RNA from a deproteinised HeLa cell S100 extract as described 
previously 121. 
 
Anti-Mi-2 - Presence of anti-Mi-2 autoantibodies was determined by ELISA. Four overlapping 
fragments (NT, aa 1-679; NM, aa 475-970;M, aa 635-1294; CT, aa 1235-1912), spanning the 
complete amino acid sequence of the Mi-2β autoantigen, were used. The cDNAs of NT, M, and CT 
were synthesised essentially as described for fragment NM and ligated into an in house modified 
pEX34 expression vector containing only 10 amino acids of the vectors MS2 polymerase fusion 
protein 136. Proteins were expressed in transformed E. coli 537 cells and purified by Ni2+-affinity 
chromatography followed by preparative SDS-PAGE. With 0.2 µg/well of each of the proteins, medium 
binding microtiter plates (Greiner, Nürtingen, Germany) were coated as described 136. Antibody 
screening was performed with 200 µl of diluted serum samples (1:100 in 20 mM Tris-HCl pH7.4, 150 
mM NaCl, 0.05% NaN3, 0.05% Tween-20, 2.5% bovine serum). After incubation (30 minutes, 370C) 
and washing (3 times with PBS, 0.01% Tween-20) plates were incubated (30 minutes, 370C) with 200 
µl/well of alkaline phosphatase-conjugated AffiniPure Fcγ-fragment specific goat anti-human IgG 
(Jackson Laboratories, West Baltimore Pike, USA) diluted 1:2000 in 20 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 0.5% BSA, 0.05% Tween-20, 1 mM MgCl2, 0.1 mM Zn-acetate, 0.05% NaN3. Bound antibodies 
were visualised with 38 mM disodiumparanitrophenyl-phosphate, 50 mM diethanolamine pH 9.8, 1 
mM MgCl2, 0.05% NaN3. The enzyme reaction was stopped by adding 50 µl 3N NaOH. ODs were 
measured bichromatically at 492 nm/620 nm (Titertek Multiscan MCC340 Mkll; Flow, Meckenheim, 
Germany). Tests were regarded positive at ≥2.5 fold ODs compared to that of three negative control 
sera. Positive and negative controls as well as patients sera were run in duplicate on every test plate.  
Anti-SRP – Immunoprecipitations were performed as previously described 121. Immunoprecipitated 
RNA recovered after phenol/chloroform extraction was spotted on Hybond N+ membranes 
(Amersham, United Kingdom). After drying and UV crosslinking, the dotblots were hybridised with an 
antisense RNA probe in (pre)hybridisation mix (6x SSC, 5x Denhardt’s, 0.1% SDS, 100 µg/ml 
sheared, denatured herring sperm DNA). After overnight incubation at 650C, membranes were washed 
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three times with 0.1x SSC/0.1% SDS at 650C and exposed to Kodak X-Omat AR imaging film 
(Eastman Kodak, Rochester, NY). Antisense RNA probes were in vitro transcribed in the presence of 
32P-UTP from linear templates. To detect anti-SRP reactivity, a 7SL cDNA/pSP64 construct, kindly 
provided by dr. K. Strub (University of Geneva, Switzerland), was used. Antisense 7SL RNA probe 
was in vitro transcribed from the EcoRI linearised template by SP6 RNA polymerase. 
      
Anti-Ro52, anti-Ro60, anti-La – Expression and purification of the Ro52, Ro60, and La autoantigens 
and corresponding ELISAs were performed as described previously 135. 
 
Anti-PM/Scl – The presence of anti-PM/Scl75 and anti-PM/Scl100 autoantibodies was determined by 
ELISA. For synthesis of the PM/Scl proteins cDNAs from HEpG2 cell RNA (ATCC HB 8065) were 
constructed according to their sequence data (PM/Scl-75: Acc. No. M58460; PM/Scl-100: Acc. No. 
X66113) and processed essentially as described above for Mi-2 protein synthesis and purification. 
Each protein (0.4 µg/well of PM/Scl-75 and 0.2 µg/well of PM/Scl-100) was coated on microtiter plates. 
Coating, blocking, and assay performance followed the Mi-2 autoantibody protocols. 
 
Statistical analysis 
Discontinuous grouped data were analysed by chi-square frequency distribution. Fisher’s exact test 
was used in cases of a predicted frequency ≤2. Continuous data were analysed using the Wilcoxon-
Mann-Whitney test. A p-value <0.05 was considered statistically significant. Patients whose data for a 
particular valuable were not available were excluded from the analysis of that variable, and the 
number used for the calculation of percentages was adjusted accordingly.  
 
 
Results 
 
Myositis specific autoantibodies 
MSA’s were detected in 32% of the sera. The most frequently encountered MSA was the anti-Jo-1 
autoantibody which was present in 20% of the patients. Anti-Mi-2 autoantibodies were present in 6%, 
anti-SRP in 4%, and anti-tRNAHis autoantibodies in 6% of the patients. Data from patients with anti-Jo-
1, anti-Mi-2, or anti-tRNAHis autoantibodies and from patients without MSAs (MSAneg) were statistically 
analysed.  
 
Diagnosis (figure 7,8) – MSAs were hardly ever encountered in IBM (figure 7). Only three IBM patients 
had a MSA (1 with anti-Jo-1, 2 with anti-Mi-2). All three were atypical cases. The patient with the anti-
Jo-1 autoantibody was diagnosed with a definite IBM according to the criteria of Verschuuren et al. 140. 
The patient improved significantly (clinically, chemically, and electrophysiologically) on corticosteroids. 
Of the two patients with anti-Mi-2 autoantibodies, one had a probable IBM with Sjögren’s syndrome 
and the second had a probable IBM with rheumatoid arthritis. Both demonstrated some improvement 
on immunosuppressive therapy. Anti-Jo-1 autoantibodies were more frequently seen in CTM than in 
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DM or PM but this did not reach statistical significance. Anti-Mi-2 and anti-SRP were seen in DM as 
well as in PM patients. Anti-tRNAHis autoantibodies were seen significantly more frequent in CTM than 
in DM. With the exception of anti-tRNAHis autoantibodies, which were only found in the presence of 
anti-Jo-1 autoantibodies, no patient had two types of MSA. MSAs were not found in patients with a 
miscellaneous IIM diagnosis, and only in one patient with CAM (anti-SRP). 
 
 
 
 
 
 
0%
10%
20%
30%
40%
50%
total Jo-1 Mi-2 tRNAhis SRP
IBM 
 CTM 
  DM 
PM 
Figure 7: Prevalence of myositis-specific autoantibodies per IIM diagnosis.
Numbers given in percent of patients. Abbreviations used: CTM: myositis
with another rheumatic disorder; DM: dermatomyositis; PM: polymyositis;
IBM: inclusion body myositis.   
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Demographic data (table 12) – There were no differences found in the age of onset, disease duration, 
time interval between clinical onset and time of diagnosis and month or season of onset between the 
different MSA groups. The sex ratio (female:male) of the Mi-2 and tRNAHis group tended to be lower 
than that of the Jo-1 and MSAneg group. 
 
Clinical characteristics (table 12) – Patients with anti-Jo-1 autoantibodies had significantly more often 
fevers, Raynaud’s phenomenon, dry mouth/eyes, arthralgia, arthritis, myalgia, dyspnoea and 
rheumatic disorders than patients without MSAs. They also tended to have more frequent interstitial 
lung disease and a subacute disease onset. In general, patients with anti-tRNAHis autoantibodies had 
comparable characteristics as those with just anti-Jo-1 autoantibodies. They exhibited more often 
carpal tunnel syndrome (CTS) than patients without MSAs. Patients with anti-Mi-2 autoantibodies had 
more weight loss compared to patients with anti-Jo-1 autoantibodies and significantly more often dry 
 
Figure 8: Prevalence of myositis-associated autoantibodies per IIM diagnosis. 
Numbers given in percent of patients. Abbreviations used: CTM: myositis with
another rheumatic disorder; DM: dermatomyositis; PM: polymyositis; IBM:
inclusion body myositis. 
0%
10%
20%
30%
40%
50%
60%
70%
total Ro52 Ro60 La PMScl75 PMScl100
   CTM 
 DM 
 PM 
IBM 

	
Table 12: Clinical characteristics per serologic group. 
 
 
 
characteristic serologic group statistical significant difference 
      
 Jo-1 
n=25 
tRNAHis 
n=8 
Mi-2
n=7 
MSAneg 
n=87 
 
demographic data      
  age at onset (years) 40.6 41.7 55 47.9 - 
  sex (F:M) 3.4:1 1.3:1 1.3: 2.7:1 - 
disease onset      
  subacute 59 75 50 34 Jo-1 vs MSAneg1 
  insidious 29 25 40 62 Jo-1 vs MSAneg4 
signs and symtoms        
  fever 35 0 10 12 Jo-1 vs MSAneg3 
  weigth loss 0 0 40 34 Jo-1 vs Mi-24, MSAneg6  
  dry mouth/eyes 39 50 20 10 Jo-1 vs MSAneg5  Mi-2 vs MSAneg3 
  Raynaud’s 53 60 30 19 Jo-1 vs MSAneg5 
  arthralgia 89 75 30 33 Jo-1 vs Mi-26, MSAneg7 
  myalgia 83 75 60 45 Jo-1 vs MSAneg6
  arthritis 69 80 20 9 Jo-1 vs Mi-23, MSAneg7  
     tRNAhis vs Mi-21, MSAneg7 
  atrophy 21 20 40 33 Jo-1 vs MSAneg2
  unexpected falling 0 0 0 23 Jo-1 vs MSAneg4
  dyspnoea 61 75 20 34 Jo-1 vs Mi-22, MSAneg2 
  chest pain 11 25 20 2 -
  oedema 22 25 10 5 Jo-1 vs MSAneg1
  CTS 17 50 0 7 tRNAhis vs MSAneg1 
associated disorders      
  interstitial lung disease 33 50 10 17 - 
  rheumatoid disorders 30 40 10 7 Jo-1 vs MSAneg4
lab. investigations      
  creatine kinasea 2411 2547 221 1389 - 
  normal EMG 21 50 18 2 Jo-1 vs MSAneg4 , tRNAhis vs MSAneg5
treatment response      
  complete 28 25 10 13 - 
  partial 72 75 60 68 - 
  none 0 0 30 18 - 
Numbers given in percent of patients. a creatine kinase upon presentation in U/l. Adjusted p values: 1, 
p<0.05;  2, p<0.04; 3, p<0.03;  4, p<0.02;  5, p<0.01; 6, p<0.005; 7, p<0.0005 
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mouth/eyes and chest pain than patients without MSAs. In all anti-Mi-2 positive patients the chest pain 
was atypical and there were no clinical signs of coronary heart disease or cardiomyopathy.    
Creatine kinase levels tended to be lower in the group without MSAs compared to those in the  
anti-Jo-1, anti-tRNAHis, and anti-Mi-2 group. The other muscle-associated enzymes exhibited a similar 
difference. A normal EMG was significantly more frequently seen in patients with anti-Jo-1 and anti-
tRNAHis autoantibodies than in patients without MSAs.  
There were no significant differences found in responses to immunosuppressive treatment between 
the different MSA groups. Patients with MSAs tended to have a slightly better response than patients 
without MSAs. 
 
Anti-SRP – Autoantibodies to SRP were found in five patients, four with PM and 1 with DM. Four of 
the five patients were women, and one was diagnosed with breast cancer at the time of diagnosis of 
myositis. All patients had general signs of systemic disease, severe myalgia and arthralgia, a disease 
onset after the age of 40 years, creatine kinase levels between 5.000 and 10.000 U/l, and a moderate 
response to immunosuppressive treatment. Cardiac involvement, investigated by clinical examination 
and laboratory investigations including electrocardiography and CKMB-ratios, was absent in all five. 
Two patients died within a year of diagnosis, one with pulmonary complications and one with the 
complications of her cancer. 
 
Myositis associated autoantibodies 
MAAs were found in all diagnostic groups, including IBM (figure 8). Anti-Ro52 autoantibodies occurred 
significantly more frequent in patients with anti-Jo-1 or anti-tRNAHis autoantibodies than in patients 
without MSAs (74% and 62% respectively versus 14%). No associations were found between MAAs 
and specific demographic data or clinical characteristics. 
 
 
Discussion 
 
The prevalence of MSAs and MAAs in this study was comparable to those in other large series (table 
13) 120, 125, 128, 129. Clinical differences between patients with and without MSAs could in part be 
explained by the fact that almost all IBM patients, with their distinct clinical phenotype, were included 
in the latter group. This explained partially the virtual lack of symptoms of systemic disease, the lower 
levels of muscle-associated enzymes, and the worse response to treatment in the group without 
MSAs.  
The presence of the anti-Jo-1 autoantibody was clearly associated with the anti-synthetase syndrome: 
Raynaud’s phenomenon, arthritis, myalgia, and interstitial lung disease.  
Autoantibodies against tRNAHis only occurred, as previously described, in the presence of anti-Jo-1 
autoantibodies 121. The cause of the generation of these autoantibodies and the reason for their 
association with anti-Jo-1 autoantibodies are unclear but may involve epitope spreading 121. The 
primary response may be directed against the protein component of the tRNA-tRNA synthetase 
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complex, while prolonged exposure to the Jo-1 antigen may induce an antibody response to additional 
portions of the antigen complex, including accessible sites of the tRNA molecule 121. Patients with 
these autoantibodies had, with the exception of a higher prevalence of CTS, the same clinical 
characteristics as patients with just anti-Jo-1 autoantibodies. 
 
 
Table 13: Characteristics of myositis specific autoantibodies in 125 Dutch myositis patients. 
 
   
MSA frequency clinical characteristics 
   
anti-Jo-1 20% anti-synthetase syndrome* 
anti-tRNAHis 6% anti-synthetase syndrome with carpal tunnel syndrome 
anti-SRP 4% severe PM with myalgia, arthralgia, and moderate response 
anti-Mi-2 6% DM and PM with dry eyes/mouth and atypical chest pain 
* myositis with arthritis, Raynaud’s phenomenon, interstitial lung disease, and a moderate response to 
  treatment 
 
 
Anti-Mi-2 autoantibodies were, unlike previously described 129, 132, not associated with a classic DM 
and not with a good response to immunosuppression. In our patient population anti-Mi-2 
autoantibodies were seen in DM as well as in PM and were clinically associated with dry eyes/mouth 
(only two of the 14 patients met the diagnostic criteria for Sjögren’s syndrome) and atypical chest pain 
without signs of cardiac involvement. The detection of anti-Mi-2 autoantibodies in patients with PM 
might be explained by the increased sensitivity of the extended ELISA we used in this study compared 
to the techniques used by others.  
Autoantibodies to SRP were associated with PM with severe myalgia and arthralgia, and a moderate 
response to treatment. In contrast to other reports 129, 132 no cardiac abnormalities were found in this 
group.  
No associations were found between the presence of MAAs and specific clinical characteristics. Anti-
Ro52 autoantibodies were, as previously described, clearly associated with the anti-Jo-1 autoantibody 
135. It is unknown what the role of anti-Ro52 autoantibodies is in IIM and what causes their association 
with anti-Jo-1. The overt association between the two does suggest that the immune response against 
Jo-1 and Ro52 might be coupled 135. 
Recently, we showed that the presence of the most common MSA, the anti-Jo-1 autoantibody, virtually 
excludes the diagnosis of IBM 126, which can be difficult to distinguish from DM and PM, even 
histologically 42. This differential diagnosis is of clinical importance as IBM, unlike DM and PM, lacks a 
consistent response to immunosuppressive treatment 5. The results of the present study strengthen 
the observation that MSAs are hardly ever detected in IBM. For the anti-Jo-1 autoantibody this was 
clearly statistically significant and for the other MSAs, due to the small number of patients exhibiting 
these antibodies, there was a clear trend. More importantly, the three IBM patients in this study with a 
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MSA demonstrated a significant clinical response to immunosuppressive treatment. It is the 
experience of many clinicians that a small subgroup of IBM patients shows a partial response to 
immunosuppressive treatment. There are no specific characteristics to identify this subgroup. The 
partial response seen in the MSA positive IBM patients in this study raises the question whether the 
presence of a MSA can aid in the identification of this subgroup.   
In summary, it can be concluded that MSAs are an important aid in the differential diagnosis and 
treatment plan of IIM by virtually excluding the diagnosis of IBM in the presence of the anti-Jo-1 
autoantibody and by questioning this diagnosis in the presence of other types of MSAs, and by 
warranting, by their presence, the start of immunosuppressive therapy. They further can define distinct 
clinical groups characterised by differences in extra-muscular complications, therapeutic responses, 
and prognosis. While some of these MSA associated syndromes are well defined (e.g. anti-Jo-1 with 
the anti-synthetase syndrome) others remain uncertain and additional studies are required to clarify 
their clinical value (e.g. anti-SRP, anti-Mi-2). Awareness of these features will aid the clinician in the 
management of the patient with an idiopathic inflammatory myopathy.  
Besides their clinical usefullness, MSAs may aid in the unraveling of the pathogenesis of IIM. Their 
specificity for IIM, the presence of certain clinical characteristics and their association with certain 
HLA-genotypes indicate a close relationship between MSAs and the primary pathogenic process 129.  
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Introduction 
 
The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic diseases 
characterised by a progressive proximal muscle weakness, raised serum creatine kinase, 
characteristic electromyographic abnormalities, and inflammatory infiltrates in skeletal muscles 5. The 
three major categories of these disorders are polymyositis (PM), dermatomyositis (DM), and inclusion 
body myositis (IBM) 5. The initial events leading to the onset of these diseases are still unknown. Both 
PM and DM are commonly regarded as autoimmune disorders. The immunopathogenesis of IBM is 
unclear as evidence has been presented for a similar cell mediated autoimmune response in PM and 
IBM, whereas others suggested that the immune response in IBM is secondary to degenerative 
changes in skeletal muscle tissue 46. 
Various autoantibodies directed to defined nuclear and cytoplasmic antigens are found in up to 55% of 
patients with PM and DM 129, 134, 142. Most of these autoantibodies, referred to as myositis associated 
autoantibodies (MAAs), are not specific for IIM, because they are commonly encountered in other 
rheumatic disorders without clinical signs of myositis. Antigens recognised by MAAs include among 
others, the PM/Scl autoantigens, the Mas autoantigen, and components of the U1 small nuclear RNP 
(snRNP) or the cytoplasmic Ro RNPs such as Ro60/SSA, La/SSB, and Ro52 143. Anti-PM/Scl 
autoantibodies recognise two components, PM/Scl-100 and PM/Scl-75, of an RNA processing 
complex called the exosome 144. The Mas autoantigen has not been identified yet, although it is known 
to be a tRNASel-binding protein of about 48 kDa molecular weight, which plays a part in the pathway of 
selenocysteine incorporation 145, 146. The U1 snRNP is involved in pre-messenger RNA splicing 147. 
The function of the Ro RNPs remains to be established 148. 
Some patients have autoantibodies which are specific for IIM. The myositis specific autoantibodies 
(MSAs) target a subset of aminoacyl-tRNA synthetases, transfer RNAs, components of the signal 
recognition particle (SRP), and the nuclear helicase/ATPase Mi-2 136, 143, 149. Anti-synthetase 
autoantibodies are directed towards a subset of aminoacyl-tRNA synthetases 149-151. These enzymes 
are critical components of the translation machinery because each enzyme catalyses the esterification 
of one amino acid to its cognate tRNA. The most commonly directed and best characterised MSA is 
the anti-Jo-1 antibody (anti-histidyl-tRNA synthetase) which is found in up to 25% of the myositis sera 
129, 149, 150. Autoantibodies directed toward five other synthetases (specific for alanine (anti-PL12), 
glycine (anti-EJ), isoleucine (anti-OJ), threonine (anti-PL7), and asparagine (anti-KS)) have been 
reported to occur much less commonly 129, 149-151. Also, naked tRNA may be recognised by 
autoantibodies in about a third of the anti-Jo-1 sera and in most anti-PL12 sera 121, 122. 
The SRP complex consists of an 7SL RNA and six proteins of 9 kDa, 14 kDa, 19 kDa, 54 kDA, 68 
kDa, and 72 kDa 152. This particle functions in the co-translational translocation of secretory and 
membrane proteins to the membrane of the endoplasmic reticulum 152. Anti-SRP autoantibodies have 
been detected in about 4% of patients with myositis who show a distinct seasonal onset of disease, no 
associations have been found with other MSAs, and almost all patients had PM rather than DM 129, 153, 
154. 
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Two autoantigenic forms of the Mi-2 antigen, Mi-2α and Mi-2β, have been reported 136, 155, 156. The Mi-
2β antigen is part of a protein complex which exhibits several chromatin remodelling functions to 
regulate transcription 157, 158. Autoantibodies recognising the Mi-2 antigen are detected in about 20% of 
the myositis sera, and are reported to occur primarily in patients with DM 136. 
Analysis of autoantibody profiles has been shown to be important in the diagnosis of some 
autoimmune diseases, such as anti-dsDNA and anti-Sm autoantibodies in systemic lupus 
erythematosus (SLE) 159 and anti-cyclic citrullinated protein in rheumatoid arthritis 160. A classification 
system based on the MSA profiles has been proposed as a useful alternative for classification into 
clinical groups 129. The most important clinical association is referred to as the “anti-synthetase 
syndrome” which is characterised by the presence of autoantibodies directed toward a subset of 
aminoacyl-tRNA synthetases and a clinical syndrome consisting of myositis, arthritis, Raynaud’s 
phenomenon, interstitial lung disease, and other clinical features 129, 142. Other remarkable clinical 
associations are the high incidence of anti-Mi2 autoantibodies in sera of patients with DM, the 
exclusion of IBM when anti-Jo-1 autoantibodies are present 126, and more severe myositis which is 
often resistant to treatment when anti-SRP autoantibodies are present 129, 143. 
Over the past two decades a number of studies analysing the autoantibody profiles in small cohorts of 
sera from patients with myositis have been published 36, 38, 125, 128, 161-165. However, studies describing 
the more or less complete serological analysis of large numbers of myositis sera (n>200) are limited 
120, 129. Here, we present a serological study analysing the MSA and MAA antibody profiles of more 
than 400 European patients with myositis. 
 
 
Patients and methods 
 
Patients 
Serum samples were collected from 417 patients with IIM from several European rheumatological and 
neurological institutes located in the Czech Republic (n=72), Finland (n=30), Germany (n=8), Greece 
(n=56), Iceland (n=13), Italy (n=16), the Netherlands (n=122) 121, 126, 127, 135 , Slovenia (n=27), Sweden 
(n=37), Switzerland (n=6), and the United Kingdom (n=30). Patients were classified as PM, DM, or 
IBM using recently published criteria 5, 140. When anti-Mi2 autoantibodies were found, patients were 
also classified according to the established criteria published by Bohan and Peter 3, which, however, 
did not change the diagnosis. The patient group studied comprised 198 patients with PM, 181 with 
DM, and 38 with IBM. Standardised questionnaires containing clinical data on signs and symptoms, 
course of the disease, response to treatment, results of laboratory investigations, electromyographic 
findings, and muscle biopsy specimens were provided by the treating doctors. Incomplete 
questionnaires and questionnaires that contained insufficient information for an accurate diagnosis 
were excluded from the study. 
A pool of 10 human sera from subjects without any known history of autoimmune disease was used as 
a control in all assays performed.  
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Serological analysis of myositis sera 
All autoantibody specificities were analysed in the Nijmegen laboratory, except for the anti-Mi2 and the 
anti-PM/Scl enzyme linked immunosorbent assays (ELISAs), which were performed in Professor HP 
Seelig’s laboratory (Karlsruhe, Germany). 
 
Anti-synthetase autoantibodies – Anti-synthetase autoantibodies were detected by immunoprecipita-
tion (IP) using a HeLa cell S100 extract as described previously 121. Sera which precipitated RNA in 
the tRNA range as determined by denaturing polyacrylamide gel electrophoresis were designated anti-
synthetase positive. Anti-Jo-1 autoantibodies were distinguished from “other anti-synthetase 
autoantibodies” by performing additional immunoblotting and ELISA analyses as described previously 
135. All anti-Jo-1 sera were positive in both IP and ELISA or immunoblot. Presence of anti-Jo-1 activity 
was also determined by the dotblot analysis described below. In addition, anti-synthetase positive sera 
were analysed for the presence of anti-tRNA autoantibodies by IP using total RNA from a 
deproteinised HeLa cell S100 extract as described previously 121. 
 
Anti-Mi-2 autoantibodies – The presence of anti-Mi-2 autoantibodies was determined by ELISA. Four 
overlapping fragments depicted in figure 9 (NT=N-terminal, M=middle, NM=N-terminal/middle, and 
CT=C-terminal) spanning the complete amino acid sequence of the Mi-2β autoantigen were used. The 
cDNAs of NT, M, and CT fragments were synthesised essentially as described for fragment NM 136 
and ligated into an in house modified pEX34 expression vector containing only 10 amino acids of the 
vectors MS2 polymerase fusion protein. Proteins were expressed in transformed E Coli 537 cells and 
purified by Ni2+ affinity chromatography followed by preparative sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE). With 0.2 µg/well of each of the proteins, medium 
binding microtitre plates (Greiner, Nürtingen, Germany) were coated as described 136. Antibody 
screening was performed with 200 µl of diluted sera (1:100 in 20 mM Tris HCl pH 7.4, 150 mM NaCl, 
0.05% NaN3, 0.05% Tween-20, 2.5% bovine serum). After incubation (30 minutes, 37oC) and washing 
(three times with phosphate buffered saline, 0.01% Tween-20) plates were incubated (30 minutes, 
37oC) with 200 µl/well of alkaline phosphatase conjugated AffiniPure Fcγ fragment specific goat 
antihuman IgG (Jackson Laboratories, West Baltimore Pike, USA) diluted 1:2000 in 20 mM Tris-HCl 
pH 7.4, 150 mM NaCl, 0.5% bovine serum albumin, 0.05% Tween-20, 1 mM MgCl2, 0.1 mM Zn 
acetate, 0.05% NaN3. Bound antibodies were visualised with 38 mM disodium p-
nitrophenylphosphate, 50 mM diethanol-amine pH 9.8, 1 mM MgCl2, 0.05% NaN3. The enzyme 
reaction was stopped by adding 50 µl 3 N NaOH. Optical densities were measured bichromatically at 
492 nm/620 nm (Titertek Multiscan MCC340 Mkll; Flow, Meckenheim, Germany). Tests were regarded 
as positive at ≥2.5-fold optical densities compared with that of three negative control sera. Positive 
and negative controls as well as patients’ sera were run in duplicate on every test plate. The anti-Mi-2 
activity detected by ELISA was also analysed by western blotting using the purified recombinant Mi-2β 
fragments shown in figure 9. 
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                     475     NM fragment     970  1235       CT fragment       1912   
 
                                                   635         M fragment       1294 
 
          1           NT fragment           679 
 
 
 
 
 
Figure 9: Schematic representation of the Mi-2β autoantigen and the fragments used in 
ELISA. NT=N-terminal; M=middle; NM=N-terminal/middle; CT=C-terminal 
 
 
 
Anti-PM/Scl autoantibodies – Reactivity with PM/Scl-100 and PM/Scl-75 was determined by ELISA. 
For synthesis of the PM/Scl proteins cDNAs from HepG2 cell RNA (ATCC HB 8065) were constructed 
according to their sequence data (PM/Scl-75: Acc. No M58460; Pm/Scl-100: Acc. No X66113) and 
processed essentially as described above for Mi-2 protein synthesis and purification. Each protein (0.4 
µg/well of PM/Scl-75 and 0.2 µg/well of PM/Scl-100) was coated onto microtitre plates. Coating 
blocking, and assay performance followed the Mi-2 autoantibody protocols. 
 
Anti-Ro60, anti-Ro52, and anti-La autoantibodies – Expression and purification of the Ro60, Ro52, 
and La autoantigens and corresponding ELISAs were performed as described previously 135. 
 
Detection of anti-Mas, anti-SRP, anti-Jo-1, and anti-U1 snRNP autoantibodies by dotblot analysis – 
Immunoprecipitations were performed as previously described 121. Immunoprecipitated RNA recovered 
after phenol/chloroform extraction was spotted onto Hybond N+ membranes (Amersham, United 
Kingdom). After drying and ultraviolet cross linking, the dotblots were hybridised with various 
antisense RNA probes in (pre)hybridisation mix (6 x saline sodium citrate (SSC), 5 x Denhardt’s 
solution, 0.1% SDS, 100 µg/ml sheared, denatured herring sperm DNA). After overnight incubation at 
65oC, membranes were washed three times with 2 x SSC/0.1% SDS (antisense tRNASel and antisense 
tRNAHis) or with 0.1 x SSC/0.1%SDS (antisense 7SL RNA) at 65oC and exposed to Kodak X-Omat AR 
imaging film (Eastman Kodak, Rochester, NY). Antisense RNA probes were transcribed in vitro in the 
presence of [32P]UTP from linearised templates. To determine anti-Jo-1 reactivity, antisense tRNAHis 
was transcribed by SP6 RNA polymerase using a HindIII linearised template of tRNAHis 
cDNA/pSP65p. To detect anti-Mas reactivity, a construct containing the tRNASel cDNA, kindly provided 
by Dr A Krol (CNRS, Strasbourg, France), was used. After recloning into pSP65 (BamHI/EcoRI), 
antisense tRNASel probe was transcribed in vitro from BamHI linearised template by SP6 RNA 
Mi-2 autoantigen 
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polymerase. To detect anti-SRP reactivity, a 7SL cDNA/pSP64 construct, kindly provided by Dr K 
Strub (University of Geneva, Switzerland), was used. Antisense 7SL RNA probe was transcribed in 
vitro from the EcoRI linearised template by SP6 RNA polymerase. Anti-U1 snRNP reactivity was 
detected by the antisense U1 RNA probe, which was produced by in vitro transcription using an EcoRI 
linearised U1 cDNA/pGEM7-ZF(+) construct. 
 
 
Results 
 
In this study sera from 417 European patients with myositis were analysed for the presence of major 
MSAs and MAAs using various established methods as well as a newly described dotblot assay which 
was used to determine the presence of several anti-ribonucleoprotein complex autoantibodies. Most 
patients had either PM (n=198 (48%)) or DM (n=181 (43%)), while IBM was diagnosed in 38 patients 
(9%). 
Table 14 provides an overview of the results. Autoantibodies (MAAs and/or MSAs) were detected in 
232 sera (56%), including 122 PM (62% of PM sera), 98 DM (54% of DM sera), and 12 IBM sera (32% 
of IBM sera). MSAs were detected in 157 sera (38%), including 76 PM (38% of PM sera), 74 DM (41% 
of DM sera), and seven IBM sera (18% of IBM sera). 
 
Analysis of MSAs 
Anti-synthetase autoantibodies – Only two groups of anti-synthetase autoantibodies were 
discriminated: anti-Jo-1 positive and “other anti-synthetase” positive sera. Owing to the low incidence 
of autoantibodies directed towards other synthetases and the fact that a detailed specification of the 
anti-synthetase antibody is clinically of minor importance, the precise nature of the antigen recognised 
by “other tRNA” precipitating sera was not determined. 
As shown in table 14, anti-Jo-1 was found in 73 (18%) of the myositis sera, which were diagnosed 
mostly as PM (43 (22%) of the PM sera) or DM (28 (16%) of the DM sera). Only a few IBM sera 
contained anti-Jo-1 reactivity (2 (5%) of the IBM sera). A similar tendeny was observed for “other anti-
synthetase” reactivities, though the total number of positive number was much lower (12 (3%)). Again, 
mostly PM sera (six) and DM sera (five) immunoprecipitated tRNA (other than tRNAHis), while only one 
IBM serum contained autoantibodies directed to a non-Jo-1 synthetase. 
Some myositis sera contain anti-tRNA autoantibodies next to the cognate anti-synthetase 
autoantibodies 121, 122. Twenty six anti-Jo-1 positive sera (36% of Jo-1 positive sera) appeared to 
contain anti-tRNAHis activity. Anti-tRNA activity was also found in two of the 12 sera which contained 
an anti-synthetase activity that was not analysed in detail. 
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       Table 14: P
revalence of m
yositis specific autoantibodies and m
yositis associated autoantibodies in serum
 sam
ples from
 E
uropean patients w
ith m
yositis. 
  
  A
utoantibodies 
  Tests 
 N
um
ber of P
M
‡ 
sera (%
) 
 N
um
ber of D
M
‡ 
sera (%
) 
 N
um
ber of IB
M
‡ 
sera (%
) 
 Total num
ber of 
sera (%
) 
 P
revalence (%
)  120, 128, 
129  
 
 
 
198 (100) 
181 (100) 
38 (100) 
417 (100) 
 
 
M
yositis specific autoantibodies 
 
 
 
 
 
 
 
A
nti-synthetase antibodies 
 
 
 
 
 
 
 
   anti-H
is-tR
N
A
 synthetase (Jo-1) 
E
LIS
A
, IB
‡, IP
‡ 
43 (22) 
28 (16) 
2 (5) 
73 (18) 
(17-29) 
 
   anti-tR
N
A
H
is 
IP
 
18 (9) 
7 (4) 
1 (3) 
26 (6) 
N
D
* 
 
   other anti-synthetases 
IP
 
6 (3) 
5 (3) 
1 (3) 
12 (3) 
(6-7) 
 
   anti-tR
N
A
 (other) 
IP
 
2 (1) 
0 
0 
2 (0.5) 
(1)* 
 
A
nti-signal recognition particle (S
R
P
) 
D
otblot 
14 (7) 
5 (3) 
1 (3) 
20 (5) 
(3-6) 
 
A
ntinuclear helicase/A
TP
ase (M
i-2) 
E
LIS
A
 
17 (9) 
38 (21) 
3 (8) 
58 (14) 
(4-5)† 
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yositis associated autoantibodies 
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nti-exosom
e com
plex 
 
 
 
 
 
(0-4) 
 
   anti-P
M
/S
cl-100 
E
LIS
A
 
13 (7) 
10 (6) 
0 
23 (6) 
 
 
   anti-P
M
/S
cl-75 
E
LIS
A
 
5 (3) 
6 (3) 
0 
11 (3) 
 
 
A
nti-tR
N
A
Sel binding protein (M
as) 
D
otblot 
6 (3) 
2 (1) 
0 
8 (2) 
(1) 
 
A
nti-cytoplasm
ic R
o R
N
Ps 
 
 
 
 
 
 
 
   anti-R
o60/S
S
-A
 
E
LIS
A
, IB
 
5 (3) 
8 (4) 
4 (11) 
17 (4) 
(10-20) 
 
   anti-R
o52 
E
LIS
A
, IB
 
54 (27) 
44 (24) 
8 (21) 
106 (25) 
N
D
 
 
   anti-La/S
S
-B
 
E
LIS
A
, IB
 
12 (6) 
6 (3) 
3 (8) 
21 (5) 
(2-8) 
 
A
nti-U
1 snR
N
P
 
IP
, dotblot 
17 (9) 
7 (4) 
1 (3) 
25 (6) 
(4-16) 
       * A
pproxim
ately one third of anti-Jo-1 positive serum
 sam
ples contain anti-tR
N
A
H
is autoantibodies
 121; m
ost of the anti-PL12 positive serum
 sam
ples  
       contain anti-tR
N
A
A
la autoantibodies 122. † 20%
 of D
M
 sera, only a few
 anti-M
i-2 positive PM
 sera 167. ‡ P
M
 = polym
yositis; D
M
 = derm
atom
yositis; IB
M
= 
       inclusion body m
yositis; IB = im
m
unoblotting; IP = im
m
unoprecipitation. 
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Anti-SRP autoantibodies – Anti-SRP positive sera are known to co-immunoprecipitate the 7SL RNA 
component of the particle 166. Therefore, all sera were screened by IP followed by a dotblot assay 
rather than by ELISA or immunoblotting using purified recombinant proteins. In the dotblot assay, 
RNAs recovered after IP were hybridised to an antisense 7SL RNA probe. As shown in figure 10, the 
antisense 7SL RNA probe hybridised specifically to RNA precipitated by the anti-SRP reference serum 
and not to RNA precipitates of control sera. When a number of SRP positive sera were used the 
specificity of the dotblot assay was confirmed by IP of 7SL RNA from a metabolically 32P labelled 
HeLa cell extract (data not shown). 
Because the 7SL RNA is an RNA polymerase III transcript and the La autoantigen is known to bind 
the pre-RNA polymerase III transcripts, the possibility existed that false positives were included. 
However, IPs performed with 32P labelled HeLa cell extracts and anti-La positive sera indicated that 
the amount of 32P labelled pre-7SL RNA precipitated by anti-La positive/anti-SRP negative sera is 
rather low and clearly distinguishable from the signals obtained with anti-SRP sera (data not shown). 
As shown in table 14, 20 myositis sera (5%) were anti-SRP positive, including 14 PM sera (7%), five 
DM sera (3%), and one IBM serum (3%). None of the SRP positive sera were anti-La positive (see 
below, table 17). 
 
 
 
    
            
 
Figure 10: Analysis of reference myositis sera and a pool of 10 normal human sera (NHS)  
by dotblot. RNA precipitated by autoantibodies in myositis sera was spotted on nylon filters 
and probed with antisense RNA probes to detect anti-Mas, anti-SRP, and anti-Jo-1 reactivitiy.  
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Anti-Mi-2 autoantibodies – Detection of anti-Mi-2 autoantibodies has previously been performed by 
ELISA using a recombinant internal fragment of the Mi-2β antigen 136. Although this NM fragment 
(formerly known as the MB fragment) appears to contain the major epitope region, some positive sera 
may not be detected using only this fragment. Therefore, in this study, four overlapping fragments 
spanning the complete amino acid sequence of the Mi-2β antigen were used in ELISA, including the 
NM fragment (figure 9). As shown in table 14, 58 myositis sera (14%) were reactive with one or more 
fragments. As expected, the majority of the Mi-2 positive patients had DM (38 (21%)). However, also, 
a substantial number of patients were diagnosed as PM (17 (9%)) and three patients had IBM (8%). 
We did not find consistently lower ELISA titres for PM or IBM sera compared with DM sera, as has 
been reported by Roux et al. 167. The anti-Mi-2 reactivity of most of the PM, DM, and IBM sera could 
be confirmed by western blotting using the purified recombinant Mi-2β fragments shown in figure 9 
(data not shown). 
Table 15 shows the reactivity of the Mi-2 positive sera with each of the four fragments. These results 
confirm that most Mi-2 positive sera (42 (72%)) recognise epitope(s) present in the NM fragment. 
Table 16 shows the reactivity of individual sera with the fragments. It is evident that the neighbouring 
sequences of the NM fragment also contribute to the antigenicity of the Mi-2 protein, because a 
substantial number of NM positive sera also recognise the NT or M fragments (30 (17%) of NM 
positive sera). Unexpectedly, 16 Mi-2 positive sera did not recognise the NM fragment, but exclusively 
the NT or CT fragment, or both. Seven sera recognised exclusively epitopes on the NT fragment, eight 
sera reacted only with the CT fragment, and one serum recognised epitopes present on both CT and 
NT fragments, but not on the NM or M fragments. Furthermore, these results indicate that while 29 
sera recognised the M fragment (table 15), this reactivity does not increase the sensitivity of the 
assay. All of the M positive sera also reacted with the NM fragment. As shown in table 16, 18 sera 
were reactive with both NM and M fragments, 10 sera recognised both NT, NM, and M fragments, and 
one serum recognised all four fragments. 
 
 
 
Table 15: Reactivity of anti-Mi-2 positive sera with recombinant Mi-2 fragments. 
 
 
(n) 
Number of 
NT* positive 
Number of 
NM* positive 
Number of 
M* positive 
Number of 
CT* positive 
Total number of 
positives 
PM* (198) 8 9 5 6 17 
DM* (181) 12 30 23 5 38 
IBM* (39) 0 3 1 0 3 
Total Mi-2 positives (%) 20 (34) 42 (72) 29 (50) 11 (19) 58 (100) 
 
*NT= N-terminal; NM=N-terminal/middle; M=middle; CT=C-terminal; PM=polymyositis; DM=dermatomyositis; 
IBM=inclusion body myositis. 
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Taking into account the fact that the NM and M fragments share epitopes, a difference in the anti-Mi-2 
response may be noticed between PM and DM sera. Results shown in table 15 and 16 suggest that 
Mi-2 positive PM sera recognise the NT, NM, and CT fragments more or less equally. In contrast, Mi-2 
positive DM sera seem preferentially to recognise the NM fragment. However, since there is overlap 
between the fragments and the total number of Mi-2 positive sera in each diagnosis is rather small, no 
statistically meaningful conclusions can be drawn. 
 
 
Table 16: Detailed analysis of the reactivity of anti-Mi-2 positive sera with the recombinant fragments. 
 
 Number of PM* Number of DM* Number of IBM Total number 
Monovalent     
   NT* 4 3 0 7 
   NM* 2 7 2 11 
   M* 0 0 0 0 
   CT* 3 5 0 8 
Divalent     
   NT + NM 1 0 0 1 
   NT + M 0 0 0 0 
   NT + CT 1 0 0 1 
   NM + M 3 14 1 18 
   NM + CT 1 0 0 1 
   M + CT 0 0 0 0 
Multivalent     
   NT + NM + M 2 8 0 10 
   NT + NM + M + CT 0 1 0 1 
     
Total number 17 38 3 58 
 
*PM=polymyositis; DM=dermatomyositis; IBM=inclusion body myositis; NT=N-terminal; NM=N-
terminal/middle; M=middle; CT=C-terminal. 
 
 
Analysis of MAAs 
Anti-Mas autoantibodies – Anti-Mas autoantibodies have been detected in only a few patients with 
myositis or autoimmune chronic active hepatitis and may also be associated with alcoholic 
rhabdomyolysis 145. 
In this study anti-Mas autoantibodies were identified by detection of the co-precipitating RNA 
component in the dotblot assay. As shown in figure 10, the antisense tRNASel probe hybridised 
specifically with the precipitated RNA of the anti-Mas reference serum and not with the RNA 
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precipitates of control sera which included anti-synthetase sera. In this way (table 14), eight sera (2%) 
were shown to contain anti-Mas antibody (3% of PM sera v 1% of DM sera). Anti-Mas reactivity was 
not detected in IBM sera. 
 
Anti-PM/Scl autoantibodies – Anti-PM/Scl autoantibodies have been reported to occur in sera of 
patients with myositis (5-8%), myositis-systemic sclerosis overlap (24-50%), and systemic sclerosis (2-
3%) 134, 168. PM/Scl-100 and PM/Scl-75 are recognised by ~98% and ~63% of the PM/Scl positive 
sera, respectively 169-172. 
In our collection of sera from European patients with myositis, anti-PM/Scl-100 and anti-PM/Scl-75 
autoantibodies were detected in 23 (6%) and 11 (3%) of the myositis sera, respectively. Both 
specificities were only detected in PM and DM sera without any significant association with either 
diagnosis (table 14). In agreement with previous reports, all of the PM/Scl-75 positive sera were also 
reactive with PM/Scl-100 172. 
 
Anti-La, anti-Ro60, and anti-Ro52 autoantibodies – Anti-Ro60 and anti-La autoantibodies are mainly 
associated with SLE or primary Sjögren’s syndrome, but have been reported to occur in 5-15% of 
myositis sera as well 173, 174. Anti-Ro52 autoantibodies may be present in ~20% of myositis sera 135. 
Anti-Ro60, anti-Ro52, and anti-La autoantibodies were found in 17 (4%), 106 (25%), and 21 (5%) of 
the European myositis sera, respectively (table 14). None of these antigens was strongly associated 
with PM, DM, or IBM. However, anti-Ro52 autoantibodies appear to be associated with particular 
types of autoantibodies (see below). 
 
Anti-U1 snRNP autoantibodies – Anti-U1 snRNP autoantibodies are most commonly detected in sera 
of myositis patients with overlap disease (SLE, mixed connective tissue disease, or systemic 
sclerosis), but have been reported to be present in 5-15% of the patients with myositis 120, 129. Myositis 
appears to be generally milder in patients with anti-snRNP autoantibodies than in patients without 
them 163.  
In this study anti-U1 snRNP autoantibodies were found in 25 (6%) of the sera analysed. Most of the 
U1 snRNP positive patients had PM (17 patients) rather than DM (seven) or IBM (one). In all cases 
the anti-U1 snRNP reactivity was confirmed by [32P]pCp labelling of the immunoprecipitated RNA or by 
ELISA using purified recombinant U1-A protein (data not shown). 
 
Associations between MSAs and MAAs 
The incidence of combined MSA specificities found in the screened European group was low (table 
17). Anti-synthetase and anti-Mi-2 autoantibodies were found in four sera (5% of anti-synthetase 
positive sera), including three PM sera and one DM serum. The DM serum was weakly reactive with 
the anti-Jo-1 antigen and moderately reactive with the NT fragment of the Mi-2 antigen. The three PM 
sera were moderately reactive with the Jo-1 antigen and moderately to strongly reactive with the CT 
fragment alone (one serum) or in combination with the NT fragment (one serum, strongly) or with the 
NM fragment (one serum, moderately). Thus all four sera were anti-Jo-1 positive and reactive with 
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either or both NT and CT fragments of the Mi-2 antigen, while one serum also recognised the NM 
fragment. In addition, anti-SRP autoantibodies co-occurred with anti-synthetase autoantibodies in two 
sera, including one anti-Jo-1 positive PM serum and one “other anti-synthetase” positive DM serum. 
Associations between MSAs and MAAs seem to occur more frequently 120, 135, 175. The most apparent 
correlation was found between anti-Ro52 and several MSAs (table 17). In this study anti-Ro52 
autoantibodies were present in 56 out of 85 anti-synthetase positive sera (66%). This association is 
more clear for anti-Jo-1 positive sera (52 (71%) of Jo-1 positive sera) than for “other synthetase” 
positive sera (4 (33%)). In addition, anti-Ro52 antibody was present in combination with anti-SRP 
antibodies (6 (30%)) and anti-PM/Scl antibodies (3 (13%)). A number of anti-Mi-2 positive sera (both 
PM and DM) were found to contain anti-Ro52 autoantibodies as well (12 (21%)). Other autoantibody 
activities, like anti-Ro60 or anti-La, appeared not to be associated with MSA activities (table 17). 
Surprisingly, most of the anti-Ro52 activities in IIM sera were not accompanied by anti-Ro60 
autoantibodies as is seen in patients with primary Sjögren’s syndrome, but not, for example, in 
patients with SLE 176. 
 
 
Table 17: Associations of myositis specific autoantibodies and myositis associated autoantibodies in 
serum samples from European patients with myositis. 
 
(n) Anti-U1 
snRNP 
(25) 
Anti-La 
(21) 
Anti-Ro52 
(106) 
Anti-Ro60 
(17) 
Anti-Mas 
(8) 
Anti-PM/Scl 
(23) 
Anti-Mi-2 
(58) 
Anti-SRP 
(20) 
Anti-synthetase (85) 3 7 56 3 3 0 4 2 
Anti-SRP (20) 1 0 6 1 0 0 0  
Anti-Mi-2 (58) 3 2 12 3 0 2   
Anti-PM/Scl (23) 2 2 3 1 0    
Anti-Mas (8) 0 0 2 0     
Anti-Ro60 (17) 2 8 12      
Anti-Ro52 (106) 11 12       
Anti-La (21) 1        
 
 
 
Prevalence of autoantibody types relative to the latitude 
A previous study, which included some of the patients studied here, reported that patients with DM 
were more prevalent in the cohorts from the southern countries of Europe, while the prevalence of 
patients with PM was more pronounced in the northern countries 127. Therefore, the autoantibody 
prevalence in northern (Finland, Iceland, and Sweden (80 patients)), middle (UK, the Netherlands, 
Germany, Switzerland, and Czech Republic (238)), and southern (Italy, Slovenia, and Greece (99)) 
European countries was assessed.  
Although the total number of positive sera is small for some autoantibody types, an interesting trend 
was noticed in the autoantibody prevalence relative to the latitude. A latitudinal gradient similar to the 
DM prevalence was found for the MSAs (anti-synthetase, anti-Mi-2, and anti-SRP autoantibodies) – 
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that is, they occur more commonly in the southern countries. In contrast, the analysed MAAs, with 
exception of the anti-Ro52 and anti-U1 snRNP autoantibodies, were more commonly detected in 
patients from the northern countries as compared with the southern countries (data not shown). Anti-
Ro52 autoantibodies seem to be more evenly distributed, whereas the anti-U1 snRNP autoantibodies 
were most abundant in the middle of Europe. 
 
 
Discussion 
 
This study describes the serological analysis of the largest group of patients with myositis to date. 
Sera were collected from various European rheumatological and neurological institutes located in the 
north (Iceland, Finland, Sweden), the middle (UK, the Netherlands, Germany, Czech Republic, 
Switzerland), and the south of Europe (Italy, Greece, Slovenia). This is relevant because we recently 
showed that the relative prevalence of PM and DM appeared to be dependent on the geographical 
latitude 127. All patient sera were analysed for the presence of a number of well known myositis 
specific and myositis associated autoantibody specificities by established methods as well as by a 
newly described dotblot assay. 
Autoantibodies were detected in 53% of the sera. Because sera were only analysed for well defined 
autoantigens, these results do not imply that only half of the myositis sera contain autoantibodies. 
Indeed, it has been suggested that up to 90% of patients with myositis may produce autoantibodies 
when tested by indirect immunofluorescence or other serological techniques 134. 
In most cases the prevalence of the autoantibody activities tested in this study corresponded well with 
those previously reported in (smaller) cohorts of North American and Japanese patients with myositis 
120, 128, 129. However, some interesting differences were noted. Firstly, our European collection 
contained more PM/Scl positive sera than the North American or Japanese groups (6% v 2% and 0%, 
respectively). Although we could not find significant differences in PM/Scl positivity between the 
individual European countries included in this study, it should be mentioned that these antibodies were 
not found in 40 Polish patients with PM/DM without overlap disease studied by Hausmanowa and 
coworkers 125. Secondly, the number of anti-Mi-2 positive sera is significantly higher in this study than 
the prevalence reported by others 125, 129, 138, but comparable with results obtained by Roux and 
coworkers 167. Because the number of anti-Mi-2 positive DM sera (21% of DM sera) corresponds with 
results of other studies, the difference is obviously caused by the relatively high number of anti-Mi-2 
positive PM sera (9% of PM sera). About one in three anti-Mi-2 positive sera were from patients with 
PM and in most cases (8/17) the anti-Mi-2 activity could be confirmed by western blotting. It is likely 
that the increased sensitivity of the extended ELISA used in this study compared with the techniques 
used by others may account for the observed discrepancy. The inclusion of the NT and CT fragments, 
as well as the NM fragment, spanning the complete open reading frame of the Mi-2 autoantigen, 
clearly improved the sensitivity of our ELISA assay by 25-30% (see tables 15 and 16) compared with 
the ELISA originally described by Seelig and coworkers 136. Additionally, anti-Mi-2 antibodies in 
patients with PM appeared to recognise the NT and CT fragments more frequently than the NM 
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fragment, whereas antibodies from patients with DM seem preferentially to recognise the NM 
fragment. Application of the diagnostic criteria of Bohan and Peter 3, which were used in similar 
studies assessing autoantibody prevalence in patients with myositis 120, 125, 128, 129, did not alter the 
diagnoses of the anti-Mi-2 positive patients with PM or DM. Only the three anti-Mi-2 positive patients 
with IBM were classified as PM according to the Bohan and Peter criteria. Thus it may be concluded 
that the extended ELISA as described in this study is responsible for the high incidence of anti-Mi-2 
autoantibodies in the European group studied. Our results confirm the fact that anti-Mi-2 
autoantibodies occur predominantly in sera of patients with DM, but suggest that they are more 
commonly present in PM than has been described previously 5, 138. For future studies we therefore 
recommend the use of an ELISA assay which includes the NT, NM, and CT fragments as substrates 
for the detection of anti-Mi-2 autoantibodies.  
It has been suggested that the immunogenetic background influences autoantibody status of patients 
and may explain (in part) the observed discrepancies outlined above 120, 129, 177. Indeed, it has been 
proposed that genetic and environmental factors, or both, may regulate the occurrence of anti-PM/Scl 
autoantibodies, and such influences could explain the difference found between our study and the 
North American and Japanese results 128, 129. Analyses of these genetic factors may also be interesting 
in view of the observed trend in latitudinal occurrence of some of the analysed autoantibodies. 
In addition to the extended ELISA for detection of anti-Mi-2 autoantibodies, a second newly described 
application of an established method, the dotblot assay, was used to detect some more uncommon 
autoantibody activities. The major advantage of this application is that sera can be screened for 
multiple autoantibody activities after one single IP because the blots can be reprobed several times. In 
this study, the dotblot assay was used to detect anti-SRP, anti-Mas, anti-Jo-1, and anti-U1 snRNP 
reactivity, but the method would probably also detect autoantibodies directed to other 
ribonucleoprotein complexes, such as the Ro RNPs using anti-Y RNA probes. Furthermore, using 
different antisense tRNA probes, it should be possible to discriminate between the known 
autoantigenic aminoacyl-tRNA synthetases without needing to carry out, for example, in vitro inhibition 
assays 150.  
This study focused on the prevalence of some of the autoantibody activities that are common to 
patients with myositis. It gives an overview of the autoantibody status of European patients with 
myositis, which will hopefully lead to further understanding of these diseases and their cause. 
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Introduction 
 
The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of disorders characterized 
by an acquired muscle weakness and the presence of inflammatory infiltrates in skeletal muscle tissue 
15. The main disorders within this group are dermatomyositis (DM), polymyositis (PM), and inclusion 
body myositis (IBM). The pathogenesis of these disorders is unknown. In all three diseases there is 
evidence of an abnormal immune response, which is T-cell mediated in PM and IBM, and humorally 
mediated in DM 15. As part of this abnormal immune response, autoantibodies against nuclear and 
cytoplasmic antigens can be found in a large number of patients with IIM 116. Most of these 
autoantibodies, referred to as myositis associated autoantibodies, are not specific for IIM and are also 
encountered in patients with inflammatory connective tissue disorders (ICTDs) without the presence of 
myositis. A subset of patients has autoantibodies that are considered to be specific for IIM. Most of 
these myositis specific autoantibodies (MSAs) bind to cytoplasmic ribonucleoproteins involved in the 
process of translation 116.  
The specificity of MSAs for the diagnosis IIM has only been established in comparison with other 
ICTDs 128, 183. Clinically, the differential diagnosis of patients presenting with signs and symptoms 
suggestive of IIM can also include various neuromuscular diseases. We therefore prospectively 
determined the specificity of the most common MSAs for the diagnosis IIM in a large group of patients 
with neuromuscular disorders. Special attention was paid to patients with facioscapulohumeral 
muscular dystrophy (FSHD) because this disease is histologically characterized by the presence of 
marked mononuclear inflammatory infiltrates in skeletal muscle, strongly resembling PM 178, 181. 
 
 
Methods 
 
Patients and controls 
Sera from 107 adult patients with a well-defined neuromuscular disorder other than myositis, seen 
between May 2002 and September 2003 at the Neuromuscular Centre Nijmegen, were prospectively 
screened for the presence of the most common MSAs. The group consisted of 48 patients with a 
muscular dystrophy (11 myotonic dystrophy, 8 oculopharyngeal muscular dystrophy, 7 limb-girdle 
muscular dystrophy, 21 facioscapulohumeral muscular dystrophy, 1 Miyoshi muscular dystrophy), 19 
with a metabolic myopathy (14 mitochondrial myopathy, 3 McArdle disease, 2 lipid myopathy), 11 with 
a motor neuron disease (8 amyotrophic lateral sclerosis, 2 progressive spinal muscular atrophy, 1 
post-polio syndrome), 9 with a poly(radiculo)neuropathy (8 hereditary motor and sensory 
polyneuropathy type I or II, 1 chronic inflammatory demyelinating polyradiculoneuropathy), 3 with a 
congenital myopathy (2 nemaline rod myopathy, 1 multicore disease), and 17 with miscellaneous 
neuromuscular disorders (6 myasthenia gravis, 6 toxic myopathy, 3 ocular myositis, 1 sarcoid 
myopathy, 1 hypokalemic periodic paralysis). The results were compared with a control group of 97 
well-defined DM/PM patients, reported previously 44. IBM patients were not included in the control 
group because we have previously shown that MSAs are virtually absent in this disorder 44. 
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Serological assays 
All sera were tested for the presence of the three most prevalent MSAs: anti-Jo-1, anti-Mi-2, and anti-
SRP autoantibodies, with the exception of 18 FSHD sera, which were only tested for anti-Jo-1. Anti-
Jo-1 autoantibodies were detected by immunoprecipitation (IP) using a HeLa cell S100 extract 
followed by a dot-blot analysis as described previously 117, 121. Furthermore, all sera were tested by 
immunoblotting and ELISA analysis 135. Sera were considered positive for anti-Jo-1 if a positive ELISA 
or immunoblot could confirm a positive IP.  
The presence of anti-Mi-2 autoantibodies was determined by ELISA using four overlapping fragments 
spanning the complete amino acid sequence of the Mi-2β autoantigen 117. When test result was 
positive, a Western blot was performed using a nuclear extract from Raji-cells. The blot was blocked 
with MPBSNP (5% Marvel in PBS / 0.1% NP40) for one hour and incubated with 1.8 µl serum diluted 
in 1.5 ml MPBSNP for one hour. After washing three times with MPBSNP, the blot was incubated for 
one hour with a second antibody: a rabbit anti-human peroxidase (HRP)-conjugated antibody (IgG, 
IgA, IgM, kappa, lambda, DAKopatts, Glostrup, Denmark:P212), diluted in MPBSNP 1:2000. The blots 
were washed twice with MPBSNP and once with PBS and bound HRP-conjugated antibody was 
detected by enhanced chemiluminescence (ECL). Sera were considered positive for anti-Mi-2 if both 
techniques used showed positive results. Anti-SRP autoantibodies were detected by IP followed by a 
dot-blot analysis 117, 121.        
 
Statistical analysis 
Sensitivity, specificity, and likelihood ratios were calculated for anti-Jo-1, anti-Mi-2, and anti-SRP 
autoantibodies for the diagnosis DM/PM. Ninety-five percent confidence limits were determined using 
the Clopper-Pearson method. The likelihood ratios were adjusted for extremes if specificity was 100%.  
 
 
Results 
 
None of the sera from the neuromuscular disorder group tested positive for the anti-Jo-1 and anti-SRP 
autoantibodies, compared with 25% and 5%, respectively, in the DM/PM group (table 18). The 
calculated specificity of both autoantibodies was 100% with a 95% confidence interval of 96-100%. Six 
sera from the neuromuscular disorder group tested positive for anti-Mi-2 on ELISA of which only one 
could be confirmed by Western blot using Raji cells. This particular patient had a mitochondrial 
myopathy with the phenotype of a chronic external ophthalmoplegia. She had no signs or symptoms 
suggestive of myositis or another autoimmune disease. Twelve sera from the DM/PM group tested 
positive for anti-Mi-2 resulting in a specificity of 99% (95% CI 94-100%). Combined, the three tested 
MSAs had a sensitivity of 42% for the diagnosis DM/PM (95% CI 32-53%) and a specificity of 99% 
(95% CI 94-100%). 
 
Specificity of MSAs 
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Table 18: Myositis specific autoantibodies in various neuromuscular disorders other than myositis and 
in dermatomyositis/polymyositis. 
 
 NMD 
n=107 
DM/PM 
n=97 
Specificity 
(95% CI) 
Sensitivity 
(95% CI) 
Likelihood ratio 
      
anti-Jo-1 0 24 100% (96-100%) 25% (17-35%) 45.0 
anti-Mi-2 1* 12■ 99% (94-100%) 13% (7-21%) 11.4 
anti-SRP 0* 5 100% (96-100%) 5% (2-12%) 10.1 
MSAs combined 1* 41 99% (94-100%) 42% (32-53%) 38.0 
   
Abbreviations and symbols used: NMD: neuromuscular disorders other than myositis (see text); DM: 
dermatomyositis; PM: polymyositis; CI: confidence interval; MSAs: myositis specific autoantibodies; * 
number of patients tested 89; ■ number of patients tested 94. 
 
 
 
Discussion 
 
Several studies have shown that MSAs are specific for DM/PM unlike other ICTDs when found in 
patients presenting with features suggestive of IIM 128, 183. A few cases have been published of 
patients with a MSA but without clinically apparent IIM, although in most of these reports it is not clear 
whether analysis included serum creatine kinase levels, electromyography, and muscle biopsy to fully 
exclude the presence of myositis 118, 179. Clinically, the differential diagnosis of patients presenting with 
signs or symptoms suggestive of IIM not includes other ICTDs but also various neuromuscular 
disorders. Few studies have investigated the presence of MSAs in other neuromuscular disorders 6, 
182. In a small study of 17 patients with Duchenne muscular dystrophy, none of the MSAs was found 
182. In another study, Tanimoto et al. were unable to detect the anti-Jo-1 autoantibody in sera from 33 
patients with a neuromuscular disorder other than myositis 6. Unfortunately, they did not describe their 
serological technique nor did they specify the type of neuromuscular disorders examined.  
In the present study, we found that the three most prevalent MSAs are highly specific for DM/PM. Only 
one patient without myositis tested positive for a MSA. There are at least two possible explanations for 
this false-positive test result. First, it has been shown that MSAs can be detected in sera before the 
onset of clinically apparent myositis 180. It is thus conceivable that the patient will develop myositis in 
the future. Secondly, the anti-Mi-2 autoantibody may not be specific for myositis but may be 
associated with some, but not all, neuromuscular disorders. In our study, sera from 14 patients with a 
mitochondrial myopathy were examined. The calculated sensitivity of anti-Mi-2 for mitochondrial 
myopathies is 7% with a specificity of 87%. These figures do not differ significantly from those for 
DM/PM. Testing sera from a larger group of patients with mitochondrial myopathies for the presence 
of anti-Mi-2 is required to fully answer this question. 
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The sensitivity of the MSAs combined in the present study was 42%, which is comparable to 
sensitivity figures published previously 44, 117, 128, 129. The reason for this low sensitivity is uncertain but 
it is well known that DM and PM are clinically heterogeneous and may actually consist of various 
diseases with their own pathophysiology and serology. This hypothesis is supported by the fact that 
MSAs define well-defined subtypes of myositis that differ from each other in clinical, histological, and 
serological characteristics 129.  
Although it has been suggested that MSAs are somehow involved in, or linked to the specific 
pathophysiology of IIM, the possibility that they could be a result of muscle inflammation in general still 
existed. For this reason, we paid special attention to patients with FSHD, an autosomal dominant 
muscular dystrophy with marked inflammation shown in muscle biopsy specimens 178, 181. The muscle 
biopsy findings in FSHD can resemble those seen in PM, although detailed analysis of the 
inflammatory infiltrates in FSHD has shown that the immune response in this disease probably differs 
from that in PM 178. The fact that none of the FSHD patients had anti-Jo-1 suggests that this antibody 
is not merely a result of muscle inflammation but is specifically linked to the immunopathophysiology 
of myositis.     
In conclusion, this study shows that the three most common myositis specific autoantibodies are 
highly specific for dermatomyositis and polymyositis compared with other neuromuscular disorders. 
Thus, the identification of one of these autoantibodies in a patient presenting with signs or symptoms 
suggestive of idiopathic inflammatory myopathy virtually proves the presence of dermatomyositis or 
polymyositis. Secondly, the study shows that the most prevalent MSA, the anti-Jo-1 antibody, is not 
merely a result of muscle inflammation but a result, or is part, of the pathophysiology of idiopathic 
inflammatory myopathy. 
         Chapter Nine
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Introduction 
 
Depending on the initial signs and symptoms, patients suffering from the so-called anti-synthetase 
syndrome can present to physicians from various different medical specialties, including internal 
medicine, rheumatology, pulmonology, neurology, and dermatology. It is important that the treating 
physician has a thorough knowledge of the disease, and especially of the signs and symptoms of the 
syndrome that are not always a subject of the treating physician’s field of specialty. The clinical 
characteristics of the anti-synthetase syndrome are demonstrated by presenting three cases. 
 
 
Cases 
 
Patient A is a 60-year old woman. She developed dyspnoea on exertion following a flu-like episode a 
year before consultation at the Neuromuscular Centre Nijmegen. A diagnosis of “bronchiolitis 
obliterans” was made elsewhere and treatment with oral prednisone 60 mg daily had been initiated. A 
few months later, after an initial improvement of symptoms, the dyspnoea on exertion became worse, 
and she complained of feverish episodes and the development of Raynaud’s phenomenon. At that 
time she was using oral prednisone 30 mg daily. She had no musculoskeletal complaints but she was 
unable to ride her bicycle and had difficulty with climbing the stairs due to the severe dyspnoea. She 
was referred to our Centre for further evaluation. 
It was decided to taper the prednisone in order to obtain a good clinical impression of the disease she 
was suffering from. After the prednisone was stopped, no increase occurred of the dyspnoea. Instead, 
a symmetric proximal muscle weakness developed of the upper and lower extremities accompanied 
by myalgia, the latter also being present at rest. She also complained of pain in several large joints.  
Physical examination revealed marked muscle weakness of the neck flexors and of the proximal 
musculature of the upper and lower extremities. Marked muscle atrophy was present of the proximal 
muscles. Examination of the skin revealed erythema over the extensor sides of the distal and proximal 
interphalangeal joints. No abnormalities were noted of the joints. Basal end-inspiratory crepitations 
were heard on auscultation of the lungs.  
Laboratory examination showed an elevated level of serum creatine kinase (CK): 357 U/l (normal 
<200 U/l) and a cytoplasmic immunoblot revealed the presence of anti-Jo-1 autoantibodies. 
Electromyography demonstrated myopathic abnormalities with spontaneous activity in the proximal 
muscles of arms and legs. A muscle biopsy of the quadriceps muscle showed several abnormalities 
compatible with myositis (atrophic muscle fibres, increased number of internal nuclei, basophilic 
muscle fibres, necrotic muscle fibres, myophagia, and positive HLA-ABC staining of the sarcolemma). 
Inflammatory infiltrates were not observed in the muscle biopsy. Pulmonary function tests revealed a 
restrictive pattern with a decreased diffusion capacity (CO-transfer factor 1.10 mmol/min/kPa/l; normal 
1.40-1.60). Characteristics of pulmonary fibrosis were seen on chest X-ray, especially in the right lung. 
A high-resolution CT-scan (HRCT) of the lungs revealed honeycombing, most clearly in the basal lung 
fields (figure 11).  
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The patient was diagnosed with the anti-synthetase syndrome characterised by myositis (further 
differentiation between dermatomyositis and polymyositis was not possible), interstitial pulmonary 
fibrosis, Raynaud’s phenomenon, and arthralgia of the large joints. Treatment with oral prednisone 40 
mg once daily and azathioprine 125 mg once daily was initiated, after which muscle strength slowly 
increased, serum CK normalised, the patient clearly started to feel better, and the dyspnoea nearly 
disappeared. 
The patient is doing well, two years after her initial consultation, with the exception of a residual 
muscle weakness that limits her walking distance. 
 
Patient B is a 45-year-old woman. She consulted a medical specialist for the first time at the age of 36 
years because of painful fingers and wrists accompanied by morning stiffness. She was subsequently 
treated with a non-steroidal anti-inflammatory drug (NSAID). Her medical history included a euthyroid 
struma and Raynaud’s phenomenon. A few months later she developed an erythematosquamous rash 
over the extensor sides of the finger joints, the wrists, and ankles. She also felt an increased 
fatigability of the shoulder- and hip girdle musculature without experiencing clear muscle weakness. 
Furthermore, she started to complain of painful knees.  
Physical examination revealed a raised violaceous rash over the extensor sides of the 
metacarpophalangeal and proximal interphalangeal joints, the knees, and the wrists. Also, cuticular 
erythema with micro-infarctions was observed along with teleangiectasia. Physical examination of the 
Figure 11: High-resolution CT scan of the thorax of patient A 
(basal aspect), with marked honeycombing. 
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joints showed that passive movement of the shoulders, elbows, wrists, knees, and ankles were painful 
without signs of arthritis. A slight symmetric proximal muscle weakness was noticed of the arms and 
legs. 
Laboratory investigations showed an elevated level of serum CK (360 U/l) and the presence of the 
anti-Jo-1 autoantibody. Electromyography showed myopathic abnormalities without the presence of 
spontaneous activity. Muscle biopsy of the deltoid muscle revealed the classic abnormalities of 
dermatomyositis including perivascular inflammatory infiltrates and perifascicular atrophy (figure 12). 
Pulmonary function tests demonstrated a restrictive pattern with a normal diffusion capacity (CO-
transfer factor: 1.61 mmol/min/kPa/l). A chest X-ray showed basal fibrotic and reticulonodular 
abnormalities (figure 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The diagnosis of the anti-synthetase syndrome was made characterised by dermatomyositis, possible 
idiopathic pulmonary fibrosis, polyarthralgia, and Raynaud’s phenomenon. Treatment with oral 
prednisone in a daily dosage of 1 mg/kg was started; resulting in a complete relief of arthralgia, clear 
improvement of the rashes, and slow increase in muscle strength. Two months after treatment 
initiation, the prednisone could be tapered successfully under control of the clinical condition, serum 
CK levels, and pulmonary function. The patient is still doing well seven years after the complete 
withdrawal of prednisone. 
 
Figure 12: Muscle biopsy from the deltoid muscle of patient B: an
inflammatory infiltrate mainly consisting of mononuclear cells is
located around a venule with a thickened wall. The muscle fibres
themselves appear rather normal (HE-phloxine staining; bar is 50 µm) 
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Patient C is a 38-year-old woman who experienced, four months prior to consultation at the 
Neuromuscular Centre Nijmegen, a flu-like episode consisting of general malaise, fever, and anorexia. 
She recovered from this episode but continued to complain of symmetric arthralgia initially of the distal 
and proximal interphalangeal joints and later also of knees and shoulders. Two months after the initial 
symptoms she developed general malaise, feverish episodes, and anorexia. A spontaneous 
improvement in her condition occurred after two weeks. She started to notice myalgia though, 
especially in her proximal arm and leg muscles. Initially this was only present after exercise, but later it 
also occurred at rest. The arthralgia was still present and she continued to have a non-productive 
cough ever since the second feverish episode. Slowly she started to notice that the strength of her 
proximal muscles was decreasing.  
Basal crepitations were heard over the lungs and signs of arthritis of the knees were observed on 
physical examination. There was a severe weakness of the neck flexors and of the proximal 
musculature of the upper and lower extremities. Laboratory investigations revealed a marked increase 
of serum CK (3905 U/l) and the presence of the anti-Jo-1 autoantibody. Electromyography showed 
myopathic abnormalities with spontaneous activity in proximal and distal muscles. Muscle biopsy from 
the quadriceps muscle revealed the presence of myositis with endomysial and perivascular 
Figure 13: Chest X-ray of the thorax of patient B. Basal fibrotic and 
reticulonodular abnormalities are present in both lungs. 
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inflammatory infiltrates, necrotic muscle fibres, and positive HLA-ABC staining of the sarcolemma. 
Pulmonary function tests showed a decreased diffusion capacity of 1.11 mmol/min/kPa/l and a high-
resolution CT scan of the thorax revealed the presence of pulmonary fibrosis with, especially in the 
basal fields, increased interstitial lining, ground glass aspect, and several thickened septae. 
The diagnosis of the anti-synthetase syndrome was made consisting of myositis (differentiation 
between dermatomyositis and polymyositis could not be made), interstitial pulmonary fibrosis, and 
arthritis. The patient was treated with immunosuppressive therapy resulting in a marked decrease of 
serum CK levels, a near normalisation of skeletal muscle strength, and a marked improvement of 
pulmonary function. At present (six months after treatment initiation), she is using oral prednisone 10 
mg once daily and methotrexate 15 mg once a week.  
 
 
Discussion 
 
The idiopathic inflammatory myopathies are a heterogeneous group of diseases characterised by an 
acquired, usually proximal, muscle weakness, elevated levels of serum CK, electromyographic 
abnormalities, and the presence of inflammatory infiltrates in skeletal muscle tissue 5, 7. The diseases 
dermatomyositis and polymyositis are included in this group 5, 7. The estimated prevalence of 
dermatomyositis and polymyositis is 1 per 100.000 5.  
 
Myositis specific autoantibodies. In a subset of patients with an idiopathic inflammatory myopathy, 
autoantibodies can be found that are specific for myositis 44, 116, 117, 124, 125, 128, 129, 132, 139. Most of these 
myositis specific autoantibodies are directed against cytoplasmic ribonucleoproteins involved in 
protein synthesis 124, 132, 139. The most common myositis specific autoantibodies are directed against 
amino-acyl tRNA synthetases 44, 116, 117, 125, 128, 129, 132. The anti-Jo-1 autoantibody, directed against 
histidine-tRNA synthetase, is the most prevalent within the group of anti-aminoacyl-tRNA synthetase 
autoantibodies 44, 116, 117, 125, 128, 129, 132. This autoantibody is found in the sera of approximately 20% of 
patients with dermatomyositis and polymyositis 44, 116, 117, 129. Several studies have shown that the 
presence of autoantibodies directed against aminoacyl-tRNA synthetases is associated with a distinct 
clinical syndrome: the anti-synthetase syndrome. This syndrome is characterised by myositis, 
idiopathic interstitial lung disease, polyarthritis, Raynaud’s phenomenon, and the presence of 
autoantibodies directed against aminoacyl-tRNA-synthetases. The different components of the 
syndrome will be discussed. 
 
Myositis. Myositis is present is nearly all cases, with dermatomyositis and polymyositis occurring in the 
same frequency 44, 125, 128, 129, 132. Usually the clinical features are straight forward with proximal muscle 
weakness, myalgia, elevated levels of serum CK, myopathic abnormalities on electromyography with 
spontaneous activity, and the presence of inflammatory infiltrates in skeletal muscle tissue 5, 7. 
A less classic presentation is not uncommon. Some patients do not complain of muscle weakness 
because they are limited in their activities due to for instance dyspnoea on exertion (patient A). It is 
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also not uncommon that patients use immunosuppressive medications for other reasons, resulting in 
lower levels of serum CK, less pronounced muscle weakness, and the absence of inflammatory 
infiltrates in muscle biopsy (patient A).  
Myositis as part of the anti-synthetase syndrome responds relatively well to immunosuppressive 
therapy (usually consisting of oral prednisone 1 mg/kg in the acute phase, followed by azathioprine or 
methotrexate for a longer period). Relapses are not uncommon during tapering of the medication 
(usually a temporary increase in dosage will be sufficient, sometimes it is needed to add azathioprine 
or methotrexate (patient A)) 44, 125, 129, 132. 
 
Interstitial lung disease. Interstitial alveolitis or pulmonary fibrosis is seen in 33-96% of patients with 
the anti-synthetase syndrome 44, 125, 128, 129. The clinical presentation varies from a subacute severe 
disease leading rapidly to respiratory insufficiency, to a subclinical condition with only abnormalities on 
chest X-ray 118. Most patients complain of dyspnoea on exertion, usually combined with a non-
productive cough. End-inspiratory basal crepitations are heard on auscultation of the lungs. Pulmonary 
function tests reveal a restrictive pattern usually with a decreased diffusion capacity. The chest X-ray 
shows fibrotic and reticulonodular abnormalities, especially in the basal fields. Occasionally, 
honeycombing or a ground glass aspect is seen. A similar, but more detailed pattern can be seen on a 
high-resolution CT-scan of the thorax. 
Patients with the anti-synthetase syndrome and interstitial lung disease do not always complain of 
dyspnoea (patient B and C). Most frequently, these patients do not notice dyspnoea on exertion 
because of severe muscle weakness resulting in decreased physical activity (patient C). Another 
practical problem in the diagnosis of idiopathic interstitial lung disease in a patient with the anti-
synthetase syndrome is the fact that a restrictive pattern on pulmonary function tests can not only be 
caused by pulmonary diseases, but also by weakness of the respiratory muscles due to the myositis 
itself. 
The response of the interstitial lung disease to immunosuppressive therapy varies considerably 118. 
Sometimes complete remission can be achieved, but it can also occur that the disease progresses 
rapidly despite adequate therapy, eventually resulting in death 118. 
The overall prognosis of patients with the anti-synthetase syndrome strongly depends on the 
respiratory component 7. The average 5-year and 10-year survival is roughly 70% 129. 
 
Polyarthritis. Polyarthritis is seen in 69-100% of patients with the anti-synthetase syndrome 44, 125, 128, 
129. Usually it consists of a relatively mild, non-erosive symmetric polyarthritis of distal and proximal 
joints. Arthralgia of the distal and proximal joints occurs even more frequently. The joint involvement 
can occasionally be so severe, that muscle weakness or dyspnoea on exertion is not noticed due to 
the decreased mobility of the patient. Usually, polyarthritis responds favourable to immunosuppressive 
therapy. Adding a NSAID is required in a small number of patients. 
 
Raynaud’s phenomenon. More than half of the patients with the anti-synthetase syndrome have 
Raynaud’s phenomenon. The figures in the literature vary between 53 and 62% 44, 125, 129. This 
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frequently seen symptom can be present years prior to the other components of the anti-synthetase 
syndrome. 
 
Diagnosis. The differential diagnosis of the anti-synthetase syndrome depends on signs and 
symptoms in individual cases. Usually the differential diagnoses included are those for an acquired 
symmetric proximal muscle weakness and for inflammatory connective tissue disorders (table 19). 
 
 
Table 19: Differential diagnosis of the anti-synthetase syndrome 
 
  
 Acquired symmetric proximal muscle weakness 
Limb-girdle muscular dystrophies 
Becker muscular dystrophy 
Fascioscapulohumeral muscular dystrophy 
Inclusion body myositis 
Metabolic myopathies 
Mitochondrial myopathies 
Toxic myopathies (e.g. due to drugs) 
Endocrine myopathies (especially hypothyroidism) 
Myasthenia gravis 
Lambert-Eaton myasthenic syndrome 
Amyotrophic lateral sclerosis 
 
Inflammatory connective tissue diseases 
Rheumatoid arthritis 
Systemic lupus erythematosus 
Sjögren’s syndrome 
Scleroderma 
CREST syndrome 
Mixed connective tissue disease 
Undifferentiated connective tissue disease 
CREST: Calcinosis, Raynaud’s phenomenon, Esophageal sclerosis, Sclerodactaly,  
Teleangiectasia. 
 
 
 
The detection of the anti-Jo-1 autoantibody, by far the most common anti-aminoacyl-tRNA synthetase 
autoantibody, is relatively easy and is recommended in every patient with signs and symptoms 
suggestive of the anti-synthetase syndrome. Some authors recommend screening for anti-Jo-1 in 
every patient with an inflammatory connective tissue disorder 94. In daily practice this may not be 
feasible but it is advised to look for anti-Jo-1 autoantibodies in patients with one of the four core 
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symptoms (myositis, interstitial lung disease, polyarthritis, Raynaud’s phenomenon), or two of the four 
core symptoms in case the first symptom met is Raynaud’s phenomenon 116. Indirect 
immunofluoresence (IF) with HEp-2 cells shows a cytoplasmic staining pattern, and occasionally also 
a nuclear pattern, in case of presence of anti-Jo-1 autoantibodies 119. Either a commercially available 
ELISA or a cytoplasmic immunoblot should follow a positive IF-result. Research laboratories, including 
ours, can always be contacted in case of doubt or in case additional tests are required (for instance 
screening for anti-aminoacyl-tRNA synthese autoantibodies other than anti-Jo-1). 
 
 
Conclusions 
 
The anti-synthetase syndrome is a distinct disease entity consisting of myositis, interstitial lung 
disease, polyarthritis, and Raynaud’s phenomenon. The components of the syndrome do not emerge 
simultaneously or in a specific order, causing patients to consult physicians of many different 
specialties. A thorough knowledge of the syndrome is important in order to be able to anticipate on 
other components, which sometimes are masked and not necessarily subject of the field of specialty 
of the treating physician.                     
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	
	

Ann Neurol 1998;44:423 
GJD Hengstman1,2, BGM van Engelen1,2, UA Badrising3, FHJ van den Hoogen4,  
WJ van Venrooij5 
 
and 
  
J Neurol Neurosurg Psychiatry 2001;70:706 
GJD Hengstman1,2, HJ ter Laak1, WJ van Venrooij5, BGM van Engelen1,2  
 
1 Neuromuscular Centre Nijmegen, Department of Neurology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands 
2 Institute of Fundamental and Clinical Human Movement Sciences, Radboud University Nijmegen, Nijmegen, The Netherlands 
3 Department of Neurology, University Medical Centre Leiden, Leiden, The Netherlands  
4 Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands 
5 Department of Biochemistry, Centre of Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, The Netherlands 
	

	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgements 
 
The authors would like to thank WTM Vree Egberts, BAW de Jong, and E Nuy-Terwindt for their expert 
technical assistance.  
 
Part of this study was presented at the Ixth International Congress on Neuromuscular Diseases, 
Adelaide, Australia.  
 
Reproduced with written permission from John Wiley & Sons, Inc. 
          	    
                                                                                                              105
Introduction 
 
Myositis specific autoantibodies (MSAs) are encountered in patients with dermatomyositis (DM) and 
polymyositis (PM), and the fact that these autoantibodies are disease specific implies that somehow 
their formation in closely linked to the pathophysiological mechanisms underlying DM and PM. 
Although inclusion body myositis (IBM) is still listed under the heading of the idiopathic inflammatory 
myopathies, the disease is probably not a primary immune mediated disorder but a degenerative 
muscle disorder with secondary inflammation 42. There is convincing evidence that the immune 
response in IBM differs strongly from that seen in DM and PM 53. It can therefore be hypothesized that 
the prevalence of MSAs in IBM differs from that in DM and PM. We examined the presence of the 
most common MSA, the anti-Jo-1 autoantibody, in a large group of IBM patients. Later we described 
the remarkable clinical characteristics of a patient with IBM and the anti-Jo-1 autoantibody.   
 
 
Anti-Jo-1 in IBM 
 
The idiopathic inflammatory myopathies are a heterogeneous group of systemic diseases 
characterized by a progressive muscle weakness, elevated levels of creatinine kinase, characteristic 
electromyographic abnormalities, and inflammatory infiltrates in skeletal muscles 18. The three major 
categories of this disorder are dermatomyositis (DM), polymyositis (PM), and inclusion body myositis 
(IBM). The clinical differentiation between DM/PM and IBM can be difficult to make, even histologically 
42.  Yet it is of extreme importance, as IBM, unlike DM and PM, lacks a consistent response to 
immunosuppression 18. 
Because it has been suggested that IBM is not a primary inflammatory myopathy like DM and PM, but 
a myopathy in which the inflammatory response plays a secondary role 42, we investigated the 
presence of the anti-Jo-1 autoantibody, a myositis-specific autoantibody 129, in IBM on the one hand 
and in DM/PM on the other.   
Sixty-nine patients with DM or PM and 18 patients with IBM were examined for the presence of anti-Jo-
1 autoantibodies. They had been diagnosed according to recently published criteria 18, 41 which include 
the observation of typical vacuoles in muscle fibers of IBM patients. The anti-Jo-1 activity was 
determined by immunoblotting, enzyme-linked immunosorbent assay, and RNA precipitation as Rutjes 
and associates have previously described 135. All positive sera scored positive and all negative sera 
negative with all three methods.  
We found a significant difference in the prevalence of anti-Jo-1 autoantibodies in IBM and DM/PM. 
Anti-Jo-1 activity was present in 30% of the DM and in 21% of the PM sera. However, anti-Jo-1 could 
not be detected in any of the 18 IBM sera. We confirmed this finding in 40 additional IBM patients, all 
lacking the anti-Jo-1 autoantibody (table 20). 
It can thus be concluded that the presence of the anti-Jo-1 autoantibody virtually excludes the 
diagnosis of IBM, and therefore can assist in the differential diagnosis of idiopathic inflammatory 
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myopathy and predict respons to treatment. These data further support the hypothesis that the 
inflammatory response in IBM differs from that in DM and PM. 
 
 
Table 20: Presence of the anti-Jo-1 autoantibody in DM/PM and IBM 
 
     
  DM/PM 
n=69 
IBM 
n=58 
Statistical significance 
     
 anti-Jo-1 25% 0% p<0.001 
 
    
 
Case report  
 
The most important clinical feature distinguishing IBM from DM and PM is the lack of responsiveness 
to immunosuppressive treatment 5, 41. Yet, it is the experience of many clinicians that a small subgroup 
of patients with IBM show at least a partial response to immunosuppressive treatment. There are no 
specific characteristics which can identify this subgroup. In this report we present an anti-Jo-1 positive 
patient with IBM who showed a marked and sustained clinical improvement after treatment with oral 
prednisone.  
A 74 year old man, with no relevant medical history, presented with a slowly progressive proximal 
muscle weakness of the lower limbs. On presentation there were no complaints of muscle weakness 
of the upper limbs, dysphagia, myalgia, arthralgia, or feelings of general malaise. He denied any 
sensory symptoms. His family history was negative for neuromuscular or rheumatic disorders and he 
did not use any myotoxic drugs. 
Physical examination showed asymmetric proximal and distal muscle weakness (muscle strength in 
MRC grades: neck flexors 3, right and left triceps 4, right and left iliopsoas 4, right and left gluteus 
maximus 4, right quadriceps 4, left quadriceps 2,5, right and left hamstrings 4, right and left anterior 
tibial 2, left gastrocnemius 4, all other muscles 5), marked atrophy of the quadriceps muscles and low 
symmetric tendon reflexes. The muscles were not painful to palpation. All other aspects of the general 
and neurological examination were normal.  
Laboratory investigations showed slightly increased concentrations of serum creatine kinase (260 U/l; 
normal <200 U/l). All other aspects of the routine laboratory investigation including erythrocyte 
sedimentation rate, lactate dehydrogenase, vitamins, thyroid function tests and antinuclear factor were 
normal or negative. Serum was screened for the presence of myositis specific autoantibodies (MSAs) 
using immunoblotting, enzyme-linked immunosorbent assay (ELISA) and immunoprecipitation as 
previously described 135. Assays were positive for the anti-Jo-1 autoantibody.  
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Electromyography demonstrated fibrillation potentials with positive sharp waves, polyphasia, short 
duration small amplitude motor unit potentials, and several high amplitude motor unit potentials in 
proximal and distal muscles. Nerve conduction studies were normal. 
Muscle biopsy of the right quadriceps muscle showed the presence of small endomysial inflammatory 
infiltrates, invasion of non-necrotic muscle fibres, basophilic rimmed vacuoles, increased number of 
muscle fibres containing internal nuclei, ragged-red fibres, atrophic muscle fibres and positive staining 
of the sarcolemma for HLA-ABC. Electron microscopy demonstrated the presence of 15-18 nm 
tubulofilaments in the cytoplasm. The diagnosis of definite IBM was made 41.  
Because the patient was in good general health and the degree of inflammation on muscle biopsy was 
rather extensive, the decision was made to start treatment with oral prednisone (60 mg once daily). 
Three months after the initiation of treatment a marked improvement of muscle strength was found 
(figure 14), serum creatine kinase had normalised (62 U/l), the anti-Jo-1 autoantibody was no longer 
detectable and EMG demonstrated a significant improvement with less spontaneous activity and fewer 
short duration small amplitude motor unit potentials. Prednisone was slowly tapered and stopped 1 
year after the initiation of treatment. Muscle strength remained stable (muscle strength in MRC grades 
18 months after treatment initiation: right and left triceps 4, right and left quadriceps 4, right and left 
hamstrings 4, right and left anterior tibial 2, all other muscles 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
    
 
Figure 14: Cumulative MRC scores (MRC sum) and dosage of oral prednisone (mg/day) over time (in 
months). Cumulative MRC score is calculated by adding the MRC grades of the following muscle 
groups: neck flexors, neck extensors, biceps, triceps, forearm flexors, forearm extensors, iliopsoas, 
gluteus maximus, quadriceps, hamstrings, anterior tibial, and gastrocnemius.      
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What makes this particular case of great interest are the presence of the anti-Jo-1 autoantibody and 
the marked and sustained clinical improvement after treatment with oral prednisone. Although a few 
studies have reported mild improvement in IBM with various immunomodulating agents, significant and 
sustained improvement remains extremely rare in IBM 5, 41.  
The anti-Jo-1 autoantibody is the most prevalent MSA and is found in 25% of patients with DM and PM 
126. In patients with IBM the antibody is hardly ever detected 51, 126. Until now, only three patients with 
IBM have been reported in whom the antibody was found 51. Unfortunately, the clinical picture of these 
patients was not described. The relative absence of Jo-1 in IBM is seen as support for the hypothesis 
that the immune response in this disease differs from that in DM and PM 126. It has therefore been 
suggested that the anti-Jo-1 autoantibody can aid in the differential diagnosis between the three 
entities by virtually excluding IBM in case of anti-Jo-1 positivity and therefore providing an additional 
argument for the start of immunosuppressive therapy 126. 
The clinical and electrophysiological improvement after immunosuppressive therapy in the presented 
patient, together with the presence of a disease specific autoantibody, suggests a prominent role of the 
inflammatory response. Although it is only based on one case history, this report raises the question 
whether the presence of an MSA can aid in the identification of patients with IBM who might show a 
response to immunosuppressive therapy. It is not known how MSAs are generated and whether they 
represent an epiphenomenon or whether they are somehow involved in the pathogenesis of IIM. Based 
on their specificity for myositis it does seem likely that they are the result of a yet unidentified 
immunological mechanism which is specific for IIM and which is, directly or indirectly, linked to the 
occurrence of clinical myopathy. It can be hypothesised that the presence of an MSA in IBM is the 
result of an identical immunological mechanism as in MSA positive patients with DM or PM and that 
thus immunosuppressive treatment would be of benefit, as in this patient. Additional studies are 
required to consider these questions. 
In conclusion, the present data suggests that in a patient with an idiopathic inflammatory myopathy, 
even IBM, and the presence of an MSA, immunosuppressive treatment should be started and 
continued for at least 3 months.          
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Introduction 
 
Defined autoantibodies are detected in about 50% of myositis patients and are traditionally divided into 
myositis specific autoantibodies (MSAs) and myositis associated autoantibodies (MAAs), the latter 
also occurring in autoimmune diseases without the presence of myositis 117. One of the MSAs is the 
anti-SRP autoantibody, which is directed against components of the signal recognition particle (SRP) 
133.  
Earlier studies suggested an association between anti-SRP autoantibodies and the presence of an 
acute and severe form of polymyositis (PM) with cardiac involvement, a poor response to 
immunosuppressive treatment, and an increased mortality rate 125, 128, 129, 153. Others confirmed the 
presence of a relatively aggressive disease, but cardiac involvement was not found 44. In a recent 
study the clinical and pathological features of seven patients with anti-SRP autoantibodies were 
described 184. It was shown that anti-SRP is associated with an immune mediated necrotizing 
myopathy, characterized by a rapidly progressive severe proximal muscle weakness with an 
incomplete response to corticosteroids, and no clinical signs or symptoms suggestive of multi-organ 
involvement. Furthermore, a predilection for the disease to start in the fall was noted. In another study 
several of these observations could not be confirmed 179. Furthermore, multi-organ involvement was 
found in 25% of the patients in this particular study. 
In order to elucidate whether or not anti-SRP is associated with a specific form of immune mediated 
myopathy, we analyzed the clinical and histological data of the largest group of anti-SRP positive 
patients ever to be studied in a systematic manner and compared this group with a large group of 
myositis patients published previously 44.          
 
 
Patients and methods 
 
Patients and patient evaluation 
Serum samples were collected from 417 patients with an idiopathic inflammatory myopathy (IIM) from 
several European neurological and rheumatologic institutes. The autoantibody profile of this large 
group of IIM patients has been reported previously 117. In addition, serum samples were collected from 
all IIM patients seen between 2000 and 2003 at the Neuromuscular Centre Nijmegen. Patients were 
classified as dermatomyositis (DM), PM, or inclusion body myositis (IBM) using established criteria 5, 
140. All patients with anti-SRP autoantibodies were included in the study. In total, 27 patients were 
included from various European countries (Czech Republic 3, Greece 5, Italy 5, The Netherlands 8, 
Slovenia 1, Sweden 2, Switzerland 1, and United Kingdom 2).  
Before the collection of clinical data, a standardized questionnaire was devised, and all evaluators 
agreed upon study definitions and conventions for evaluation. The questionnaires were sent to the 
treating physicians and included detailed clinical and laboratory information. Clinical data of all 
patients known at the Neuromuscular Centre Nijmegen (n=8) were obtained by questioning and 
examining the patients, reviewing their charts, and consulting their treating physician. Fifteen 
questionnaires were returned of the 19 included non-Dutch patients. The clinical data recorded 
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included: patient characteristics, demographic data, and epidemiology; diagnosis; signs and 
symptoms; results of diagnostic investigations; and treatment response. The recorded patient 
characteristics were: sex, age at onset (defined as the age in years at which the patient for the first 
time experienced signs or symptoms which can be attributed to the inflammatory myopathy), season 
at onset (defined as the season at which the patient for the first time experienced signs or symptoms 
which can be attributed to the inflammatory myopathy), previous medical history, medication at onset, 
exposure to toxins, special circumstances, death, age at death. The recorded diagnosis included: 
inflammatory myopathies using established diagnostic criteria 3, 6; various rheumatic diseases 
including mixed connective tissue disease 185, rheumatoid arthritis 186, systemic lupus erythematosus 
187, Sjögren’s syndrome 188, and systemic sclerosis 189; and cardiac and pulmonary disease including 
myocarditis 190, pericarditis 190, and idiopathic interstitial lung disease 191. Recorded signs and 
symptoms occurring during the disease course included: dry eyes, dry mouth, carpal tunnel syndrome, 
dysphagia, cause of death, palpitations, pitting edema, dyspnea, dyspnea on exertion, presence of 
heart murmurs, orthopnea, paroxysmal nocturnal dyspnea, chest pain, nonproductive cough, 
abnormalities on auscultation of the lungs, arthralgia, arthritis, destructive arthritis, Raynaud’s 
phenomenon, heliotrope rash, Gottron’s sign, shawl-sign, V-sign, nailfold lesions, calcinosis, other 
rashes, muscle weakness, and muscle atrophy. The recorded diagnostic investigations included: 
electromyography, muscle biopsy, serum levels of creatine kinase (CK), CKMB/CK ratio, results of 
chest X-ray, results of high-resolution computed tomography (HRCT) scans of the thorax, results of 
pulmonary function tests, electrocardiography (ECG), and results of cardiac ultrasound. When 
possible, muscle biopsies were sent to the Neuromuscular Centre Nijmegen for evaluation by an 
experienced pathologist (HJtL). Stains included: hematoxylin-phloxine, myofibrillar ATPase, acid 
phosphatase, and trichome stain. Furthermore, the following immunohistochemical stainings: 
membrane attack complex (MAC), HLA-ABC, CD8, and CD68. The recorded treatment information 
included: drugs used, whether a patient had become drug-free (defined as the absence of active 
disease after full termination of immunosuppressive or immunomodulatory drugs), clinical response 
(complete: no clinical evidence of active disease; partial: minimal response to almost complete 
response; no: no evidence of clinical improvement), and laboratory response (complete: muscle-
associated enzymes have normalized; partial: decrease in level of muscle-associated enzymes; no: no 
decrease in level of muscle-associated enzymes) 37. 
 
Control group 
Whenever possible, data were compared to data from a large group of myositis patients published 
previously 44. This group of 125 patients included 5 patients with anti-SRP autoantibodies; all other 
patients had negative test results for this autoantibody. These anti-SRP positive patients were 
excluded from the comparator myositis group. 
 
Serological assay 
The presence of anti-SRP autoantibodies was determined by immunoprecipitation and dotblot analysis 
as described previously 117. Immunoprecipitated RNA, recovered after phenol/chloroform extraction 
was spotted onto Hybond N+ membranes (Amersham, United Kingdom). After drying and ultraviolet 
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cross-linking, the dotblots were hybridised with radiolabeled antisense 7 SL RNA in hybridisation mix 
(6 x saline sodium citrate (SSC), 10 x Denhardt’s solution, 0.1% SDS, 100 µg/ml denatured herring 
sperm DNA). After overnight incubation at 65oC, membranes were washed three times with 0.1 x 
SSC/0.1%SDS at 65oC and exposed to Kodak X-Omat AR imaging film (Eastman Kodak, Rochester, 
NY).  
 
Statistical analysis 
Discontinuous grouped data were analyzed by chi-square frequency distribution. Fisher’s exact test 
was used in cases of a predicted frequency ≤2. Continuous data were analyzed using the Wilcoxon-
Mann-Whitney test. A p-value <0.05 was considered statistically significant. Patients whose data for a 
particular variable were not available were excluded from the analysis of that variable, and the number 
used for the calculation of percentages was adjusted accordingly.  
 
 
Results 
 
Diagnosis 
The clinical data of 23 patients with autoantibodies directed against components of the signal 
recognition particle were analyzed. Three patients were diagnosed with DM while, depending on the 
diagnostic criteria used, 17 or 19 patients were diagnosed with PM. None of the patients was 
diagnosed with IBM. All three patients with DM had typical DM rashes (heliotrope rash, Gottron’s 
sign).  
 
Demographic data 
The average age at disease onset was 47.7 years, which did not differ from that in the comparator 
myositis group (table 21). As in the comparator myositis group, there was a clear female 
predominance in the anti-SRP group (table 21). Almost half the cases had a disease onset in the fall, 
while only a few patients had a disease onset in spring or summer. Two of the 23 patients had a 
malignancy in their medical history (breast cancer, suspected gynecological cancer), one patient used 
potentially myotoxic drugs at the time of presentation (simvastatine, renitec), and three patients may 
have been in contact with myotoxic industrial agents. 
 
Clinical signs and symptoms 
Patients with anti-SRP autoantibodies had significantly more often dysphagia and severe muscle 
atrophy, and less frequently associated rheumatic diseases than patients in the comparator myositis 
group (table 21). Average weight loss at the time of presentation was 8.4 kg (18.6 lbs.). Other signs 
and symptoms did not differ significantly between the anti-SRP positive patients and the patients in the 
comparator myositis group. Detailed clinical information on the clinical presentation, other than that 
included in the standardized questionnaire, was available for the eight Dutch patients. Muscle 
weakness was the presenting symptom in seven of these patients, while one patient presented with 
dysphagia. Myalgia was only present in two patients at the time of presentation.  
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Table 21: Clinical characteristics of anti-SRP positive patients compared to a large group of anti-SRP 
negative myositis 44. 
 
    
characteristic anti-SRP patients 
(n=23) 
anti-SRP negative myositis 
patients (n=125) 
statistical 
significance 
    
demographic data    
   age at onset 47.7 47.9 ns 
   sex (F:M) 3.6 : 1 2.5 : 1 ns 
signs and symptoms    
   dry eyes/mouth 8% (2) 16% ns 
   CTS 10% (2) 16% ns 
   dysphagia 69%(16) 43% p=0.013 
   edema 17% (4) 8% ns 
   dyspnea on exertion 34% (8) 38% ns 
   chest pain 8% (2) 4% ns 
   arthralgia 39% (9) 44% p=0.015 
   arthritis 13% (3) 22% ns 
   Raynaud’s phenomenon 26% (6) 26% ns 
   muscle atrophy 70% (14) 30% ns 
   myalgia 66% (4) 53% ns 
   interstitial lung disease 21% (5) 19% ns 
associated disorders    
   rheumatic disorders 0% (0) 12%  p=0.017 
lab. Investigations    
   normal EMG 4% (1) 6% ns 
   CK 6872 U/l 1535 U/l p<0.001 
treatment response (clinical)    
   complete  26% (6) 15% ns 
   partial 60% (14) 70% ns 
   none 13% (3) 14% ns 
 
 
 
Muscle symptoms – Twenty-two of the 23 patients had marked muscle weakness. The muscle 
weakness was symmetric in all cases and the proximal muscles were clearly more affected than the 
distal ones. Five patients only had weakness of the proximal leg musculature, two had marked 
weakness of the proximal leg musculature and less severe involvement of the proximal arm muscles, 
and in 15 patients the proximal leg and arm musculature were affected to the same extent. The 
disease was rapidly progressive in all patients with an average time to maximum disability of six 
months. Of the eight Dutch patients, one became bedridden, two were unable to stand, three were 
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barely able to walk, and one could walk a few hundred yards. Myalgia was present in more than half of 
the patients and muscle atrophy was present in 70% of cases. The muscle atrophy had a clear 
proximal predilection in all cases.  
 
 
 
 Table 22: Cardiopulmonary characteristics in anti-SRP positive patients. 
 
   
 characteristic frequency in anti-SRP patients 
   
 signs and symptoms  
    palpitations 13% (3) 
    pitting edema 17% (4) 
    dyspnea 34% (8) 
    dyspnea on exertion 52% (12) 
    orthopnea 9% (2) 
    paroxysmal nocturnal dyspnea 9% (2) 
    chest pain 8% (2) 
    nonproductive cough 26% (6) 
    heart murmurs 17% (4) 
    pulmonary abnormalities on auscultation      30% (7) 
 laboratory investigations  
    elevated CKMB/CK ratio    0% 
    cardiomegaly  5% (1) 
    pulmonary abnormalities on chest X-ray 40% (8) 
    abnormal HRCT 46% (6)  
    restrictive pulmonary function test 60% (9) 
    obstructive pulmonary function test 6% (1) 
    decreased CO diffusion capacity 46% (6) 
    abnormal ECG 58% (10) 
    abnormal cardiac ultrasound 50% (6) 
 cardiopulmonary diagnosis  
    interstitial lung disease 21% (5) 
    myocarditis 0% 
    pericarditis 0% 
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Cardiopulmonary involvement –Dyspnea on exertion was present in half of the patients, while 
palpitations, signs or symptoms suggestive of heart failure, and chest pain were found in less than 
20% of patients (table 22). 
Laboratory investigations revealed the presence of cardiomegaly in only one patient, who was also 
diagnosed with interstitial lung disease (ILD). Elevated CKMB/CK ratios were not found in any of the 
patients. More than half of the patients had an abnormal ECG, most frequently consisting of signs of 
prior myocardial infarctions. Four other patients had conduction abnormalities and two patients had 
signs of left ventricular strain due to hypertension. Patients with an abnormal ECG did not have more 
signs and symptoms suggestive of cardiopulmonary disease than patients without ECG abnormalities, 
with the exception of chest pain (both patients with chest pain had an abnormal ECG; 1 with signs of 
prior infarctions and 1 with a slightly elongated PQ-interval). The cardiac ultrasound was abnormal in 6 
out of the 12 patients who had an ultrasound performed. A hypokinetic left ventricle was seen in 3 
patients secondary to prior myocardial infarctions, two patients had minor valve abnormalities, and 1 
patient had a reduced ejection fraction with traces of pericardial fluid. The latter had signs of cardiac 
ischemia on ECG with clinical signs and symptoms suggestive of cardiac failure. None of the patients 
with anti-SRP autoantibodies was diagnosed with myocarditis or pericarditis. 
Almost half of the patients had an abnormal chest X-ray, mostly consisting of abnormalities strongly 
suggestive of ILD. In 75% of the cases, this diagnosis could be substantiated with HRCT. More than 
half of the patients had an abnormal pulmonary function test, usually a restrictive pattern secondary to 
muscle weakness. Six patients had a decreased CO diffusion capacity consistent with the diagnosis 
ILD. The diagnosis ILD was eventually made in five out of the 23 patients. 
 
Histopathology 
A total of 15 muscle biopsy specimens were evaluated (table 23). In total, 6 biopsies from the 
Netherlands, 5 from Greece, 2 from the Czech Republic, and 2 from Sweden were analyzed. Available 
material was stained in those cases that specific stains had not been performed previously. 
Occasionally, no material was available from a patient in order to perform these additional stains. 
Myopathic features, consisting of swollen nuclei, increased amount of internal nuclei, and presence of 
atrophic and hypertrophic fibers, were seen in almost all biopsies. Atrophy of muscle fibers was not 
confined to any particular region of the fascicle or to a specific fiber type. Perifascicular atrophy was 
not seen in any of the biopsies (including the biopsies of the 3 patients diagnosed with DM). Swollen 
capillaries were present in 85% of the biopsy specimen while compact cellular inflammatory infiltrates 
were never found. Necrotic muscle fibers with or without myophagia were abundant in most patients 
while they were absent in only four out of the 15 biopsies examined. Positive staining of the 
sarcolemma with HLA-ABC was not seen in any of the muscle biopsy specimen and endomysial 
fibrosis was only encountered sporadically. Depositions of the membrane attack complex were only 
found in necrotic muscle fibers, but not in the capillaries and none of the biopsies showed features 
suggestive of pipestem capillaries.  
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Treatment and prognosis 
The disease was responsive to immunosuppresion and immunomodulation in almost all patients. The 
treatment response in general did not differ significantly from that of the comparator myositis group 
(table 21). Most patients were treated with corticosteroids combined with other immunomodulators. 
Only two patients were treated with prednisone alone. Other drugs/treatments used were: 
methotrexate (in 15 patients), azathioprine (11), cyclosporine (5), intravenous immunoglobulins (5), 
cyclophospamide (2), and plasmapheresis (2). Hardly any patient became drug-free. At the time of the 
study, 19 of the 23 patients were still being actively treated. In general, the relapse rate on tapering of 
dosages or stopping of medications was high (70%).  
Most patients had a fairly good clinical recovery, although the majority still had residual muscle 
weakness. At the time of the study, 75% had a (near) normal walking pattern. Five out of the 23 
patients had died, on average 12 years after the myopathy was diagnosed. Death was clearly not 
associated with the inflammatory myopathy in three patients, and possibly associated in two (one 
patient who had ILD died of pneumonia, and one patient who had a severely reduced walking distance 
and breast cancer died of a pulmonary embolism).   
 
 
Discussion 
 
Two recent studies have cast a different light on the clinical importance of anti-SRP autoantibodies, 
although there are marked differences between the findings of the studies 179, 184. In the first study, 7 
patients were studied with the anti-SRP autoantibody and it was concluded that the antibody was a 
marker for a relatively rapidly progressive immune mediated necrotizing myopathy with severe muscle 
weakness, no extramuscular involvement, a partial response to immunosuppressive therapy, and a 
predilection for the disease to start between August and January 184. In the second study 19 patients 
were examined with the antibody (16 patients with PM, 2 with systemic sclerosis, 1 with an overlap 
syndrome) and no clear seasonal pattern of onset was found 179. Furthermore, extramuscular 
involvement was found in five patients (three with ILD, two with arthritis) who all suffered from a 
severe proximal muscle weakness with marked atrophy and highly elevated levels of serum CK. The 
authors did find necrotic fibers in the muscle biopsies but they did not grade the severity.   
In order to elucidate the clinical importance of the anti-SRP autoantibody, we analyzed the clinical and 
histological data of the largest group of anti-SRP positive patients ever to be studied in a systemic 
retrospective manner. The retrospective multi-center design of our study has several disadvantages. 
First of all the participating centers have variable expertise in the evaluation of muscle disorders 
resulting in incomplete data, especially with regard to histopathology. Secondly, detailed information 
other than that included in the standardized questionnaire was only available of all Dutch patients. 
Thirdly, not all muscle biopsies were available for evaluation. Because data was not selected in any 
manner other than availability, several conclusions can be drawn from this study baring the 
methodological shortcoming in mind. 
The myopathy associated with anti-SRP autoantibodies depicted a seasonal pattern of onset with a 
predilection of the disease to start in the fall and the winter, thus confirming prior observations 154, 184. 
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The disease has a rapidly progressive course and causes severe disability within months. Within a few 
months after the onset of the first symptoms, most patients are barely able to walk, let alone stand. 
The muscle weakness is symmetric and mainly affects the proximal muscles of the upper and lower 
extremities. Dysphagia is a prominent symptom of the disease and can result in marked weight loss. 
Serum CK levels are strongly elevated, thus reflecting the severity of the myopathic process. Muscle 
biopsy reveals the presence of a necrotizing myopathy with capillary abnormalities. The typical 
histological features of myositis (presence of inflammatory infiltrates, positive HLA-ABC staining of the 
sarcolemma 15, 192) are absent. The disease is responsive to immunosuppression and 
immunomodulation, and patients in general have a moderate to good recovery. It appears that the 
treatment needs to be continued for a long time (years) because most patients studied were not drug-
free and the relapse rate was high. None of the studied patients had another inflammatory connective 
tissue disorder, thus indicating that the anti-SRP autoantibody is not, like for instance the anti-Jo-1 
autoantibody, a marker of an overlap syndrome. Extramuscular involvement does occur though, with 
interstitial lung disease being diagnosed in almost a quarter of the patients. Cardiac involvement 
attributable to the myopathy was not present in any of the patients despite extensive investigations. 
Most frequently, necrotizing myopathies occur as a paraneoplastic phenomenon or secondary to 
myotoxic drugs or toxins 193. Several muscle biopsies showed diffuse staining of the necrotic muscle 
fibers with antibodies to the membrane attack complex and slight or absent inflammation, as has been 
described for paraneoplastic necrotizing myopathy 194. In our study, only two out of the 23 patients had 
a neoplastic disease and only one patient had used medications associated with a myopathy (in this 
particular patient cessation of the medication did not stop the progression of the disease).  
A few cases have been published of patients with a necrotizing myopathy who responded more or less 
favorable to immunosuppressive drugs 195. Inflammatory infiltrates were not found in the muscle 
biopsy specimen of these patients and in some of these cases signs and symptoms suggestive of an 
inflammatory connective tissue disorder were present 195. The disease was named “necrotizing 
myopathy with pipestem capillaries” because the capillaries had thick walls with accumulation of PAS-
positive material and a small lumen. Furthermore, microvascular deposits were present of membrane 
attack complex. None of our patients with anti-SRP autoantibodies had capillary abnormalities 
suggestive of pipestem capillaries and none of the muscle biopsies showed capillary deposition of 
membrane attack complex. Therefore, the necrotizing myopathy seen in our patients with anti-SRP 
autoantibodies seems to be a distinct disease entity. The clinical syndrome of the described patients 
with necrotizing myopathy with pipestem capillaries also differs from that seen in our anti-SRP patients 
with a relatively mild myopathy, and marked extramuscular involvement in the few patients that have 
been described in the literature until now 195, 196.   
The presence of a disease specific autoantibody and a favorable response to immunosuppressive and 
immunomodulating agents strongly suggest an immune mediated pathogenic mechanism underlying 
the anti-SRP myopathy despite the absence of clear inflammation. The fact that we found clear 
extramuscular involvement in our patients strengthens the hypothesis that the primary 
immunopathogenic mechanism is not directed against muscle fibers, as this would not explain the 
occurrence of for instance ILD in these patients. It has been suggested that the myopathy is 
secondary to multifocal ischemia, based on the findings of deposition of membrane attack complex in 
		
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capillaries, a reduction of the capillary density, and an increase of endomysial connective tissue 184. 
We were unable to confirm these observations with the exception of the presence of swollen 
capillaries.  
The pathogenesis of this disease, that should be placed within the spectrum of the immune mediated 
myopathies, is unclear. Further studies will be needed to elucidate the pathogenesis and to clarify the 
role of the anti-SRP autoantibodies in this unique disease. 
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Introduction 
 
A subset of patients with myositis has unique autoantibodies that are considered to be specific for this 
disorder 116. One of these so-called myositis specific autoantibodies (MSAs) recognises the Mi-2 
antigen, a 220 kDa protein in a nuclear protein complex containing histone deacetylase and 
nucleosome remodelling activities 141. These anti-Mi-2 autoantibodies are detected in approximately 
20% of myositis sera, and are reported to occur primarily in patients with dermatomyositis (DM) 125, 129, 
138.   
Recently, we showed that anti-Mi-2 autoantibodies are present in sera of patients with polymyositis 
(PM) and inclusion body myositis (IBM) 44, 117. An explanation for this finding could be the fact that we 
used an ELISA technique in which four overlapping fragments were used spanning the entire amino 
acid sequence of the Mi-2β autoantigen (figure 15) whereas previous studies only used the NM 
fragment that is thought to contain the major epitope region.  
 
 
Figure 15: Schematic representation of the Mi-2β autoantigen, and the fragments used for detection of 
anti-Mi-2 autoantibodies. 
 
 
 
 
 
 
 
 
 
Methods 
 
Patients and patient evaluation 
Serum samples were collected from 417 patients with myositis from several European neurological 
and rheumatologic institutes. The autoantibody profile of this large group has been reported previously 
117. In addition, serum samples were collected from all patients with myositis seen between 2000 and 
2003 at the Neuromuscular Centre Nijmegen. All patients with anti-Mi-2 autoantibodies were included 
in the study. In total, 48 patients were studied from five European countries (Czech Republic 11, 
Greece 8, Italy 7, The Netherlands 17, Sweden 5). 
Before the collection of clinical data, a standardized questionnaire was devised, and study definitions 
and conventions for evaluation were agreed upon by all evaluators. The questionnaires were sent to 
 
1                   NT fragment                   679
475       NM fragment          970
635                M fragment             1294
1235              CT fragment                1912
1                                                                              1912Mi-2β autoantigen 
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the treating physicians and included detailed clinical and laboratory information. Additional clinical data 
of all Dutch patients was obtained by questioning the patients, reviewing their charts, and consulting 
their treating physician. 
 
Control group 
Whenever possible, data were compared to data from a large group of patients with myositis 
published previously 44. This group of 125 patients included 7 patients with anti-Mi-2 autoantibodies, 
all other patients had negative test results for this autoantibody. These anti-Mi-2 positive patients were 
excluded from the comparator myositis group. 
 
Serological techniques 
The presence of anti-Mi-2 autoantibodies was determined by ELISA, as previously described 117. In 
short, four overlapping fragments spanning the complete amino acid sequence of the Mi-2β 
autoantigen were used (figure 15). Optical densities were measured bichromatically at 492 nm/620 nm 
(Titertek Multiscan MCC340 Mkll; Flow, Meckenheim, Germany). Tests were regarded as positive at 
≥2.5-fold optical densities compared to that of three negative control sera. Positive and negative 
controls as well as patients’ sera were run in duplicate on every test plate.  
Sera were also tested for the presence of the most common other MSAs (anti-Jo-1 and anti-SRP), as 
previously described 117. All sera tested negative for these MSAs. 
 
Statistical analysis 
Besides comparing data from anti-Mi-2-positive patients with anti-Mi-2-negative patients, comparison 
was made between patients with autoantibodies directed against different fragments of the Mi-2β 
antigen. Discontinuous grouped data were analysed by chi-square frequency distribution. Fisher’s 
exact test was used in cases of a predicted frequency ≤2. Continuous data were analysed using the 
Wilcoxon-Mann-Whitney test. A p-value <0.05 was considered statistically significant. Patients whose 
data for a particular variable were not available were excluded from the analysis of that variable, and 
the number used for the calculation of percentages was adjusted accordingly.  
 
 
Results 
 
The anti-Mi-2 group in general did not differ significantly from the comparator myositis group with the 
exception of a slightly better treatment response (table 24). The disease onset was rarely acute (data 
not shown). Most patients complained of insidious onset of slight muscle weakness and myalgia, 
usually preceded by arthralgia or the occurrence of a rash (data not shown).   
There were no specific histological characteristics for the anti-Mi-2 group in general. A large proportion 
of muscle biopsies revealed atypical abnormalities, while others had the distinct features of DM 
(perifascicular atrophy, perivascular inflammatory infiltrates) or IBM (basophilic rimmed vacuoles, 
endomysial inflammatory infiltrates with invasion of non-necrotic muscle fibres). The muscle biopsy 
Anti-Mi-2β 
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Table 24: Clinical and laboratory characteristics of 48 patients with anti-Mi-2 autoantibodies, divided 
into three groups based on the reactivity of the antibodies to different components of the Mi-2β 
autoantigen, compared to a large group of patients with myositis published previously 44. 
 
       
 type A 
(n=12) 
type B 
(n=28) 
type C 
(n=7) 
Total Mi-2 
(n=48)* 
Control  
(n=118) 
Statistical 
significance 
       
Myositis diagnosis3, 140       
   DM  33 54  57  50  36 ns 
   PM  58  39  14  40  57 ns 
   IBM  8  10  0  8  22 p<0.051 
Demographics       
   sex (F:M) 1.4 : 1 2.1 : 1 1: 1.3 1.5 : 1 2.6 : 1 ns 
Signs and symptoms       
   dysphagia 33 39 14 33 43 ns 
   muscle atrophy 25 53 57 46 25 ns 
   dry eyes/mouth 8 17 42 14 16 ns 
   CTS 11 0 25 6 17 ns 
   dyspnoea  33 30 14 28 39 ns 
   arthralgia 58 34 28 39 45 ns 
   arthritis 25 30 14 26 22 ns 
   Raynaud’s phenomenon 33 25 14 25 26 ns 
   interstitial lung disease 25 14 14 16 20 ns 
Dermatologic signs and symptoms      
   heliotrope rash 33 37 57 40 18 ns 
   Gottron’s sign 33 48 57 47 17 p<0.011 
   shawl-sign 8 7 14 9 na ns 
   V-sign  17 30 43 28 na ns 
   nail fold lesions 33 24 43 29 15 ns 
   calcinosis 0 7 0 4 na ns 
Associated disorders      
   cancer 25 4 0 8 3 ns 
   rheumatic disorders  33 17 14 20 12 ns 
Laboratory investigations       
   creatine kinasea   1118  3726 2883 2864 1495 ns 
Treatment response (clinical)       
    complete 40 34 80 41 15 p<0.011, p<0.052 
    partial 50 53 20 40 71 p<0.011 
    none 10 11 0 9 14 ns 
 
Abbreviations used: DM: dermatomyositis; PM: polymyositis; IBM: inclusion body myositis; F: female; 
M: male; CTS: carpal tunnel syndrome; na: not assessed; ns: not statistically significant. Numbers are 
percentages of total. * one patient could not be classified into one of the three groups; a mean creatine 
kinase upon presentation in U/l; 1 control group vs total Mi-2 group; 2 pattern B vs pattern C. 
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was normal in three patients. None of the patients without DM associated dermatologic abnormalities 
had histological features suggestive of DM (MAC deposition in capillaries, perivascular inflammatory 
infiltrates, perifascicular atrophy).  
Several different patterns of autoantibody reactivity to fragments of the Mi-2β autoantigen were found. 
In sera with reactivity to more than one fragment, the reactivity was always to adjacent or overlapping 
fragments. In total, three different patterns of reactivity could be distinguished: pattern A with reactivity 
solely to the NT-fragment (thus indicating that the antigenic site was between amino acid 1 and 475), 
pattern B with the strongest reactivity to the NM and/or M-fragment, and pattern C with reactivity only 
to the CT-fragment (antigenic site between amino acid 1294 and 1912).  
No clear differences were found between the three patterns of reactivity with regard to age of onset 
(table 24), season of onset (data not shown), clinical signs and symptoms at onset (data not shown), 
or histological characteristics (data not shown). Several clinical differences were seen between the 
three patterns, although none of them was statistically significant (table 24). Patients with pattern A 
were more frequently diagnosed with cancer than patients with pattern B or C (table). In total, 4 
patients with anti-Mi-2 autoantibodies were diagnosed with a malignancy (1 vaginal carcinoma, 1 Non-
Hodgkin lymphoma, 1 renal adenocarcinoma, and 1 gastric cancer). Three of these patients (one 
diagnosed with PM, and two diagnosed with DM) had pattern A, whereas only one patient (diagnosed 
with gastric cancer several years before the diagnosis of PM) had pattern B.   
 
 
Discussion 
 
Most studies have used the NM-fragment of the Mi-2β autoantigen, which is thought to contain the 
major antigenic epitope. By using four different fragments spanning the entire amino acid sequence of 
the Mi-2β autoantigen, we were able to detect the presence of anti-Mi-2 autoantibodies in a relatively 
large number of sera from patients with PM and IBM 44, 117. In order to elucidate the clinical 
implications of the presence of autoantibodies directed against different parts of the Mi-2β 
autoantigen, we systematically studied the clinical, laboratory, and histological characteristics of the 
largest cohort of anti-Mi-2 positive patients ever to be studied.  
 
Anti-Mi-2 positive myositis 
Unlike other MSAs, anti-Mi-2 autoantibodies do not appear to be a marker for a specific subtype of 
myositis. The anti-Mi-2 positive patients did not differ from a large control group of patients with 
myositis, with the exception that the clinical treatment response was better in the anti-Mi-2 group. This 
feature might be explained by the fact that the control group included a larger number of patients with 
IBM. In general, myositis with anti-Mi-2 autoantibodies in this study was characterised by a relatively 
mild myositis (mild muscle weakness) that can be accompanied by extramuscular signs and 
symptoms including arthralgia, arthritis, Raynaud’s phenomenon, and interstitial lung disease. Cardiac 
involvement was not seen, and the treatment response appeared to be fair.     
Anti-Mi-2β 
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We were unable to confirm the fact that anti-Mi-2 is specific for DM. Only half of the anti-Mi-2 positive 
patients was diagnosed with DM and the other patients did not have DM associated dermatologic 
abnormalities, or histological characteristics of DM. The high prevalence of anti-Mi-2 autoantibodies in 
non-DM patients cannot be explained by the serological technique used because non-DM patients 
were also identified with autoantibodies mainly directed to the NM-fragment, the main antigenic 
fragment used in other studies.  
 
Anti-Mi-2 fragments 
Several differences were noticed between patients with antibodies to different fragments of the 
autoantigen, but none of these were statistically significant. The most remarkable difference was the 
more frequent occurrence of cancer in patients with autoantibodies directed to the N-terminal 
fragment. It has been suggested that anti-Mi-2 autoantibodies may serve as an exclusion criterion for 
paraneoplastic myositis 24, 211. Only a few patients with a malignancy and anti-Mi-2 autoantibodies 
have been described 129, 138. The prevalence of malignancy in anti-Mi-2-positive patients appears to be 
lower as compared to DM patients in general (3% vs 32%) 24, 44, 117, 129, 138, 167, 211, 215. In our study, we 
found a slightly higher prevalence of malignancy in anti-Mi-2-positive patients as compared to the 
literature (8% vs 3%). The finding that patients with autoantibodies directed to the N-terminal fragment 
of the Mi-2β antigen appear to have a higher risk for malignancy raises the question whether the 
presence of autoantibodies to different fragments of the Mi-2β autoantigen may serve as a marker of 
an increased risk of paraneoplastic myositis. Future studies are needed to answer this clinically 
relevant question. 
 
From these data we conclude that anti-Mi-2 autoantibodies are not a marker of a specific subtype of 
myositis. Testing for anti-Mi-2 autoantibodies may be helpful in establishing the diagnosis myositis, but 
once this diagnosis has been made we do not advise routine testing for anti-Mi-2 autoantibodies. 
Future studies are required to further examine the potential association between the presence of 
autoantibodies directed against certain fragments of the Mi-2β antigen and an increased risk for 
cancer. 
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Introduction 
 
Autoantibodies can be found in the sera of most patients with myositis 134. Defined autoantibodies are 
detected in about 50% of myositis patients and are traditionally divided into myositis specific 
autoantibodies (MSAs) and myositis associated autoantibodies (MAAs), the latter also occurring in 
autoimmune diseases without the presence of myositis 117. Most MSAs are directed against 
cytoplasmic RNA-protein complexes involved in the process of protein synthesis 121, 122, 130, 131, 133, 137, 
138, 141, 151. The best- characterized MSAs are directed to several tRNA-synthetases and their cognate 
tRNAs, to components of the signal recognition particle (SRP), and to components of a nucleosome 
remodeling complex called Mi-2 121, 122, 130, 131, 133, 137, 138, 141, 151 . Several clinical and epidemiologic 
studies have shown that MSAs are associated with specific clinical characteristics 37, 129. Table 25 
gives an overview of the most common MSAs, their antigens, their frequency of occurrence in myositis 
patients, and their clinical associations.  
In the past couple of years, several studies have changed our insights about the MSAs. It is now 
becoming clear that some MSAs, in particular anti-Jo-1 and anti-signal recognition particle (anti-SRP) 
antibodies, are markers of very specific disease entities and not just of myositis in general.  
Furthermore, new ideas are emerging about the pathophysiology of MSAs, in particular anti-Jo-1.    
 
 
Table 25: Overview of the most common myositis specific autoantibodies 
    
Antibody Antigen Frequency Clinical associations 
    
anti-ARS    
   anti-Jo-1 his-tRNA synthetase 11-20% anti-synthetase syndroom 
   anti-PL-7 thr-tRNA synthetase 2% anti-synthetase syndroom 
   anti-PL-12 ala-tRNA synthetase 1% anti-synthetase syndroom 
   anti-EJ gly-tRNA synthetase 1-3% anti-synthetase syndroom 
   anti-OJ ile-tRNA synthetase 1% anti-synthetase syndroom 
   anti-KS asp-tRNA synthetase <1% anti-synthetase syndroom 
anti-tRNA    
   anti-tRNAhis tRNAhis 7% anti-synthetase syndroom 
   anti-tRNAala tRNAala 1% anti-synthetase syndroom 
miscellaneous    
   anti-SRP SRP-complex 4% “aggressive” PM 
   anti-Mi-2 nuclear helicase 4-14% classic DM 
Abbreviations used: Anti-ARS: anti-aminoacyl-tRNA synthatese; SRP: signal recognition particle; PM: 
polymyositis; DM: dermatomyositis 
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Changing diagnostic criteria 
 
Many studies have described the association of MSAs with specific subtypes of myositis and several 
extramuscular complications. Essential to the validity of these observed associations are the 
definitions used for diagnosis and identification of clinical signs and symptoms. Traditionally, most of 
the articles describing the MSA associations have used the Bohan and Peter criteria 3. However, 
recent papers, especially in the neurologic literature, have challenged the concept of polymyositis 
(PM) 15, 58, 59. The advocates for a more detailed histological definition of PM state that inflammatory 
infiltrates in skeletal muscle tissue are not only present in PM but also in other myopathies including 
facioscapulohumeral dystrophy (FSHD), dysferlinopathies etc. (table 26) 15, 59. Bohan and Peter only 
excluded some of these diseases 3. With present knowledge, it is probably best to state that all 
diseases mentioned in table 26 should be excluded (on clinical grounds or histologically) in patients 
suspected of having PM. It is because of these ongoing changes in diagnostic criteria that 
associations we thought were once clear (eg, anti-SRP is only seen in PM) are now being 
reconsidered (eg, anti-SRP is specific for a type of necrotizing myopathy).     
 
 
Table 26: Myopathies with inflammatory infiltrates on muscle biopsy 
  
 Immune mediated myopathies 
      Dermatomyositis 
      Inclusion body myositis 
      Polymyositis 
 Muscular dystrophies 
      Duchenne muscular dystrophy 
      Becker muscular dystrophy 
      Facioscapulohumeral muscular dystrophy (FSHD) 
      Dysferlinopathies 
      Limb-girdle muscular dystrophy 
 Necrotizing myopathies 
 Toxic myopathies 
 
    
 
 
Anti-aminoacyl-tRNA synthetases 
 
The most prevalent MSAs are directed against aminoacyl-tRNA synthetases (ARS). The presence of 
anti-ARS antibodies is strongly associated with the anti-synthetase syndrome, consisting of myositis, 
idiopathic interstitial lung disease (ILD), nonerosive arthritis, and Raynaud’s phenomenon 92, 125, 128, 129, 
143.  
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Anti-Jo-1 and interstitial lung disease 
A recent prospective study performed by Fathi et al. confirmed the association of anti-Jo-1 with ILD 
and arthritis 198. A small group of 17 newly diagnosed dermatomyositis (DM)/PM patients were 
investigated for the presence of ILD defined as the occurrence of radiographic signs of ILD on chest 
X-ray or high-resolution CT scan (HRCT) and/or restrictive ventilatory defect. Eleven patients were 
diagnosed with ILD, four of whom had the anti-Jo-1 autoantibody. Of the six patients without ILD, none 
was anti-Jo-1 positive.  
Another retrospective study also examined the presence of ILD in DM/PM and compared ILD in 
patients with and without anti-Jo-1 199. In a group of 156 patients, ILD was diagnosed in 23.1%. The 
anti-Jo-1 autoantibody was found in only 15 patients (9%), a remarkably low number of patients 
raising some questions on the methodology of the study, especially since the authors do not describe 
the serological tests used. The prevalence of ILD in the anti-Jo-1 group was 73%, again confirming the 
association of this antibody with ILD. The only differences found between the anti-Jo-1 positive and 
anti-Jo-1 negative group were that the anti-Jo-1 positive group were less likely to have a symptomatic 
form of ILD and bronchiolitis obliterans organizing pneumonia (BOOP). The authors noticed that 
patients with anti-Jo-1 had similar ILD outcome, compared to those without this antibody, with respect 
to resolution, improvement, or deterioration of ILD and mortality rate related to ILD complications. 
They concluded that patients with and without anti-Jo-1 require similar management and follow-up of 
ILD.      
 
Specificity of anti-Jo-1 
Although it has been shown that anti-Jo-1 is specific for DM/PM compared to other inflammatory 
autoimmune rheumatic disorders, few studies have investigated its specificity compared to other 
neuromuscular disorders 6, 128, 182, 183. In a small study of 17 patients with Duchenne muscular 
dystrophy, anti-Jo-1 was not found 182. In another study, Tanimoto et al. were unable to detect the anti-
Jo-1 autoantibody in sera from 33 patients with a neuromuscular disorder other than myositis 6. 
Unfortunately, they did not describe their serological technique nor specify the type of neuromuscular 
disorders examined. In a recent study, we were unable to detect anti-Jo-1 in sera from 18 patients with 
FSHD, a muscular dystrophy with marked inflammation on muscle biopsy 200. Based on these findings, 
it can be concluded that the anti-Jo-1 autoantibody is highly specific for DM/PM and that the formation 
of anti-Jo-1 is not merely the result of muscle inflammation but is closely linked to the pathophysiology 
of DM/PM.  
 
The anti-synthetase syndrome 
Because earlier studies only looked for anti-ARS antibodies in patients with myositis and other 
autoimmune rheumatic tissue diseases, and only found them in myositis patients, it was thought that 
anti-ARS antibodies are myositis specific. Based on more recent work, it became clear that anti-ARS 
antibodies are specific for their own disease entity of which myositis may be a component: the anti-
synthetase syndrome (table 27) 94, 118. Histological studies confirmed that the anti-synthetase 
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syndrome is a separate disease entity within the spectrum of myositis 201. Mozaffar and Pestronk 
demonstrated that the myopathological changes in the anti-synthetase syndrome include perimysial 
connective tissue fragmentation and inflammation, with muscle fiber pathology in neighbouring 
perifascicular regions 201. Based on their findings they suggested that myositis in the anti-synthetase 
syndrome may result from an immune-mediated disorder of connective tissue. This hypothesis can 
explain more easily why ILD is such a prominent feature of the anti-synthetase syndrome.     
 
 
 
Table 27: Characteristics of the anti-synthetase syndrome 
   
 Clinical myositis 
  interstitial lung disease 
  non-erosive arthritis 
  Raynaud’s phenomenon 
 Laboratory anti-ARS antibodies 
 Biopsy fragmentation of perimysial connective tissue 
  macrophage predominant perimysial inflammation 
  perifascicular myopathic changes 
  normal capillary density 
 Treatment normal response of interstitial lung disease to treatment 
  moderate response of myositis to treatment 
 
 
 
 
The immunopathogenesis of the anti-Jo-1 autoantibody 
 
Ever since its first description almost 25 years ago, researchers have hoped that the anti-Jo-1 
autoantibody would provide a better understanding of the pathogenesis of myositis. To elucidate the 
role of anti-Jo-1 in myositis, two questions must be answered: why are they formed and what do they 
do? Neither question can be fully answered but new insights are emerging based on recent studies 
casting a different light on the Jo-1 antigen. 
 
Cellular localization of Jo-1 
Knowledge of the cellular localization of an autoantigen is important for the understanding of its 
cellular function and for gaining further insight in the pathogenesis of the disease studied. Anti-Jo-1 
autoantibodies are directed against His-tRNA-synthetase, an enzyme with a cytoplasmic function and 
therefore a presumably cytoplasmic localization. However, contradictory results have been reported 
regarding the cellular localization of Jo-1. Cytoplasmic, nuclear, nucleolar, and all forms of 
combinations of these localizations have been reported 91, 119, 134, 202, 203. Kamei examined the cellular 
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localization of Jo-1 tagged with green fluorescent protein in transfected T24 cells 204. The tagged-Jo-1 
localized solely and diffusely in the cytoplasm of almost all cells. Occasionally though, small 
aggregates or spots could be seen in or near to the nucleus. The author subsequently demonstrated 
that these seemingly nuclear spots coincide with cytoplasmic invaginations of the nuclear membrane, 
indicating that tagged-Jo-1 is not localized in the nucleus but solely in the cytoplasm. 
 
Anti-Jo-1 antibody formation 
Earlier work has shown that the anti-Jo-1 autoantibody response is antigen-driven and very closely 
linked to the disease process 205. There are several hypotheses as to why anti-Jo-1 is the subject of 
antibody targeting. One is that anti-Jo-1 autoantibodies result from a direct interaction of Jo-1 with 
RNA from picornaviruses, thus rendering it foreign to the immune system 130. Another hypothesis 
proposes that the immune response is primarily directed against picornaviral proteins with regions 
homologous to regions present in Jo-1, thus causing autoantibody formation via the mechanism of 
molecular mimicry 206. A third hypothesis is based on the formation of anti-idiotypic antibodies, again 
triggered by a presumed viral protein 207. A more recent model hypothesizes that certain self-proteins 
become modified (e.g., during apoptosis or as a result of inflammatory or infectious processes) and 
are subsequently recognized as non-self by the immune system 116. The immune response might then, 
via epitope spreading, evolve into a full-blown immune reaction directed to the whole protein, including 
the nonmodified parts. 
 
Jo-1 and the immune system 
Jo-1 has traditionally been seen as a ubiquitously expressed intracellular protein catalyzing the 
binding between the amino acid histidine and its tRNA. But why is Jo-1 the target of a disease-specific 
antibody response? Because anti-Jo-1 antibodies were thought to occur only in patients with myositis, 
most studies have looked at the muscle as the site of antigen expression. This notion led to the 
development of a hypothesis in which a presumably altered Jo-1 is expressed by muscle tissue thus 
eliciting an immune reaction directed against muscle tissue along with a specific antibody response 
(figure 16a). Others have postulated that necrosis or apoptosis of muscle fibers causes modifications 
of Jo-1, which are subsequently exposed to the immune system as the muscle fibers disintegrate 
(figure 16b). Recent studies, however, showed that fragments of several tRNA synthetases function as 
chemokines with a potential role in the immune response of myositis 208, 209. It is thus conceivable that 
anti-Jo-1 antibodies are not directed to the entire Jo-1 antigen but initially only against its chemokine-
fragment. Through epitope-spreading, antibodies can eventually be formed against other components 
of Jo-1. If the chemokine-fragment is the actual antigen, it becomes more likely that the immune 
system rather than muscle is the site were the initial antigen is expressed (figure 16c).  
The latter hypothesis is attractive for several reasons. First, one can now understand better why 
myositis is a multisystem disorder. If the muscle is the initial site of the immune response, it is hard to 
understand why the lung, or the joints, or the skin become involved. Several studies have shown that 
patients with the anti-Jo-1 autoantibody do not always have myositis at the time of the detection of the 
antibody 94, 118. Cases like these cannot be explained by anti-Jo-1 formation in muscle tissue. 
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Figure 16: Hypotheses on the role of the Jo-1 antigen and the formation of anti-Jo-1 autoantibodies in 
myositis. 
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Figure 16 (continued) 
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A) Initiated by a factor X (step 1), altered Jo-1 is formed (step 2) and presented by MHC class I 
molecules on the sarcolemma (step 3) to the immune system (step 4) with subsequent formation of 
anti-Jo-1 antibodies. 
B) Inflammation of muscle tissue (step 1) results in necrosis/apoptosis of muscle cells. In this process 
of necrosis/apoptosis, Jo-1 is altered (posttranslational modification) (step 2). As the cell disintegrates, 
the altered Jo-1 antigen is phagocytized (step 3 and 4) and subsequently presented to the immune 
system by antigen-presenting cells (step 5), resulting in formation of anti-Jo-1 antibodies (step 6). 
C) Initiated by factor X, immune cells form the chemokine-fragment of Jo-1 (step 1), which is 
subsequently secreted together with other pro-inflammatory molecules (step 2) resulting in 
inflammation of muscle tissue and induction of aberrant MHC class I expression on the sarcolemma 
(step 3). 
 
 
 
 
But why are antibodies formed against a chemokine? Several explanations are possible. First, the 
immune response is always a battlefield between proinflammatory and antiinflammatory components. 
As part of the antiinflammatory reaction, antibodies may be formed, which suppress the function of 
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proinflammatory molecules, like chemokines. The formation of anti-Jo-1 antibodies may thus be a 
consequence of the immune system trying to suppress the immune response. Secondly, the immune 
response in myositis may be abnormal with formation of abnormal chemokines, which are foreign to 
the immune system. Thirdly, apoptosis of inflammatory cells plays an important role in the regulation 
of the immune response. Through abnormal apoptotic cleavage, unique fragments of Jo-1 may be 
formed and presented to the immune system, causing the formation of anti-Jo-1 antibodies.          
 
Jo-1-induced T-cell proliferation 
In an interesting study, Ascherman et al. looked at antigen-presenting cells (APCs) and their role in 
eliciting a T-cell response to the Jo-1 antigen 210. Using recombinant full-length Jo-1 (generated from 
the RNA of a healthy control subject) and four fragments of this recombinant antigen, T-cells from the 
peripheral blood of anti-Jo-1-positive myositis patients and from healthy controls were stimulated in 
the presence of PBMC-derived APCs and dendritic cells (DCs). In anti-Jo-1-positive patients and in 
healthy controls T-cell proliferation was found to both full-length Jo-1 and to its individual fragments in 
a dose-dependent manner. An absolute dependence on DCs was found for the productive 
presentation of Jo-1 fragments, and this was not the case for the productive presentation of full-length 
Jo-1. It was further shown, through antibody-blocking experiments, that the T-cell proliferation driven 
by full-length Jo-1 as well as by Jo-1 fragments is MHC class II dependent. Although the authors 
demonstrated elegantly that Jo-1 and its fragments can induce a T-cell proliferation, they failed to 
identify differences between healthy controls and anti-Jo-1-positive patients. A potential explanation 
for this is that they used a recombinant Jo-1 product that does not contain protein modifications. 
Based on the hypothesis that Jo-1 might be altered in anti-Jo-1-positive myositis patients (eg, through 
posttranslational modifications), it would have been of interest to see whether their experiments would 
have rendered different results if they had used Jo-1 isolated from biopsies of anti-Jo-1-positive 
patients.       
 
 
Anti-signal recognition particle 
 
Several studies have shown that anti-signal recognition particle (anti-SRP) autoantibodies are mainly 
found in PM (defined by the Bohan and Peter criteria), and only occasionally in DM and inclusion body 
myositis (IBM) 3, 44, 117, 120, 125, 128, 129, 133, 153, 197. Although few patients were studied, an association 
between the antibodies and an acute and severe myositis, cardiac involvement, a poor response to 
treatment, and an increased mortality rate was noted 125, 128, 129, 153. As we have pointed out previously, 
many of these presumed associations of anti-SRP autoantibodies are weak 116. A recent study 
confirmed the presence of a relatively aggressive disease characterized by severe myalgia and 
arthralgia, high levels of serum creatine kinase, and a moderate response to immunosuppressive 
treatment in patients with the anti-SRP antibody 44. Cardiac involvement, however, was not found 44.  
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Anti-signal recognition particle myopathy 
Recent studies have shown that anti-SRP autoantibodies are markers for a specific immune-mediated 
myopathy other than PM. In an excellent paper Miller et al. described the clinical and pathologic 
features of seven patients with anti-SRP autoantibodies as detected by two different techniques: 
immunoprecipitation and immunodiffusion 184. The onset of weakness in all patients was between 
August and January. All patients progressed relatively rapidly to severe weakness with a mean time 
from onset to maximum weakness of 5 months. Most patients complained of fatigue or pain, but this 
was never the primary complaint. Physical examination revealed a severe symmetric proximal 
weakness of the upper and lower extremities. None of the patients had clinical signs or symptoms 
suggestive of cardiac involvement. Serum creatine kinase levels were markedly elevated with a mean 
of 12.900 U/l and electromyography showed myopathic features with very prominent spontaneous 
activity. Six of the seven patients improved on corticosteroids, but only partially. Three patients 
relapsed after tapering of the corticosteroids.  
The histopathology in the seven patients was remarkable. All biopsies showed myopathic features 
with regenerating fibers. Mononuclear inflammatory infiltrates were uncommon and there was no 
marked MHC-I staining of the sarcolemma. Necrotic muscle fibers and increased endomysial 
connective tissue were noticed in most biopsies as well as a reduced endomysial capillary density. 
Furthermore, the mean diameter of the endomysial capillaries was increased with deposition of 
membrane attack complex (MAC). The histopathology Miller et al. found in their anti-SRP patients 
strongly differs from the histopathology of PM in which mononuclear inflammatory infiltrates and MHC-
class I staining of the sarcolemma are usually present, the diameter of endomysial capillaries is not 
altered, and deposition of MAC in the capillaries is absent 184, 192, 201.  
Miller et al. thus concluded that the anti-SRP autoantibodies identify a specific immune-mediated 
myopathy characterized by a rapidly progressive severe proximal muscle weakness with an 
incomplete response to corticosteroids and no clinical signs or symptoms suggestive of multi-organ 
involvement. Based on the histopathological features, the authors hypothesized that the disease 
referred to as “myopathy with anti-SRP autoantibodies” is caused by a humoral immune mechanism 
primarily directed against the endomysial capillaries with subsequent multifocal ischemic pathology of 
the muscle tissue. Where the formation of antibodies directed against components of the SRP 
complex fits into the picture remains unknown.  
 
Second clinical study on anti-signal recognition particle myopathy  
In another study, Kao et al. determined the long-term outcome and associated clinical, serological, 
and pathologic features of 19 patients with the anti-SRP autoantibody 179. Sera from 263 patients with 
DM/PM, 790 patients with systemic sclerosis (SSc), and 109 patients with an overlap syndrome were 
examined. Sixteen sera tested positive for anti-SRP in the myositis group, two in the SSc group, and 
one in the overlap syndrome group. All patients in the myositis group were diagnosed with PM 
according to the Bohan and Peter criteria 3. The authors subsequently compared the anti-SRP positive 
PM patients with the anti-SRP negative PM patients. No differences were observed with regard to 
demographic features (no clear seasonal onset, although the authors do not state how they identified 
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the month of onset), cardiac involvement (defined as echocardiographic evidence of biventricular 
cardiomyopathy or electrocardiographic evidence of ventricular arrhythmias attributable to PM and not 
to coronary heart disease), or 5-year cumulative survival rate (86%). The patients with anti-SRP 
autoantibodies had more frequently severe proximal weakness at presentation, higher levels of serum 
CK at diagnosis, and more severe muscle atrophy at presentation. Three anti-SRP-positive PM 
patients were diagnosed with ILD and two with arthritis. The authors noticed that the anti-SRP-positive 
PM patients exhibited persistent muscle weakness and resistance to treatment, with a favorable 
response being achieved in only one third. Unfortunately, no clear data are presented on which these 
conclusions are based. The muscle biopsy specimens of 10 PM patients with anti-SRP autoantibodies 
were compared to those of 17 PM patients without the antibody. Compatible with the findings by Miller 
et al., the authors did not find extensive endomysial inflammation, but unlike Miller et al. they also did 
not notice marked necrosis 184. The authors state that the two patients with SSc and the one patient 
with an overlap syndrome (suffering from the anti-synthetase syndrome) had no features of myositis, 
without mentioning what they mean with “features” (are these clinical signs and symptoms, or an 
elevated serum CK or muscle biopsy abnormalities?). Based on their study, the authors conclude that 
anti-SRP is not specific for PM, that severe muscle weakness and atrophy are prominent features 
whereas cardiac involvement is less common, and survival is better than previously reported.  
In conclusion, the contours of a specific myopathy are emerging which can be identified by the 
presence of anti-SRP autoantibodies (table 28). However, several questions remain unanswered 
including the presence of necrotic fibers and the predilection of the disease to start in the fall.  
 
 
Table 28: Characteristics of the anti-SRP myopathy 
   
 Clinical rapidly progressive disease 
  severe weakness 
  symmetric proximal weakness of arms and legs 
  marked atrophy of proximal muscles 
 Laboratory high levels of serum CK 
 EMG marked spontaneous activity on EMG 
 Biopsy absence of inflammatory infiltrates 
  absence of HLA-ABC class antigens on the sarcolemma 
 Treatment responsive to treatment, but only partial 
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Conclusion 
 
In conclusion, the MSAs have aided in the identification of several distinct disease entities within the 
spectrum of myositis. More than 25 years ago, PM was defined as an acquired muscle weakness with 
the presence of inflammatory infiltrates in skeletal muscle, usually responsive to immunosuppression. 
Today we recognize several different diseases that once were included under the heading PM (figure 
17).  Besides histology and accurate clinical descriptions, MSAs have played an important role in this 
process. As several authors have pointed out, PM is most frequently a component of an overlap 
syndrome and with current knowledge, we are able to diagnose most of these patients correctly 15, 59. 
These changes in disease definitions will aid research in unraveling the pathogenesis of these 
diseases and in performing better therapeutic trials. 
Furthermore, the increasing insights in the function of the Jo-1 antigen and the emergence of new 
hypotheses on the formation of the anti-Jo-1 antibody, open new avenues for future research aimed at 
unraveling the mystery of these disabling diseases. 
 
 
         Figure 17: The different disease entities within the spectrum of myositis, past and present.  
 
 
 
More than 25 years ago, myositis was roughly divided into DM and PM. With present day knowledge, 
we are able to identify several distinct disease entities which were formerly included in 
dermatomyositis (DM) and polymyositis (PM). Several of these disease entities are characterized by 
certain specific autoantibodies, as indicated. anti-SRP: anti-signal recognition particle antibodies; anti-
ARS: anti-aminoacyl-tRNA synthetase antibodies.   
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The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic diseases 
characterised by progressive muscle weakness and the presence of inflammatory infiltrates in skeletal 
muscle tissue in the absence of an apparent causative agent 5. The three most important diseases 
within this group are: dermatomyositis (DM), polymyositis (PM), and inclusion body myositis (IBM). It 
has been shown that autoantibodies are present in nearly all patients with IIM 134. The sera of about 
half of the patients with IIM contain autoantibodies that are thought to be specific for IIM: myositis 
specific autoantibodies (MSAs) 116. These MSAs have been the subject of the research presented in 
this thesis, with emphasis on their clinical usefulness. Several conclusions can be drawn based on the 
research presented in this thesis:  
 
MSAs are specific for myositis. 
The specificity of MSAs for IIM has previously been established in comparison with other inflammatory 
rheumatic diseases 128, 183. However, their specificity compared to other neuromuscular disorders that 
are included in the differential diagnosis of patients presenting with signs and symptoms suggestive of 
IIM, was unknown. In Chapter 8 we have shown that the most common MSAs (anti-Jo-1, anti-SRP, 
and anti-Mi-2) are highly specific for DM and PM compared with other neuromuscular disorders 216. 
Thus, the presence of one of these autoantibodies in a patient presenting with signs or symptoms 
suggestive of IIM virtually proves the diagnosis of DM or PM.  
 
MSAs are not merely a result of muscle inflammation. 
Until now, the possibility existed that MSAs were merely a result of muscle inflammation, although 
evidence existed that at least some of the MSAs are involved in, or linked to the specific 
pathophysiology of IIM 180. The fact that we did not find anti-Jo-1 autoantibodies in a large group of 
sera from patients with facioscapulohumeral muscular dystrophy 200, an autosomal dominant muscular 
dystrophy with marked inflammation in muscle biopsy specimens 178, 181, provides further evidence for 
the fact that the formation of this autoantibody is not merely a result of muscle inflammation but is 
linked to the immunopathophysiology of IIM (Chapter 8).   
 
The presence of an MSA makes the diagnosis IBM less likely. 
The presence of the most common MSA, the anti-Jo-1 autoantibody, virtually excludes the diagnosis 
of IBM 126, a disease entity that can be difficult to distinguish from DM and PM, even histologically 42. 
This differential diagnosis is of clinical importance because IBM, unlike DM and PM, lacks a consistent 
response to immunosuppressive treatment 5. This observation was confirmed in a large study we 
conducted in a group of Dutch myositis patients (Chapter 6) 44. MSAs (including anti-Jo-1, anti-
tRNAHis, anti-Mi-2, and anti-SRP) could hardly ever be detected in patients with IBM (Chapter 6, 10). 
For the anti-Jo-1 autoantibody this absence was statistically significant and for the other MSAs, due to 
the small number of patients with these autoantibodies, there was a clear trend. MSAs can therefore 
be an important aid in the differential diagnosis of IIM by virtually excluding the diagnosis of IBM when 
the anti-Jo-1 autoantibody is present and by questioning this diagnosis in the presence of other types 
of MSAs. 
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Patients with an MSA and IIM (even IBM) appear to respond to immunosuppressive therapy. 
The few IBM patients with an MSA appear to share a common factor: a clinical response to 
immunosuppressive treatment 44. It is the experience of many clinicians that a small subgroup of IBM 
patients shows a partial response to immunosuppressive treatment. There are no specific 
characteristics to identify this subgroup. In Chapter 10, we reported a marked and sustained clinical 
and electrophysiological improvement after immunosuppressive therapy in an anti-Jo-1 positive 
patient with IBM 217. The described patient was included in the large Dutch cohort study presented in 
Chapter 6, which identified two additional IBM patients with an MSA (both patients had anti-Mi-2 
autoantibodies) 44. These two cases were also atypical. Both patients had probable IBM 140 and an 
inflammatory rheumatic disease (Sjögren’s syndrome and rheumatoid arthritis) and both demonstrated 
some improvement on immunosuppressive therapy. MSA-positive IBM patients were also identified in 
a large European study we conducted presented in Chapter 7 117, but detailed description of treatment 
responses was not available for these patients.  
These observations raise the question whether the presence of an MSA can aid in the identification of 
IBM patients who might show a response to immunosuppressive therapy. It is not known how MSAs 
are generated and whether they represent an epiphenomenon or whether they are somehow involved 
in the pathogenesis of IIM. Based on their specificity for IIM it does seem likely that they are the result 
of a yet unidentified immunological mechanism that is specific for IIM. It can be hypothesised that the 
presence of an MSA in IBM is the result of an identical immunological mechanism as in MSA-positive 
DM/PM patients and that thus immunosuppressive treatment would be of benefit. Additional studies 
are needed to answer these questions. For now, the presented data suggest that in a patient with IIM, 
even when a diagnosis of IBM is made, and the presence of an MSA, immunosuppressive treatment 
should be considered for a period of at least 3 months.        
 
There appears to be a latitudinal gradient for the prevalence of MSAs in patients with IIM. 
We have reported that patients with DM are more prevalent in Southern European cohorts of patients 
with IIM, while the prevalence of patients with PM is more pronounced in the northern countries 127. 
Therefore, in Chapter 7 we studied the autoantibody prevalence in cohorts of patients with IIM from 
several European countries 117. Although the total number of positive sera was small for some 
autoantibody types, an interesting trend was noticed in the autoantibody prevalence relative to the 
latitude. A latitudinal gradient similar to the DM/PM prevalence was found for the MSAs (anti-
synthetase, anti-Mi-2, and anti-SRP autoantibodies) – that is, they occur more frequently in the 
Southern European countries.  
The higher prevalence of anti-Mi-2 autoantibodies in Southern European patients with IIM can be 
partly explained by the fact that this autoantibody is more often present in DM, and it has been shown 
that DM is more common in Southern European countries than in Northern European countries 127, 129. 
But the latitudinal gradient for DM and PM does not explain the higher prevalence of anti-synthetase 
autoantibodies (including anti-Jo-1) and anti-SRP autoantibodies in Southern Europe. It is possible 
that environmental factors related to latitude are involved in the pathophysiological process leading to 
formation of these autoantibodies.  
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The anti-Jo-1 autoantibody is a marker of a specific disease: the anti-synthetase syndrome. 
Several studies have shown that the presence of autoantibodies directed to aminoacyl-tRNA 
synthetases is associated with a distinct clinical syndrome: the anti-synthetase syndrome 92, 125, 128, 129, 
143. This syndrome is characterised by myositis, idiopathic interstitial lung disease (ILD), polyarthritis, 
Raynaud’s phenomenon, and the presence of autoantibodies directed against aminoacyl-tRNA-
synthetases. In Chapter 6 we were able to confirm the association of this syndrome with anti-
aminoacyl tRNA autoantibodies in a large group of Dutch patients with myositis 44.  
In Chapter 9 we demonstrated that the disease characteristics of the anti-synthetase syndrome do not 
emerge simultaneously or in a specific order, causing patients to consult physicians of different 
medical specialties 218. A thorough knowledge of the syndrome is important in order to be able to 
anticipate on the presence or the development of other components of the syndrome, which 
sometimes are masked and not necessarily subject of the primary field of specialty of the treating 
physician.  
An analysis for the anti-Jo-1 autoantibody, by far the most common anti-aminoacyl-tRNA synthetase 
autoantibody, is recommended in every patient with signs and symptoms suggestive of the anti-
synthetase syndrome. Some authors recommend screening for anti-Jo-1 in every patient with an 
inflammatory connective tissue disorder 94. In daily practice this may not be feasible but it is advised to 
look for anti-Jo-1 autoantibodies in patients with one of the four core symptoms (myositis, interstitial 
lung disease, polyarthritis, Raynaud’s phenomenon), or two of the four core symptoms in case the first 
symptom met is Raynaud’s phenomenon 116. Indirect immunofluoresence (IF) on HEp-2 cells shows a 
cytoplasmic staining pattern, and occasionally also a nuclear pattern, in case of presence of anti-Jo-1 
autoantibodies 119. Either a commercially available ELISA or a cytoplasmic immunoblot should follow a 
positive IF-result. It has been advised that a positive ELISA for anti-Jo-1 should be confirmed by a 
second technique with a high specificity (e.g. immunoblotting, RNA immunoprecipitation or 
immunodiffusion) 95. 
 
The anti-tRNAHis autoantibody is not associated with a specific clinical syndrome. 
In about 35% of patients with anti-Jo-1 autoantibodies, antibodies directed to the cognate tRNA can be 
found 121. In a large study of 125 patients with IIM presented in Chapter 6, the anti-tRNAHis 
autoantibody was found in 6% of the patients 44. All anti-tRNAHis- positive patients had the anti-Jo-1 
autoantibody. Clinically, the anti-tRNAHis-positive patients did not differ from anti-tRNAHis-negative, 
anti-Jo-1-positive patients. Based on this study it can be concluded that anti-tRNAHis autoantibodies 
are not associated with specific clinical characteristics, and testing for these autoantibodies is 
therefore not indicated. 
 
The anti-SRP autoantibody is a marker of an immune mediated necrotizing myopathy. 
Earlier studies suggested an association between anti-SRP autoantibodies and the presence of an 
acute and severe form of PM with cardiac involvement, a poor response to immunosuppressive 
treatment, and an increased mortality rate 125, 128, 129, 153. Others confirmed the presence of a relatively 
aggressive disease, but cardiac involvement was not found 44. In a recent study, it was concluded that 
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anti-SRP autoantibodies are associated with an immune mediated necrotizing myopathy, and not with 
PM, characterized by a rapidly progressive severe proximal muscle weakness with an incomplete 
response to corticosteroids, and no clinical signs or symptoms suggestive of multi-organ involvement 
184. Furthermore, the disease appeared to have a predilection to start in the fall. Several of these 
conclusions could not be confirmed in a second study 179. Furthermore, multi-organ involvement was 
found in this second study in 25% of the patients. 
In Chapter 11 we systematically studied the characteristics of the largest group of patients with anti-
SRP autoantibodies ever and were able to provide strong evidence that the anti-SRP autoantibody 
indeed is a marker of an immune mediated necrotizing myopathy 219. The onset of the disease was 
usually in the fall or winter. The muscle weakness was rapidly progressive and mainly affected the 
proximal muscles of the upper and lower extremities in a symmetric pattern, as well as the 
oesophageal musculature. The myopathy responded, at least partial, to immunosuppressive and 
immunomodulatory treatment. Unlike earlier studies had suggested, cardiac involvement was not 
seen. Extramuscular involvement in the form of ILD and arthritis did occur though. Histologically, the 
myopathy associated with anti-SRP autoantibodies was characterized by the presence of necrotic 
muscle fibres, myophagia, and generalized myopathic features. Unlike in myositis, marked 
inflammation of the muscle was not seen, nor was there a clear expression of HLA-ABC on the 
sacrolemma.  
The presence of a disease specific autoantibody and a favourable response to immunosuppressive 
and immunomodulating agents strongly suggest an immune mediated pathogenic mechanism 
underlying the anti-SRP myopathy despite the absence of clear inflammation. The fact that we found 
extramuscular involvement in our patients strengthens the hypothesis that the primary 
immunopathogenic mechanism is not directed against muscle fibres, as this would not explain the 
occurrence of for instance ILD in these patients. It has been suggested that the myopathy is 
secondary to multifocal ischemia, based on the findings of deposition of membrane attack complex in 
capillaries, a reduction of the capillary density, and an increase of endomysial connective tissue 184. 
We were unable to confirm these observations with the exception of the presence of swollen 
capillaries.  
Based on our study and on available literature, it can be concluded that anti-SRP autoantibodies are 
associated with an immune mediated necrotizing myopathy, with a disease onset usually in the fall 
and winter, and presence of severe symmetric proximal muscle weakness resulting in marked 
disability, dysphagia, and strongly elevated levels of serum creatine kinase. The disease is associated 
with the occurrence of extra-muscular signs and symptoms of which ILD is the most important. There 
is no association with cardiac involvement and the disease carries a reasonably favourable prognosis 
with most patients responding to treatment. The pathogenesis of the disease is unclear. Further 
studies will be needed to elucidate the pathogenesis and to clarify the role of the anti-SRP 
autoantibodies in this unique disease.       
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Anti-Mi-2 autoantibodies are probably not a marker of a specific type of IIM. 
Earlier studies suggested that the anti-Mi-2 autoantibody is specific for DM 125, 129, 138. We were unable 
to confirm this observation in the largest systematic study of anti-Mi-2-positive patients to date, 
presented in Chapter 12 220. We studied 48 patients with anti-Mi-2 autoantibodies in a systematic 
manner and were unable to find significant differences with a large control group of IIM patients 44, 
with the exception that the clinical treatment response was better in the anti-Mi-2 group. This feature 
might be explained by the fact that the control group included a larger number of IBM patients, known 
to be unresponsive to treatment. Only half of the anti-Mi-2 positive patients was diagnosed with DM, 
and with the exception of one patient with calcinosis, the other patients did not have DM associated 
dermatologic abnormalities, or histological characteristics of DM. In general, myositis with anti-Mi-2 
autoantibody was characterized by a relatively mild myositis (mild muscle weakness) that can be 
accompanied by extramuscular symptoms including arthralgia, arthritis, Raynaud’s phenomenon, and 
ILD. Cardiac involvement was not seen, and the treatment response appeared to be fair.     
One of the potential explanations for the fact that we found anti-Mi-2 autoantibodies in a large group of 
PM and IBM patients, is the fact that we used an ELISA technique in which four overlapping fragments 
spanning the entire amino acid sequence of the Mi-2β autoantigen were used. Previous studies used 
only an internal fragment that is thought to contain the major epitope region. However, this does not 
fully explain the high prevalence of anti-Mi-2 autoantibodies in non-DM patients because non-DM 
patients with autoantibodies mainly directed to the internal fragment were also identified.  
A second potential explanation is the fact that the sensitivity and especially the specificity of the ELISA 
test used in the earlier publications are not fully known. Further investigations are required in order to 
fully understand the clinical implications of finding anti-Mi-2 autoantibodies in a patient. 
 
Autoantibodies to the N-terminal fragment of the Mi-2β autoantigen may be associated with an 
increased risk of cancer. 
In an ELISA technique with four overlapping fragments spanning the entire amino acid sequence of 
the Mi-2β autoantigen as substrate antigens, autoantibodies to different fragments of the Mi-2β 
autoantigen could be identified. In Chapter 12 we systematically studied the clinical, laboratory, and 
histological characteristics of a large cohort of anti-Mi-2-positive patients in order to elucidate the 
clinical implications of the presence of autoantibodies directed against different fragments of the Mi-2β 
autoantigen 220.  
Several differences were noted between patients with antibodies to different fragments of the 
autoantigen, but none of these were statistically significant. The most remarkable difference was the 
more frequent occurrence of cancer in patients with autoantibodies directed to the N-terminal 
fragment. Although the differences found were not statistically significant, our finding does raise the 
question whether the presence of autoantibodies to different fragments of the Mi-2β autoantigen may 
serve as a marker of an increased risk of paraneoplastic myositis. Future studies are needed to 
answer this clinically relevant question. 
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Future perspectives 
 
Although in this thesis a number of answers were obtained, more questions arose. It is still unknown 
why myositis specific autoantibodies are formed. New hypotheses on anti-Jo-1 autoantibody formation 
have been formulated but such hypotheses need to be tested. Is there a post-translational 
modification of the autoantigen rendering it non-self? Where is the primary autoantigen located, is it 
the immune system instead of the muscle? Is the formation of autoantibodies an epiphenomenon 
closely linked to the pathophysiology or are the autoantibodies pathogenic? Is the latitudinal gradient 
seen for the occurrence of MSAs due to genetic factors, or environmental factors, or both?  
 
The myositis specific autoantibodies have helped in recognising some specific clinical subtypes of 
myositis, which were once commonly referred to as DM/PM. The ability to recognise these different 
forms of myositis is of importance because of differences in associated disorders, complications, 
treatment responses, and prognosis. Furthermore, the MSAs have taught us that the IIM syndromes 
are systemic diseases. Even though we still do not know the cause(s) of the IIM syndromes or the 
reason(s) for MSA formation, the MSAs have facilitated our thinking on the pathophysiology of IIM. 
Further studies are needed to answer all the questions but this can only be achieved due to the 
relatively low number of patients, through intense collaboration, preferably worldwide. At present, 
international collaborations are being formed in order to create acceptable diagnostic criteria for DM, 
PM, and IBM. This collaboration, under the wings of the International Myositis Outcome Assessment 
Collaborative Study Group (IMACS), can be the start of a worldwide collaboration in IIM research. It is 
only through working together that these enigmatic diseases and autoantibodies can be understood.   
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169   
Summary  
 
The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of diseases characterised by 
an acquired progressive muscle weakness and the presence of inflammatory infiltrates in skeletal 
muscle tissue in the absence of a clear causative agent. The three main disorders grouped under the 
heading IIM are: dermatomyositis (DM), polymyositis (PM), and inclusion body myositis (IBM). These 
three diseases are very distinct disease entities with their own clinical features, pathological 
abnormalities, and pathophysiological mechanisms. PM and DM are considered to be autoimmune 
diseases, whereas IBM is frequently seen as a degenerative myopathy with secondary inflammation. 
 
Recently, a dispute has erupted over the diagnostic criteria for IIM, and especially for PM. This dispute 
is potentially harmful for patients with IIM and focuses on whether or not PM is histologically 
characterised by inflammatory infiltrates invading non-necrotic muscle fibres. By performing a 
structured literature search we examined the historical basis of this presumed histological feature and 
concluded that it may not be valid because the PM patients in the original publication may actually 
have had IBM (which is known to be characterised by inflammatory infiltrates invading non-necrotic 
muscle fibres) and not PM. Diagnostic criteria in which the presence of inflammatory infiltrates 
invading non-necrotic muscle fibres are a prerequisite for the diagnosis PM are therefore erroneous 
because they are not based on solid original data. The fact that this invalid feature has become 
embedded in the medical literature seems to be caused by the tendency to use review articles as 
references, authors who do not familiarise themselves with original publications, and authors who 
have a strong tendency to refer to themselves. Therefore, the diagnostic criteria used in this thesis, 
which do not always require the presence of certain histological characteristics, are valid.  
 
It has been shown that sera from over 90% of patients with IIM contain autoantibodies. Most of these 
autoantibodies are not specific for myositis because they are also encountered in sera of patients with 
other inflammatory rheumatic diseases (myositis associated autoantibodies (MAAs)). Some 
autoantibodies, known as myositis specific autoantibodies (MSAs), are proven to be specific for 
myositis. Their specificity has been established compared to other inflammatory rheumatic diseases 
and normal controls. The specificity compared to other neuromuscular disorders is unknown. This is of 
importance though because the differential diagnosis of IIM not only includes other inflammatory 
rheumatic diseases but also other neuromuscular disorders. We prospectively screened sera from 107 
patients with various neuromuscular disorders for the most common MSAs (anti-Jo-1, anti-Mi-2, anti-
SRP) and compared the results to the findings in a group of 97 myositis patients, published previously. 
Special attention was paid to patients with facioscapulohumeral muscular dystrophy (FSHD), an 
autosomal dominant muscle disease with marked inflammation in skeletal muscle tissue. Only one 
patient in the neuromuscular disorders group tested positive for an MSA, compared to 41 in the 
myositis group, resulting in a specificity of 99%. None of the FSHD patients tested positive. Based on 
this study it can be concluded that the tested MSAs are highly specific for myositis and that they are 
not merely associated with muscle inflammation. 
	



The pathophysiology of IIM is not fully understood but it appears that both environmental and genetic 
factors are involved. Therefore, results from studies performed in other parts of the world and in 
populations with another genetic background cannot automatically be extrapolated to the European 
and Dutch situation.  
In order to determine the prevalence of MSAs (anti-Jo-1, other anti-tRNA synthetases, anti-Mi-2, anti-
SRP) and several MAAs in a European population, we studied 417 patients with myositis from 11 
European countries (198 patients with PM, 181 with DM, and 38 with IBM). Sera were analysed by 
immunoblotting, enzyme linked immunosorbent assay (ELISA), and/or immunoprecipitation. 
Autoantibodies were found in 232 sera (56%), including 157 samples (38%) with MSAs. The most 
commonly detected MSA was anti-Jo-1 (18%). Other anti-tRNA synthetases, anti-Mi-2, and anti-SRP 
autoantibodies were found in 3%, 14%, and 5% of the sera, respectively. The incidence of most of the 
tested autoantibody activities in this large group of European patients is in agreement with similar 
studies of Japanese and North American patients. 
An interesting finding was the fact that a latitudinal gradient was found for MSAs – that is, they were 
more frequently found in the Southern European countries as compared to the Northern European 
countries. It is known that patients with DM are more prevalent in Southern European cohorts of 
patients with IIM, while the prevalence of patients with PM is more pronounced in the Northern 
countries. This latitudinal DM/PM gradient can explain the higher prevalence of anti-Mi-2 
autoantibodies in Southern European patients with IIM because of the association of this autoantibody 
with DM. But the latitudinal gradient for DM and PM does not explain the higher prevalence of anti-
synthetase autoantibodies (including anti-Jo-1) and anti-SRP autoantibodies in Southern Europe. It is 
possible that environmental factors related to latitude are involved in the pathophysiologic process 
leading to formation of these autoantibodies.  
 
In order to determine the prevalence of the most common MSAs (anti-Jo-1, anti-tRNAHis, anti-Mi-2, 
anti-SRP) in a Dutch population, and in order to study their clinical associations, we analysed the 
clinical and serological characteristics of 125 Dutch patients with IIM. Sera were analysed by 
immunoblotting, enzyme-linked immunosorbent assay, and immunoprecipitation. The most frequently 
encountered MSA was the anti-Jo-1 autoantibody (20%), followed by anti-tRNAHis (6%), anti-Mi-2 
(6%), and anti-SRP (4%). The presence of certain MSAs was clearly associated with specific clinical 
characteristics. Anti-Jo-1 was associated with the anti-synthetase syndrome (consisting of myositis, 
idiopathic interstitial lung disease, arthritis, and Raynaud’s phenomenon), and anti-SRP with PM with 
severe myalgia and arthralgia and a moderate response to immunosuppressive treatment. Anti-
tRNAHis autoantibodies were only found in sera of anti-Jo-1-positive patients. Clinically, these patients 
had the anti-synthetase syndrome and did not differ from anti-Jo-1-positive patients without tRNAHis 
autoantibodies. A novel finding was the presence of anti-Mi-2, not only in DM, but also in PM 
(previously, anti-Mi-2 autoantibodies were considered to be specific for DM). MSAs were frequently 
present in DM/PM sera, but were hardly ever detected in the sera of IBM patients. The few IBM 
patients with MSAs demonstrated a significant response to immunosuppressive treatment. Based on 
this study, it can be concluded that MSAs define specific clinical syndromes within the spectrum of IIM 
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and that they can assist in the differential diagnosis and treatment plan of these enigmatic disorders 
by virtually excluding IBM by their presence, and by potentially identifying a subgroup of steroid-
responsive IBM patients.  
 
The three most common MSAs, anti-Jo-1, anti-SRP, and anti-Mi-2, were studied in more detail. The 
anti-Jo-1 autoantibody is the most common autoantibody of the so-called anti-aminoacyl-tRNA 
synthetase autoantibodies (anti-ARS). The presence of anti-ARS autoantibodies is associated with the 
anti-synthetase syndrome mentioned above consisting of myositis, interstitial lung disease, 
polyarthritis, and Raynaud’s phenomenon. In a description of three cases of the anti-synthetase 
syndrome we illustrated the fact that the different components of this syndrome are not always present 
simultaneously, nor that they appear in a pre-set order. Furthermore, the clinical manifestations of the 
syndrome in one organ system can be masked by the manifestations in another (e.g. dyspnoea on 
exertion caused by interstitial lung disease is not noticed because of a marked decrease in the level of 
physical activity due to the presence of severe muscle weakness). A thorough knowledge of this 
syndrome is therefore required in order to be able to anticipate on manifestations of the syndrome that 
are not always part of the field of speciality of the treating physician. 
 
The clinical differentiation between DM/PM and IBM can be difficult to make, even histologically. Yet, it 
is of extreme importance as IBM, unlike DM and PM, lacks a response to immunosuppression. 
Because it has been suggested that IBM is not a primary inflammatory myopathy like DM and PM, but 
a myopathy in which the inflammatory response plays a secondary role, we investigated the presence 
of the most common MSA, anti-Jo-1, in a large group of patients with IBM on one side and in DM/PM 
on the other.  The sera of 69 patients with DM or PM and 58 patients with IBM were examined for the 
presence of anti-Jo-1 autoantibodies.  The anti-Jo-1 activity was determined by immunoblotting, 
ELISA, and RNA precipitation. Anti-Jo-1 activity was present in 30% of the DM and in 21% of the PM 
sera, but could not be detected in any of the IBM sera. Based on this study we concluded that the 
presence of the anti-Jo-1 autoantibody excludes the diagnosis of IBM and therefore aids in the 
differential diagnosis and treatment plan of IIM.  It further supports the hypothesis that the 
inflammatory response in IBM differs from that in DM and PM. 
However, a few anti-Jo-1-positive patients with IBM have been encountered. We described one of 
these patients with IBM in more detail because he had a remarkable feature: a marked and sustained 
response after treatment with oral prednisone. Based on this case, it can be hypothesised that the 
presence of an MSA in IBM is the result of an identical immunological mechanism as occurs in MSA-
positive DM/PM patients and that consequently, immunosuppressive treatment would be of benefit as 
was the case in the presented patient. The present data suggests that in a patient with IIM, even IBM, 
and an MSA, immunosuppressive treatment should be considered for a period of at least 3 months.          
 
It has been suggested that the anti-SRP autoantibody is associated with an aggressive form of PM 
frequently complicated by cardiac involvement. However, recent studies have suggested that anti-SRP 
autoantibodies are associated with a necrotizing myopathy. In order to elucidate the clinical 
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importance of the anti-SRP autoantibody, we analysed the clinical and histological data of the largest 
group of anti-SRP positive patients ever to be studied in a systematic manner. A retrospective 
systematic assessment of the clinical, laboratory, and histological characteristics was performed on 23 
anti-SRP positive patients from six European centres. Data were compared to a large group of anti-
SRP-negative myositis patients published previously. 
Clinically, patients with anti-SRP autoantibodies frequently had a disease onset in the fall and winter, 
presence of severe symmetric proximal muscle weakness resulting in marked disability, dysphagia, 
and strongly elevated levels of serum creatine kinase. The disease was associated with the 
occurrence of extra-muscular signs and symptoms including interstitial lung disease in 21% of 
patients. There was no association with cardiac involvement and the disease carried a reasonably 
favourable prognosis with most patients responding to treatment. None of the patients had the typical 
histological features of myositis. Most muscle biopsies showed an abundance of necrotic muscle 
fibres with or without myophagia, and swollen capillaries.  
Based on this study it can be concluded that the anti-SRP autoantibody is not associated with PM but 
with an immune mediated necrotizing myopathy. Further studies will be needed to elucidate the 
pathogenesis and to clarify the role of the anti-SRP autoantibodies in this unique disease.  
         
As was the case with anti-SRP, most studies describing the clinical characteristics of patients with 
anti-Mi-2 autoantibodies only described a small number of patients. Based on these studies, anti-Mi-2 
autoantibodies were thought to be specific for DM. Most of these studies had used techniques in 
which only autoantibody activity directed against certain components of the Mi-2β autoantigen could 
be detected. However, autoantibody activity against other components of the Mi-2β autoantigen has 
been shown to exist in patients with myositis. To assess the clinical implications of the presence of 
autoantibodies directed against different parts of the Mi-2β autoantigen in patients with an 
inflammatory myopathy a systematic assessment was performed of the clinical, laboratory, and 
histological characteristics of 48 anti-Mi-2-positive patients from several European centres. The 
presence of anti-Mi-2 autoantibodies was determined with an ELISA technique using four overlapping 
fragments spanning the entire amino acid sequence of the autoantigen. 
Anti-Mi-2 autoantibodies were found in DM, PM, and IBM. In general, myositis with anti-Mi-2 
autoantibodies was characterised by a relatively mild disease that could be accompanied by 
extramuscular symptoms including arthralgia, arthritis, Raynaud’s phenomenon, and interstitial lung 
disease. Cardiac involvement was not seen, and the treatment response was fair. Three different 
patterns of reactivity to fragments of the Mi-2β autoantigen could be identified. No differences were 
found between patients with autoantibodies to different fragments of the Mi-2β antigen with the 
exception of a potentially increased risk of cancer in patients with antibodies directed to the N-terminal 
fragment of the autoantigen.  
Based on this study, it can be concluded that anti-Mi-2 autoantibodies are not a marker of a specific 
subtype of myositis. Testing for anti-Mi-2 autoantibodies may be helpful in establishing the diagnosis 
myositis, but once this diagnosis has been made, routine testing for this autoantibody is not advised.  
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As is always the case with time, the time that has past between the start of the research presented in 
this thesis and the writing of the concluding remarks on the final pages has changed the landscape of 
the MSAs drastically. New theories on autoantibody formation have been formulated, especially on the 
formation of anti-Jo-1 autoantibodies. Based on recent research reported in the literature, we 
hypothesised that not the muscle but the immune system itself may be the site of antigen 
presentation. Partly through the work presented in this thesis, the MSAs have helped us to better 
understand IIM. They especially aided in the identification of several distinct disease entities which 
were once included under the heading IIM, usually under the diagnosis PM. Furthermore, the MSAs 
have shown us that the IIM syndromes are systemic diseases. 
But the MSAs still hold many mysteries, including their function and role in the pathophysiology of IIM. 
Continuing research, preferably through international collaborations, are needed in order to further 
elucidate the pathophysiological role of MSAs and in order to advance on the road towards a better 
understanding of these potentially debilitating diseases.    
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Samenvatting 
 
De idiopathische inflammatoïre myopathieën (IIM) vormen een groep van ziektebeelden die 
gekenmerkt worden door het ontstaan van spierzwakte en de aanwezigheid van ontstekingscellen in 
skeletspierweefsel zonder dat hier een duidelijke verklaring voor gevonden wordt. De belangrijkste 
ziekten binnen de groep IIM zijn: dermatomyositis (DM), polymyositis (PM) en inclusion body myositis 
(IBM). DM en PM zijn waarschijnlijk auto-immuunziekten, waarbij het afweersysteem zich per abuis 
richt tegen lichaamseigen spierweefsel. Bij IBM is de ontsteking naar alle waarschijnlijkheid een 
reactie op een verouderingsproces in de spier. 
 
Recentelijk is er veel discussie ontstaan over de diagnostische criteria voor met name PM. Eén van 
die criteria is dat bij microscopisch onderzoek van spierweefsel van patiënten met PM  
ontstekingscellen aanwezig moeten zijn die niet-necrotische (niet-afstervende) spiervezels binnen 
dringen. De aanwezigheid van dit kenmerk wordt door sommigen gezien als absolute voorwaarde 
voor het kunnen stellen van de diagnose PM. In de praktijk ziet men dit verschijnsel echter zelden. 
Betekent dit dat PM nagenoeg niet bestaat of betekent het dat de voorwaarde dat ontstekingscellen 
niet-necrotische spiervezels moeten binnendringen bij patiënten met PM niet juist is?  
Ten einde hier achter te komen is een historisch brononderzoek verricht waarbij gekeken werd waar 
de stelling dat ontstekingscellen niet-necrotische spiervezels binnendringen bij patiënten met PM 
feitelijk op gebaseerd is. Deze opvatting bleek uiteindelijk te berusten op één onderzoek waarbij het 
mogelijk is geweest dat de patiënten met PM die in dat onderzoek bestudeerd werden, niet PM 
hadden maar IBM. Van IBM weten we zeker dat daarbij ontstekingscellen niet-necrotische spiervezels 
binnendringen. De conclusie is dan ook dat er momenteel te weinig bewijs is dat ontstekingscellen 
niet-necrotische spiervezels binnendringen bij patiënten met PM. De aanwezigheid van dit 
microscopisch beeld kan dan ook geen absolute vereiste zijn voor de diagnose PM. De diagnostische 
criteria die in dit proefschrift gebruikt zijn gaan hier dan ook niet altijd van uit.  
 
Bij ongeveer 90% van de patiënten met IIM worden autoantilichamen (afweerstoffen gericht tegen 
lichaamseigen materiaal) in het bloed gevonden. Veel van deze autoantilichamen komen ook bij 
andere reumatische ziekten voor en worden daarom myositis geassocieerde autoantilichamen 
genoemd (MAA’s). Sommige autoantilichamen zijn echter specifiek voor IIM. Deze zogeheten myositis 
specifieke autoantilichamen (MSA’s) zijn specifiek voor IIM in vergelijking met andere reumatische 
ziekten. Het is echter van belang te weten of MSA’s ook specifiek zijn voor IIM in vergelijking met 
andere neuromusculaire ziekten (zenuw- en spierziekten) omdat patiënten met IIM soms alleen maar 
klagen over spierpijn en/of spierzwakte en er logischerwijs ook gedacht kan worden aan een 
onderliggende neuromusculaire ziekte anders dan IIM.  
Om een antwoord op deze vraag te krijgen werd het bloed van een grote groep patiënten met een 
neuromusculaire ziekte onderzocht op de aanwezigheid van de meest voorkomende MSA’s (anti-Jo-1, 
anti-SRP, anti-Mi-2). Hetzelfde werd gedaan bij een grote groep patiënten met IIM. Slechts bij één 
patiënt met een neuromusculaire ziekte anders dan IIM werd een MSA gevonden. Van de patiënten 
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met IIM had bijna de helft een MSA. Gebaseerd op deze gegevens is te berekenen dat de specificiteit 
(de kans dat de patiënt IIM heeft en geen andere neuromusculaire ziekte als er een MSA gevonden 
wordt) 99% is. 
Bij dit onderzoek werd tevens gekeken naar het voorkomen van MSA’s bij patiënten met de 
spierziekte facioscapulohumerale spierdystrofie (FSHD). Dit is een erfelijke spierziekte waarbij veel 
ontstekingscellen aanwezig zijn in het spierweefsel (deels dus lijkende op IIM). MSA’s werden niet 
gevonden bij patiënten met FSHD. Op basis van dit gegeven lijkt het dan ook onwaarschijnlijk dat 
MSA’s ontstaan door ontsteking van spieren, en is het waarschijnlijker dat de vorming van MSA’s 
gekoppeld is aan het specifieke ziekteproces van IIM. 
 
De exacte oorzaak van IIM is onbekend maar het lijkt erop dat zowel omgevingsfactoren als erfelijke 
factoren een rol spelen. Gegevens over het voorkomen van MSA’s bij patiënten met IIM uit andere 
delen van de wereld (Verenigde Staten, Japan enz.) kunnen dan ook niet direct doorgetrokken worden 
naar de Europese en Nederlandse patiëntenpopulaties. Om deze reden werd bij een groep van meer 
dan 400 patiënten met IIM uit 11 verschillende Europese landen onderzoek verricht naar het 
voorkomen van MSA’s en MAA’s. Uit dit onderzoek bleek dat de frequentie van voorkomen van de 
meest belangrijke MSA’s in de Europese patiëntenpopulatie vergelijkbaar is met die in de Verenigde 
Staten en Japan. 
Een opvallende bevinding was het feit dat MSA’s vaker gevonden werden bij IIM patiënten uit Zuid-
Europa dan bij patiënten uit Noord-Europa. Het is bekend dat in Zuid-Europa DM vaker voorkomt ten 
opzichte van PM, en dat in Noord-Europa PM vaker gezien wordt dan DM. Dit gegeven kan echter 
alleen het frequenter voorkomen van anti-Mi-2 autoantilichamen verklaren omdat dit antilichaam 
geassocieerd is met DM. De breedtegraad-gradiënt voor DM en PM verklaart niet waarom ook andere 
MSA’s, zoals de anti-synthetase autoantilichamen (inclusief anti-Jo-1) en anti-SRP, vaker gevonden 
werden bij Zuid-Europese patiënten met IIM dan bij Noord-Europese patiënten. Het is goed mogelijk 
dat omgevingsfactoren die gekoppeld zijn aan de breedtegraad een rol spelen in het ontstaan van 
deze autoantilichamen. 
 
Ook binnen de Nederlandse patiëntenpopulatie is gekeken naar het voorkomen van MSA’s (anti-Jo-1, 
anti-tRNAHis, anti-Mi-2, anti-SRP). Daarnaast is gekeken naar de klinische kenmerken van patiënten 
met een MSA. Ook hier was de frequentie van voorkomen van de MSA’s vergelijkbaar met eerdere 
onderzoeken. Verder bleek het anti-Jo-1 autoantilichaam geassocieerd te zijn met het zogeheten anti-
synthetase syndroom. Dit is een syndroom dat gekenmerkt wordt door DM of PM, idiopathische 
interstitiële longziekte (ILD; een auto-immuun longontsteking), ontsteking van meerdere gewrichten en 
het fenomeen van Raynaud (een verkleuring van de vingers). Anti-tRNAHis autoantilichamen kwamen 
alleen voor bij patiënten met anti-Jo-1 antilichamen. Deze patiënten hadden naast het te verwachten 
anti-synthetase syndroom, geen andere gemeenschappelijke kenmerken. Anti-Mi-2 autoantilichamen, 
waarvan gedacht werd dat deze alleen voorkwamen bij DM, werden ook gevonden bij patiënten met 
PM en IBM. Patiënten met anti-SRP autoantilichamen hadden veelal een vrij agressieve vorm van PM 
met forse spier- en gewrichtspijnen en een matige reactie op behandeling.  
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Opvallend in het Nederlandse patiëntenonderzoek was het feit dat MSA’s zelden gezien werden bij 
patiënten met IBM. De enkele patiënt met IBM en een MSA reageerde op behandeling (een opvallend 
gegeven omdat IBM normaal gesproken niet reageert op behandeling). Het kan dus gesteld worden 
dat het bepalen van MSA’s helpt bij het stellen van de diagnose en bij het opmaken van een 
behandelplan omdat de diagnose IBM zeer onwaarschijnlijk wordt bij aanwezigheid van een MSA en 
door het feit dat MSA’s mogelijk een subgroep kunnen identificeren binnen de patiëntengroep met IBM 
die wel baat hebben bij behandeling. 
 
De drie meest voorkomende MSAs (anti-Jo-1, anti-SRP, anti-Mi-2) zijn meer in detail bestudeerd. Van 
het anti-Jo-1 autoantilichaam was al bekend dat het geassocieerd was met het voorkomen van het 
anti-synthetase syndroom (zie boven). Door middel van het beschrijven van de ziektegeschiedenis 
van een drietal patiënten wordt geïllustreerd dat de verschillende onderdelen van het syndroom niet 
simultaan of in een vaste volgorde ontstaan. Daarnaast kunnen uitingsvormen in één orgaan 
(bijvoorbeeld kortademigheid bij inspanning ten gevolge van een longprobleem) gemaskeerd worden 
door die in een andere (bijvoorbeeld door forse spierzwakte komt de patiënt niet meer tot inspanning). 
Onderzoek bij Nederlandse patiënten met IIM toonde aan dat het bepalen van anti-Jo-1 
autoantilichamen ook van belang kan zijn bij het maken van onderscheid tussen DM en PM (deze 
ziekten reageren wel op behandeling met medicatie zoals prednison) aan de ene kant, en IBM (een 
ziekte die in principe niet reageert op prednison en andere medicatie) aan de andere. In een grote 
groep van patiënten met IBM kon geen anti-Jo-1 gevonden worden. Dit betekent dat de diagnose IBM 
zeer onwaarschijnlijk wordt bij een patiënt indien anti-Jo-1 aanwezig is.   
Zeer zelden worden er toch patiënten met IBM gezien met anti-Jo-1 autoantilichamen. Eén van deze 
patiënten is uitgebreider beschreven omdat hij, naast de aanwezigheid van anti-Jo-1 
autoantilichamen, nog een tweede opvallend kenmerk had: namelijk een gunstige reactie op 
prednison. Gebaseerd op de ervaringen bij deze patiënt kan de hypothese geformuleerd worden dat 
het ontstaan van MSA’s bij IBM het gevolg is van een vergelijkbaar proces als bij DM en PM, en dat 
daardoor de ziekte mogelijk wel enigszins reageert op behandeling. Mede op deze bevinding is het 
advies gebaseerd om bij iedere patiënt met IIM (zelfs IBM) èn een MSA, behandeling te starten met 
prednison gedurende tenminste 3 maanden. 
 
De aanwezigheid van anti-SRP autoantilichamen wordt in verband gebracht met een agressieve vorm 
van PM die dikwijls gepaard gaat met ontsteking van de hartspier. Meer recente onderzoeken 
suggereerden echter dat anti-SRP autoantilichamen geassocieerd zijn met een heel ander 
ziektebeeld, namelijk een necrotiserende myopathie (spierziekte). Ten einde meer duidelijkheid te 
krijgen over de klinische betekenis van anti-SRP autoantilichamen zijn de gegevens van 23 patiënten 
met deze autoantilichamen afkomstig uit 6 Europese centra systematisch bestudeerd en vergeleken 
met een groep anti-SRP-negatieve patiënten met IIM. 
Opvallend was dat de ziekte bij patiënten met anti-SRP autoantilichamen frequent in het najaar of de 
winter begon. Daarnaast hadden de patiënten een ernstige symmetrische spierzwakte van met name 
de bovenarm- en bovenbeenspieren leidend tot ernstige invaliditeit en frequent slikproblemen. Een 
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deel van de patiënten had naast de spierproblemen ook problemen in andere organen, zoals 
bijvoorbeeld het optreden van ILD bij 21%. Hartproblemen werden niet gevonden en de ziekte kende 
een redelijke prognose doordat het bij de meeste patiënten reageerde op behandeling. Bij 
microscopisch onderzoek van skeletspierweefsel bleek dat geen van de patiënten de kenmerkende 
afwijkingen had zoals die bij IIM gezien worden en dat bij de meeste patiënten zeer veel necrotische 
(afstervende) spiervezels en gezwollen bloedvaatjes aanwezig waren.  
Mede gebaseerd op dit onderzoek kan gesteld worden dat anti-SRP autoantilichamen geassocieerd 
zijn met een immuun-gemedieerde necrotiserende myopathie.  
 
Ook patiënten met anti-Mi-2 autoantilichamen zijn in de literatuur slechts summier beschreven. De 
meeste series zijn klein en hebben een test gebruikt waarmee alleen autoantilichamen gevonden 
konden worden tegen een klein deel van het autoantigeen (de structuur waartegen het antilichaam 
gericht is). Gebaseerd op deze onderzoeken werd gesteld dat anti-Mi-2 autoantilichamen specifiek zijn 
voor DM. 
In gespecialiseerde laboratoria kunnen echter ook antilichamen gevonden worden tegen andere delen 
van het Mi-2 autoantigeen. Om te achterhalen of de aanwezigheid van autoantilichamen tegen de 
andere verschillende delen van het Mi-2 autoantigen van klinisch belang is werden de gegevens van 
48 patiënten met anti-Mi-2 autoantilichamen afkomstig uit verschillende Europese centra systematisch 
bestudeerd.  
Anti-Mi-2 autoantilichamen werden niet alleen gevonden bij patiënten met DM, maar ook bij patiënten 
met PM en IBM. Over het algemeen bleek de ziekte bij patiënten met anti-Mi-2 autoantilichamen 
relatief mild met het frequent voorkomen van symptomen buiten het spierstelsel zoals 
gewrichtsontstekingen, het fenomeen van Raynaud en ILD. Hartproblemen werden niet waargenomen 
en bij de meeste patiënten reageerde de ziekte goed op behandeling. Klinisch waren er geen 
duidelijke verschillen tussen patiënten met antilichamen tegen verschillende delen van het Mi-2 
autoantigen met uitzondering met een mogelijk verhoogd risico op de aanwezigheid van kanker bij 
patiënten met autoantilichamen gericht tegen het N-terminale deel van het autoantigeen. 
Gebaseerd op dit onderzoek kan gesteld worden dat anti-Mi-2 autoantilichamen niet specifiek zijn voor 
DM en dat ze geen merker zijn voor een specifiek subtype van IIM zoals anti-Jo-1 en anti-SRP 
autoantilichamen dat wel zijn.  
 
Ten dele door het werk dat beschreven is in dit proefschrift hebben de MSA’s ons verder geholpen in 
het begrijpen van IIM. Zo kunnen we nu beter subtypen van IIM herkennen welke voorheen veelal 
onder PM geschaard werden. Tevens hebben de MSA’s laten zien dat de ziektebeelden binnen de 
groep IIM systeemziekten zijn. Daarnaast kunnen de MSA’s helpen bij het verder ontrafelen van de 
ziekteprocessen die ten grondslag liggen aan IIM. Veel vragen zijn nog onbeantwoord waaronder de 
vraag waarom MSA’s gevormd worden en wat hun rol is in het ziekteproces. Het voortzetten van 
onderzoek is dan ook van belang om uiteindelijk te komen tot een beter inzicht in deze invaliderende 
ziekten.       
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